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Estrogens,  acting  via  estrogen  receptor  a  (ERa),  stimulate  cell  proliferation  and  are  
associated  with  the  development  of  aggressive  breast  and  ovarian  cancers.  Endoplasmic  
reticulum   (EnR)   stress   signaling   cascade,   the   unfolded   protein   response   (UPR),   has  
documented  in  various  human  cancers  and  diseases.  However,  the  precise  roles  of  UPR  
signaling   in   development   of   hormone-­dependent   gynecological   cancers  were   unknown.  
Here  we  show  that  the  activation  of  UPR  prior  to  EnR  stress,  also  known  as  the  anticipatory  
UPR  activation,  is  a  new  paradigm  for  estrogen-­ERa  action.  We  found  that  17b-­estradiol  
(E2),   acting   through   ERa,   rapidly   activates   Phospholipase   C   g   (PLCg)   leading   to   the  
production  of  inositol  triphosphate  (IP3).  The  IP3  binds  to  and  opens  endoplasmic  reticulum  
(EnR)  IP3  receptors  (IP3R)  leading  to  extremely  rapid  (<1  min.)  efflux  of  calcium  (Ca2+)  from  
the   lumen   of   the   EnR   into   the   cell   body.   Elevated   intracellular   Ca2+   primes   cells   for  
subsequent   actions   of   E2-­ERa;;   depletion   of   EnR   Ca2+   activates   the   unfolded   protein  
response  (UPR),  inducing  the  important  chaperone  BiP/GRP78  (glucose-­regulated  protein  
78  kDa).  Activation  of  this  pathway  is  required  for  E2-­ERa-­regulated  gene  expression,  cell  
proliferation  and  protects  cells  against  stress.  We  target   this  pathway  with  our  medically  
promising  ERa  biomodulator,  BHPI,  which  uses  the  same  pathway  as  E2,  but  induces  toxic  
hyperactivation  of  the  anticipatory  UPR,  shifting  it  from  protective  to  cytotoxic.  As  a  result,  
at  nanomolar  concentration,  BHPI  blocked  growth  and  often  killed  diverse  therapy-­resistant  
and  ERa-­positive   breast,   ovarian,   and   endometrial   cancer   cells.  Moreover,   in   a  mouse  
xenograft,   BHPI   treatment   resulted   in   rapid   and   substantial   regression   of   pre-­existing  
tumors.  Extending   the  novel  action  of  BHPI  by  hyperactivating  anticipatory  UPR,  a  new  
approach  to  inactivating  multidrug  resistance  protein  1  (MDR1)  in  therapy  resistant  breast  
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and  ovarian  cancer  cells  was  developed.  To  evaluate  the  effectiveness  of  BHPI  in  reversing  
multidrug  resistance  in  vivo,  multidrug  resistant  OVCAR-­3  ovarian  cells,  that  are  resistant  
to  all  known  anticancer  agents,  were  used  in  an  orthotopic  mouse  tumor  model.  This  study  
demonstrated  that  BHPI  in  combination  with  the  taxane,  paclitaxel,  reduced  ovarian  tumor  
burden  and  the  circulating  tumor  antigen,  CA125,  to  undetectable  levels.  
Taken   together,   these  studies  demonstrate   the   importance  of   cross-­talk  between  
steroid  hormone  action  and  the  anticipatory  UPR  pathway  in  the  development  of  hormone-­
dependent  cancer.  We  show  that  targeting  anticipatory  UPR  signaling  is  a  promising  new  
way  to  attack  therapy-­resistant  cancers.  Moreover,  estrogens  are  known  to  have  significant  
effects  in  neurodegenerative  diseases,  metabolic  syndrome,  and  diabetes.  Our  studies  of  
the  anticipatory  UPR  pathway  stimulated  by  steroid  hormones  in  cancer  cells  open  the  way  
for   further  studies  of   the   role  of   the  estrogen-­activated  anticipatory  UPR  pathway   in   the  
pathology  of  these  diverse  disease  states.  
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THE  ESTROGEN  RECEPTOR  AND  ITS  ACTIONS  
Estrogens  play  a  crucial  role  in  the  development  of  the  female  reproductive  system  
including  the  breast,  uterus,  and  ovaries.  The  potent  circulating  estrogen,  17b-­estradiol  (E2),  
can  promote  abnormal  cell  growth,  and  cause  the  development  of  cancer  [1].  This  effect  of  
estrogens   is   primarily   mediated   through   binding   to   estrogen   receptor   a   (ERa).      ERa  
consists  of  six   functional  domains  that  elicit   its  biological  activities   [2,  3].  The  N-­terminal  
(A/B)  domain  contains  a  ligand-­independent  activating  function  (AF)-­1  domain.  The  DNA  
binding   domain   contains   the   zinc   finger   motif   that   interact   with   E2-­ERa   specific   DNA  
response   elements.   The   carboxyl-­terminal   end   of   the   DNA   binding   domain   and   hinge  
domain  contains  the  nuclear  localization  signal.  The  hinge  domain  interacts  with  heat  shock  
proteins.   The   ligand  binding   domain   interacts  with  E2,   inducing   activation   of   the   ligand-­
dependent   transcriptional   activation   function   (AF)-­2   domain.   Last,   the  C-­terminal   region  
prevents  protein  self-­dimerization  in  the  absence  of  ligand.  
There  has  been  extensive  research  on  how  binding  of  E2  to  ERa  triggers  activation  
of  its  nuclear  transcription  program.  Before  ligand  activation,  ERa  is  largely  localized  in  the  
nucleus  and  is  in  a  monomeric  complex  with  heat  shock  proteins.  When  estrogens  enter  
the  cell  and  bind  to  the  ligand  binding  domain  of  ERa,  this  induces  conformational  changes  
in  ERa  protein,  allowing  ERa  to  dissociate  from  heat  shock  proteins  [4].  Subsequently,  the  
ligand-­activated  ERa  forms  a  homodimer  with  another  ERa  monomer  and  binds  to  E2-­ERa  
specific  DNA   response  elements;;   this  allows   the   recruitment  and  docking  of  a  series  of  
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coactivators   including  members  of   the  p160  superfamily   [5].  The  p160  coactivators   then  
recruit   additional   coactivators   including   p300/CBP   histone   acetyltransferase,   CARM1  
methyltransferase,  and  ubiquitin   ligases   [6,   7].  This   series  of   events   leads   to   chromatin  
remodeling  and  RNA  polymerase   recruitment   to   the  promoter   regions  of  ERa-­regulated  
genes  to  execute  transcriptional  activities  of  ERa.  
While  ERa  often  interacts  directly  with  specific  DNA  response  elements,  ERa  can  
also   indirectly   regulate   gene   transcription   through   a   tethering  mechanism.   E2-­ERa   can  
occupy   half   sites   of   specific   DNA   response   elements   and   be   brought   to   DNA   through  
interaction  with  transcriptional  factors,  including  activator  protein  1  (AP1),  Sp1,  and  NFkB,  
at  SP1  and  AP-­1  sites   [8-­11].  Numerous  E2-­ERa   targeted  genes  are   regulated   through  
tethering  mechanisms.  
Estrogen-­regulated  transcriptional  activities  of  ERa  usually  play  out  over  many  hours,  
but   estrogens   can   also   trigger   rapid   cellular   responses   that   occur   outside   of   nucleus,  
commonly  known  as  non-­genomic  or  extranuclear    actions  of  ERa  [12].  A  disparate  set  of  
rapid   extranuclear   actions   of   ERa,   often   initiated   at   or   near   the   plasma   membrane,  
influences   diverse   cell   functions   and   also   play   pivotal   roles   in   modulating   its   genomic  
program  [12,  13].    These  events  occur  within  seconds  to  minutes  and  can  be  activated  by  
ERa   lacking   a   nuclear   localization   signal,   or   by   directly   targeting   ERa   to   the   plasma  
membrane  [12].  These  data  indicate  these  extranuclear  effects  of  estrogen  are  mediated  
through  ERa  that  is  outside  of  the  nucleus.  
Rapid  estrogen  signaling   from   the  plasma  membrane  was  described  many  years  
ago.  It  appears  5-­10%  of  cellular  ERa  is  usually  localized  to  the  plasma  membrane  [14,  15].  
Moreover,  numerous  studies  demonstrate  that  ERa  associates  with  the  plasma  membrane  
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through  a  post-­translational  palmitoylation  at   the  amino  acid  cysteine  447   [16,  17].  This  
allows  ERa  to  interact  with  caveolin-­1  [16,  18].  Membrane-­bound  ERa  also  interacts  with  
several  G  proteins,  including  Ga  and  Gbg  proteins,  leading  to  activation  of  various  kinases,  
such  as  PI3K,  ERK,  Src,  and  AKT  [19].  While  the  exact  mechanism  underlying  the  plasma  
membrane   localized  ERa  activation   remains  elusive,   these  extranuclear  actions  of  ERa  
exhibit  cross-­talk  with  transcriptional  activities  of  nuclear  ERa.  
  
ESTROGEN  RECEPTOR  IN  BREAST  AND  OVARIAN  CANCER    
Prolonged   exposure   to   estrogens   is   an   established   risk   factor   in   breast   cancer.  
Estrogens,  acting  via  ERa,  stimulate  cell  proliferation  and  tumor  growth  [1].  At  diagnosis,  
about  70%  breast  cancers  are  ERa  positive  [1].  Thus,  endocrine  therapies  that  interferes  
with  ERa  activities  have   remained  a  mainstay   in  breast  cancer   treatment.  The  mode  of  
action   of   endocrine   therapies   can   be   divided   into   two   types:   (1)   Tamoxifen,  
Fulvestrant/Faslodex/ICI  182,780  and  other  antiestrogens  work  by  competing  estrogens  
from  binding  to  ERa,  and  (2)  aromatase  inhibitors  prevent  synthesis  of  estrogen  [20,  21].  
In   clinical   trials,   endocrine   therapy   for   5-­years   immediately   following   surgery   in  patients  
diagnosed  with  early-­stage  ERa-­positive  breast  cancer  reduced  breast  cancer  mortality  by  
25%  -­  30%.  
Despite   initial   success,   endocrine   therapy   for   ERa-­positive   breast   cancers   often  
leads  to  resistance  and  progressive  development  of  resistance  to  therapy  presents  a  major  
problem   in   breast   cancer   treatment   [22].   Many   resistance   mechanisms   have   been  
characterized   in   response   to   endocrine   therapy   [22].   Since   aromatase   inhibitors   and  
antiestrogens  target  estrogen  synthesis  or  estrogen  binding  to  ERa,  changes  that  result  in  
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estrogen-­independent   proliferation   makes   breast   cancer   cells   resistant   to   endocrine  
therapy.     (i)  Alterations   in  expression  of  ERa  and   in  the   level  of  ERa  protein  can  play  a  
significant  role  in  resistance  to  endocrine  therapy.  Furthermore,  estrogenic  activity  depend  
on  the  presence  of  ERa  protein,  loss  of  ERa  expression  with  retention  of  cell  proliferation  
remains  a  primary  mechanism  for  acquisition  of  resistance  to  endocrine  therapy.  In  contrast,  
ERa  overexpression  commonly  occurs  in  the  majority  of  breast  cancers  in  postmenopausal  
women,  and   it   is   tightly  associated  with   increased   recurrence  and   reduced  sensitivity   to  
endocrine  therapy.    (ii)  Due  to  the  diverse  transcriptional  effects  of  ERa,  altered  regulation  
of   ERa   co-­regulators   is   linked   to   resistance   to   endocrine   therapy.   These   include  
overexpression   of   ERa   co-­activator  molecules,   such   as   SRC3/AIB1/nCOA3,  which   can  
lead   to   constitutive   ERa-­mediated   transcriptional   activation.   (iii)   Increasing   evidence  
suggests   that   tumors   resistant   to   endocrine   therapy   display   altered   signal   transduction  
pathways   that   can   activate   ERa   activities   independent   of   binding   to   estrogen.   Cross-­
activation   between   ERa   and   growth   factor   signaling   pathways   can   post-­translationally  
modify   ERa   protein   and   activate   ERa   activities   in   the   absence   of   estrogen   [23].   Gene  
amplification   of   EGFR   and   ERBB2   (HER2/neu)   and   insulin-­like   growth   factor   receptor  
(IGFR)   family   are   commonly   present   in   therapy-­resistant   ERa-­positive   breast   cancers.  
Activation   of   the   MAPK/ERK   pathway   by   the   EGFR   and   ERBB2   growth   factors,   the  
AKT/PI3K  pathway  by   IGF  growth   factors,  and  activation  of   the  p38  MAPK  pathway  by  
stress  and/or  cytokines  can  all  phosphorylate  critical  residues  in  the  AF-­1  domain  of  ERa  
and   lead   to   ligand-­independent  activation  of  ERa   [24,  25].  Thus,  ERa   exhibits   complex  
cellular  functions  making  it  challenging  to  overcome  therapy  resistance  in  breast  cancer.  
Despite  the  fact  that  recurrent  tumors  develop  diverse  therapy  resistance  mechanisms  and  
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acquire   multiple   growth   signaling   pathways,   many   resistant   tumors   contain   ERa,  
suggesting  additional   unexplored  modes  of  ERa   action  potentially   targetable  with   small  
molecules.  
Most  epithelial  ovarian  cancer  (EOC)  presents  at  an  advanced  stage  [26].  Although  
30-­70%  of  these  tumors  contain  ERa,  most  ERa-­positive  EOC  do  not  depend  on  estrogens  
or  ERa   for   growth   and,   therefore,   endocrine   therapies   are   largely   ineffective   in   ovarian  
cancer.   However,   ERa   expression   is   strongly   correlated   with   increased   risk   of  
lymphovascular  space  invasion  (LVSI)  and  LVSI   is  correlated  with  poor  clinical  outcome  
[27-­29].   Thus,   ovarian   cancer   patients   following   surgery   are   treated   with   combination  
chemotherapy  using  taxanes  and  platinum  [30].  After  several  cycles  of  treatment,  selection  
and   outgrowth   of   therapy   resistant   tumors   are   common.   Therapeutic   options   for   these  
resistant  tumors  are  poor,  and  most  ovarian  cancer  patient  die  within  5  years.  Paclitaxel  
resistance   in   recurrent   ovarian   cancer   is   mostly   driven   by   overexpression   of   the   ATP-­
dependent   membrane   efflux   pump,   multidrug   resistance   protein   1   (MDR1)/P-­
glycoprotein/ABCB1   [31].   Although   inhibition   of  MDR1   presents   an   intriguing  molecular  
target,  development  of  nontoxic  small  molecule  inhibitors  targeting  MDR1  has  remained  a  
difficult  therapeutic  challenge  [32].  
  
THE  UNFOLDED  PROTEIN  RESPONSE  
Protein  folding  homeostasis  and  quality  control  are  maintained  by  the  endoplasmic  
reticulum  (EnR)  stress  sensor  system,  the  unfolded  protein  response  (UPR)  [33,  34].  The  
UPR  composes  of  three  main  branches  that  together  balance  the  synthesis  of  new  proteins,  
with   the  availability  of  chaperones  and  other  proteins   to  help   fold  and   transport  proteins  
within  cells.  EnR  stress  activates   the   three  main  arms  of   the  UPR.  Autophosphorylation  
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activates   the   transmembrane   protein   kinase   RNA-­like   endoplasmic   reticulum   kinase  
(PERK).   P-­PERK   phosphorylates   downstream   eukaryotic   initiation   factor   2a   (eIF2a),  
resulting  in  transient  inhibition  of  most  protein  synthesis.  In  parallel,  UPR  activation  induces  
proteolytic  cleavage  and  activation  of  activating  transcription  factor  6  a  (ATF6a).  Activated  
ATF6a   (p50-­ATF6a),   acts   as   a   transcriptional   factor,   enters   the   nucleus   and   regulates  
expression   of   UPR   targeted   genes.   Also,   upon   activation   by   oligomerization   and  
autophosphorylation,   the   third   UPR   sensor,   inositol-­requiring   enzyme   1   a   (IRE1a),  
alternatively   splices   inactive   XBP1   mRNA,   producing   active   spliced   XBP1   (sp-­XBP1).  
IRE1a   and   ATF6a   activation   leads   to   induction   of   the   chaperone   BiP/GRP78/HSPA5  
(binding  immunoglobulin  protein/glucose  regulated  protein  78  kDa/heat  shock  protein  A5)  
and  other  chaperones  that  increase  protein-­folding  capacity,  and  to  altered  mRNA  decay  
and  translation.  Simultaneously,  degradation  of  misfolded  protein  is  increased.  
In  this  “reactive”  mode,  EnR  stress  resulting  from  the  accumulation  of  unfolded  or  
misfolded  protein,  or  other  stresses,  triggers  UPR  activation.  While  the  exact  mechanism  
of  the  UPR  sensors  activation  is  unclear,  there  is  a  general  agreement  that  IRE1a  directly  
binds  unfolded  proteins,  leading  to  structural  alterations  that  might  result  in  oligomerization  
and   autophosphorylation   [35].   The   EnR   membrane   contains   ATP-­dependent   SERCA  
(sarcoplasmic/endoplasmic   reticulum   calcium   ATPase)   pumps   that   maintain   a   high  
concentration  of  calcium  in  the  lumen  of  the  EnR.  The  SERCA  pump  inhibitor,  thapsigargin,  
and   the   ionophore,   ionomycin,   activate   the   UPR   by   depleting   EnR   calcium   [35].   The  
calcium-­dependent  chaperone  BiP  is  thought  to  bind  to  the  3  UPR  sensors,  inhibiting  their  
activation.  Unfolded  protein  or  loss  of  calcium  from  the  lumen  of  the  EnR  may  disassociate  
BiP  from  UPR  sensors,  allowing  sensor  oligomerization  and  UPR  activation  [36].  
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Diverse  mitogenic  hormones,  acting  through  their  respective  receptors,  stimulate  cell  
proliferation   and   tumor   growth   [37,   38].   Enhanced   cell   proliferation   requires   increased  
protein  production,  potentially  leading  to  insufficient  protein  folding  capacity  and  EnR  stress.  
In   addition,   UPR   activation   has   been   described   across   multiple   cancers   as   a   survival  
mechanism   in   response   to   nutrient   deprivation   in   the   tumor   microenvironment   and  
resistance  to  cancer  therapies  [34,  39].  However,  the  biological  importance  of  the  UPR  in  
hormone-­dependent  gynecological  cancers  was  largely  unexplored.  
  
OVERVIEW  OF  THESIS  
An   evolutionally   conserved  mechanism   that   links   the   action   of   several  mitogenic  
hormone  actions  to  the  UPR  stress  response  pathway  was  characterized.  This  anticipatory  
UPR  activation  provides  an  authorizing  signal  for  subsequent  mitogenic  gene  expression  
and  cell  proliferation.  Furthermore,  expression  levels  of  mRNAs  encoding  UPR  sensors  and  
UPR  induced  genes  offers  a  powerful  prognostic  marker  in  ERa  containing  breast  cancer,  
tightly  associated  with  reduced  time  to  recurrence,  tamoxifen  resistance,  and  poor  clinical  
outcome.   In  addition,   I   identified   the  binding  site  of  our  preclinical  non-­competitive  ERa  
inhibitor  in  the  receptor,  and  showed  it  binds  with  nanomolar  affinity  with  a  high  structural  
specificity.  BHPI  exhibits  promising  anti-­cancer  activity  against  a  broad  spectrum  of  ERa  
breast  cell  lines  and  in  a  mouse  tumor  model.  I  also  characterized  the  mode  of  BHPI  action  
and  showed  it  distorts  a  normal  action  of  ERa  by  selectively  hyperactivating  the  anticipatory  
UPR  pathway,  converting   it   from  protective   to  cytotoxic.   Its  unique  mechanism  of  action  
suggested  that  I  might  be  able  to  use  BHPI  to  inactive  MDR1.  I  showed  that  BHPI  action  
depletes  intracellular  ATP,  inactivating  the  ATP-­dependent  MDR1  drug  efflux  pump.  This  
restores  sensitivity  to  paclitaxel  and  doxorubicin  in  multidrug  resistant  ovarian  cancer  cells  
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and  paclitaxel  sensitivity   in  paclitaxel-­resistant  breast  cancer  cells.  Moreover,  I  extended  
the  promise  of  combination  therapy  successfully  using  BHPI  together  with  paclitaxel  in  an  
orthotopic  mouse  model   that  we  developed  using  multidrug   resistant  OVCAR-­3  ovarian  
cancer  cells.  Together,  my  research  thesis  not  only  integrated  the  EnR  stress  pathway  with  
mitogenic   hormone   actions   but   also   offered   a   new   avenue   to   understand   hormone-­
dependent  cancer  development  and  provided  a  novel  strategy  to  target  therapy-­resistant  
cancers.  
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ANTICIPATORY  ESTROGEN  ACTIVATION  OF  THE  UNFOLDED  PROTEIN  
RESPONSE  IS  LINKED  TO  CELL  PROLIFERATION  AND  POOR  SURVIVAL  IN  
ESTROGEN  RECEPTOR  a  POSITIVE  BREAST  CANCER  CELLS  1  
  
ABSTRACT  
In   response   to  cell   stress,  cancer  cells  often  activate   the  endoplasmic   reticulum  
(EnR)  stress  sensor,   the  unfolded  protein   response   (UPR).  Little  was  known  about   the  
potential  role  in  cancer  of  a  different  mode  of  UPR  activation;;  anticipatory  activation  of  the  
UPR  prior  to  accumulation  of  unfolded  protein  or  cell  stress.  We  show  that  estrogen,  acting  
via  estrogen  receptor  a  (ERa),  induces  rapid  anticipatory  activation  of  the  UPR,  resulting  
in  increased  production  of  the  antiapoptotic  chaperone  BiP/GRP78,  preparing  cancer  cells  
for  the  increased  protein  production  required  for  subsequent  estrogen-­ERa   induced  cell  
proliferation.  In  ERa  containing  cancer  cells,  the  estrogen,  17b-­estradiol  (E2)  activates   the  
UPR  through  a  phospholipase  C  g    (PLCg)-­mediated  opening  of  EnR  IP3R  calcium  channels,  
enabling  passage  of  calcium  from  the  lumen  of  the  EnR  into  the  cytosol.  siRNA  knockdown  
of  ERa  blocked  the  estrogen-­mediated  increase  in  cytosol  calcium   and   UPR   activation.  
Knockdown   or   inhibition   of   PLCg,    or   of   IP3R,   strongly  inhibited  the  estrogen-­mediated  
increases   in  cytosol  calcium,  UPR  activation  and  cell  proliferation.  E2-­ERa  activates  all  
three   arms   of   the   UPR   in   breast   and   ovarian   cancer   cells   in   culture   and   in   a  mouse  
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xenograft.   Knockdown   of   ATF6a,   which   regulates   UPR   chaperones,  blocked  estrogen  
induction   of   BiP   and   strongly   inhibited   E2-­ERa   stimulated   cell   proliferation.   Mild   and  
transient  UPR  activation  by  estrogen  promotes  an  adaptive  UPR  response  that  protects  
cells  against  subsequent  UPR-­mediated  apoptosis.  Analysis   of   data   from  ERa   positive  
breast   cancers   demonstrates   elevated   expression   of   a   UPR   gene   signature   that   is   a  
powerful  new  prognostic  marker  tightly  correlated  with  subsequent  resistance  to  tamoxifen  
therapy,  reduced  time  to  recurrence  and  poor  survival.  Thus,  as  an  early  component  of  
the   E2-­ERa   proliferation   program,   the   mitogen   estrogen,   drives   rapid   anticipatory  
activation  of   the  UPR.  Anticipatory  activation  of   the  UPR  is  a  new  role   for  estrogens   in  
cancer  cell  proliferation  and  resistance  to  therapy.  
  
INTRODUCTION  
Estrogens,  acting   via  estrogen   receptor  a   (ERa),   stimulate   cell   proliferation  and  
tumor  growth  (1-­3).  The  importance  of  estrogens  and  ERa  in  breast  cancer  is  illustrated  
by  the  central  role  of  endocrine  therapy  targeting  estrogens  and  ERa  in  treatment  of  ERa+  
breast  cancer  (1-­5).  To  help  fold  and  sort  the  increased  protein  required  for  estrogen-­ERa  
induced   cell   proliferation,   cells   must   increase   chaperone   levels.   The   endoplasmic  
reticulum   (EnR)   stress   sensor,   the   unfolded   protein   response   (UPR)   monitors   and  
maintains  protein-­folding  homeostasis  (6,  7).  The  UPR  responds  to  misfolded  proteins,  or  
other   forms   of   stress,   by   activating   three   signal   transduction   pathways,   which   reduce  
protein   production   and   increase   EnR   protein-­folding   capacity.   Protein   production   is  
regulated  by  autophosphorylation  of   the  stress-­activated   transmembrane  kinase,  PERK  
(6,  7).  P-­PERK  phosphorylates  eukaryotic  initiation  factor  2a  (eIF2a),  resulting  in  transient  
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inhibition  of  protein  synthesis.  The  other  UPR  arms  initiate  with  proteolytic  activation  of  the  
transcription   factor  ATF6a,   leading   to   increased  chaperone  production  and  activation  of  
the  EnR  splicing  factor  IRE1a,  which  alternatively  splices   the   transcription   factor  XBP1,  
leading   to   production   of   active   spliced-­XBP1,   increased   protein   folding   capacity   and  
altered  mRNA  decay  and  translation  (6,  7).  
The  UPR  is  usually  inactive  in  normal  cells,  but  is  overexpressed  in  several  cancers  
(8).  Chronic  UPR  activation  leads  to  increased  expression  of  EnR  chaperones,  such  as  
BiP   (GRP78/HSAP5),   p58IPK  and   calreticulin   that   facilitate   protein   folding   and   promote  
survival,   proliferation,   angiogenesis,   and   resistance   to   chemotherapy   and   endocrine  
therapy  (9-­12).  In  the  widely  studied  “reactive  mode”,  the  UPR  in  tumor  cells  is  activated  
in  response  to  accumulation  of  stress  from  rapid  cell  division,  hypoxia  and  therapy.  A  few  
studies   in   immune  cells  describe  a  different   type  of  UPR  activation;;   in  this  “anticipatory  
mode”,  the  UPR  is  activated  in  the  absence  of  EnR  stress  and  prior  to  the  accumulation  
of   unfolded   proteins   (13,   14).   We   explored   whether   estrogen   induces   anticipatory  
activation  of   the  UPR  in   the  absence  of  EnR  stress,   increasing  protein   folding  capacity  
prior   to   the   increased   protein   production   and   protein   folding   load   that   accompanies  
activation  of  the  genomic  estrogen-­ERa  cell  proliferation  program.  Previous  studies  of  the  
UPR  and  of  estrogen-­ERa  action   focused  on   the  estrogen-­inducible  UPR  gene,  XBP1.  
XBP1  binds  to  and  activates  ERa;;  XBP1  expression  is  associated  with  tamoxifen  resistance  
in  ERa+  breast  cancer  (15-­18).  
The   plasma   membrane   enzyme   phospholipase   C    g      (PLCg)   hydrolyzes   PIP2   to  
diacyglycerol   (DAG)   and   inositol   1,4,5-­triphosphate   (IP3).   We   show   that   the   mitogen  
estrogen,  17b-­estradiol  (E2),  acting  through  a  rapid  extranuclear  action  of  ERa,  elicits  a  
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PLCg-­mediated   opening   of   EnR   IP3R   calcium   channels,   increasing   cytosol   calcium   and  
triggering   anticipatory   activation   of   each   arm   of   the   UPR.   Opening   the   IP3R   calcium  
channel  and  activating  the  ATF6a  arm  of  the  UPR,  resulting  in  BiP  induction,  are  important  
for   subsequent   E2-­ERa   induced   cell   proliferation.  Consistent  with   an   important   role   in  
cancer  for  anticipatory  activation  of  the  UPR,  analysis  of  data  from  ~1,000  ERa+  breast  
cancer  patients  demonstrates  that  elevated  expression  of  a  UPR  gene  signature  is  tightly  
correlated  with  subsequent  resistance  to  tamoxifen  therapy,  time  to  tumor  recurrence  and  
poor  survival.  
  
MATERIALS  AND  METHODS  
Cell  Culture  and  Reagents  
Cell  culture  medium  and  conditions  were  previously  described  (19-­21).  MCF-­7,  T47D,  
and  T47D-­kBluc  cells  were  obtained  from  the  ATCC.  Drs.  S.  Kaufmann  and  K.  Korach  
provided   PEO4   cells   and   BG-­1   cells,   respectively.   E2,   4-­OHT,   U73122,   2-­APB,   and  
tunicamycin  were   from  Sigma  Aldrich.   ICI   182,780  was   from  Tocris   Biosciences   and  
ryanodine  was  from  Santa  Cruz  Biotechnology.  Phospho-­eIF2a  (#3398),  eIF2a  (#5324),  
Phospho-­PERK   (#3179),   PERK   (#5683),   and   BiP   (#3177)   antibodies   were   from  Cell  
Signaling.  Pan-­IP3R  (sc-­28613),  XBP1  (sc-­7160),  and  ERa  (sc-­56836)  antibodies  were  
from  Santa  Cruz  Biotechnology.  Other  antibodies  used  were  ATF6a   (Imgenex)  and  β-­
Actin  (Sigma).  
Cell  Proliferation  Assays  





Protein   synthesis   was   evaluated   by   measuring   incorporation   of   35S-­Methionine   into  
newly  synthesized  protein.  Cells  were  incubated  in  96  well  plates  for  20  minutes  with  3  
µCi  of  35S-­methionine  per  well  (PerkinElmer),  lysed,  and  clarified  by  centrifugation.  The  
appropriate  volume,  normalized   to   total  protein,  was  spotted  onto  Whatman  540   filter  
paper  discs  and  immersed  in  cold  10%  TCA  and  washed  in  5%  TCA.  Trapped  protein  
was  solubilized  and  filters  counted.  
  
Calcium  Imaging  
Cytoplasmic  Ca2+  concentrations  were  measured  using  the  calcium-­sensitive  dye,  Fluo-­4  
AM  (22,  23).  Cells  were  grown  on  35  mm-­fluorodish  plates  (World  Precision  Instruments)  
for   two   days   prior   to   experiments.   Cells   were   loaded   with   5   µM   Fluo-­4   AM   (Life  
Technologies)  in  buffer  (140  mM  NaCl,  4.7  mM  KCl,  1.13  mM  MgCl2,  10  mM  HEPES,  10  
mM  Glucose,  pH  =  7.4)  for  30  minutes  at  37  oC.  The  cells  were  washed  three  times  with  
this  buffer  and  incubated  with  either  2  mM  or  0  mM  CaCl2  for  10  minutes.  Images  were  
captured  for  one  minute  to  determine  basal  fluorescence  intensity,  and  then  the  appropriate  
treatment  was  added.  Measurements  used  a  Zeiss  LSM  700  confocal  microscope  with  a  
Plan-­Four  20X  objective  (N.A.  =  0.8)  and  488-­nM  laser  excitation  (7%  power).  Images  were  
obtained   through   monitoring   fluorescence   emission   at   525   nM,   and   analyzed   with  
AxioVision  and  Zen  software  (Zeiss).  
  
Luciferase  Assays,  qRT-­PCR,  and  siRNA  Transfections  
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Reporter   gene   assays   and   qRT-­PCR   were   previously   described   (19,   20).   siRNA  
knockdowns  were  performed  using  DharmaFECT1  Transfection  Reagent  and  100  nM  ON-­
TARGETplus  non-­targeting  pool  or  SMARTpools   for  ERa   (ESR1),  PLCg   (PLCG1),  PERK  
(EIF2AK3),  ATF6a  (ATF6a),  XBP1,  or  pan-­IP3R  (Dharmacon).  The  pan-­IP3R  SmartPool  
consisted  of  three  individual  SmartPools,  each  at  33  nM,  directed  against  each  isoform  of  
the  IP3R  (ITPR1,  ITPR2,  and  ITPR3).  
  
MCF-­7  Xenograft  
Experiment   were   approved   by   the   Institutional   Animal   Care  Committee   (IACUC)   of   the  
University  of   Illinois  at  Urbana-­Champaign.  The  MCF-­7  cell  mouse  xenograft  model  has  
been  described  previously  (24).  Estrogen  pellets  (1  mg:19  mg  estrogen:cholesterol)  were  
implanted  into  30  athymic  female  OVX  mice  at  7  weeks  of  age.  Three  days  later,  1  million  
MCF-­7  human  breast  cancer  cells  suspended  in  matrigel  were  subcutaneously  injected  into  
two  sites  on  each  flank,  for  a  total  of  4  tumors  per  mouse.  When  average  tumor  size  reached  
17.6  mm2,  E2  pellets  were  removed  and  a  lower  dose  of  E2  in  sealed  silastic  tubing  (1:31  
estrogen:cholesterol,  3  mg  total  weight)  was  implanted.  When  average  tumor  size  reached  
23.5  mm2,  15  mice  retained  E2  silastic  tubes  (+E2  group)  and  15  mice  received  silastic  
tubes  containing  only  cholesterol  (-­E2  group).  Tumors  were  measured  every  4  days  with  a  
caliper.  Tumor  cross  sectional  area  was  calculated  as  (a/2)*(b/2)*3.14,  where  a  and  b  were  
the   measured   diameters   of   each   tumor.   On   termination   of   the   experiments   mice   were  
euthanized  and  tumors  were  excised.  
  
Tumor  Microarray  Data  Analysis  
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Analysis  was  performed  using  several  publically  available  tumors  cohorts.  ERa  and  UPR  
gene  expression  profiles  of  histologically  normal  breast  epithelium  (GSE20437)  (25)  were  
compared  to  IDC  tumors  from  ERa+  breast  cancer  patients  (GSE20194).  ERa  and  UPR  
correlation   analysis   was   performed   on   278   invasive   ductal   carcinoma   samples  
(GSE20194)  (26).  A  “UPR  Gene  Signature”  was  constructed  to  carry  out  risk  prediction  
analysis.  The  UPR  gene  signature  was  evaluated  for  its  ability  to  predict:  (i)  tumor  relapse  
in   261   early-­stage   ERa+   breast   cancers   (GSE6532),   (ii)   tumor   relapse   in   474   ER +  
patients  receiving  solely  tamoxifen  therapy  for  5  years  (GSE6532,  GSE17705)  (27,  28),  
and  (iii)  overall  survival  in  a  mixed-­cohort  of  236  breast  cancer  patients  (GSE3494)  (29).  
Microarray   data   analysis   was   performed   using   BRB   ArrayTools   (version   4.2.1)   and   R  
software  version  2.13.2.  Gene  expression  values  from  CEL  files  were  normalized  by  use  
of   the   standard   quantile   normalization   method   (30).   Pearson   correlation   tests   and  
Spearman  log  rank  tests  were  used  to  determine  gene  expression  correlation  coefficients.  
Wald  tests  were  used  to  test  whether  UPR  genes  were  predictive  of  tumor  recurrence  and  
overall   survival.   Univariate   and   multivariate   hazard   ratios   were   estimated   using   Cox  
regression  analysis.  Covariates  statistically  significant  in  univariate  analysis  were  further  
assessed   in  multivariate  analysis.  A  patient  was  excluded   from  multivariate  analysis,   if  
data  for  one  or  more  variables  were  missing.  Risk  prediction  using  the  UPR  gene  signature  
was  carried  out  using  the  supervised  principle  components  method  (31),  and  visualized  
using  Kaplan-­Meier  plots  and  compared  using  log-­rank  tests.  
  
Statistical  Analysis  
Calcium  measurements  are  reported  as  mean  ±  SE.  All  other  data  is  reported  as  mean  ±  
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S.E.M.   Two-­tailed   student’s   t-­test   used   for   comparisons   between   groups.   One-­   way  
ANOVA  followed  by  Fisher’s  LSD  or  Tukey’s  post  hoc  test  used  for  multiple  comparisons.  
P  <  0.05  was  considered  significant.  
  
RESULTS  
Estrogen  Activates  all  3  Arms  of  the  UPR  
To  evaluate  the  ability  of  E2-­ERa  to  activate  the  UPR,  we  focused  on  production  of  
spliced  and  modified  proteins  that  result  from  activating  the  three  arms  of  the  UPR  (Figure  
2.1).  E2  rapidly  activated  the  IRE1a  arm  of  the  UPR,  as  shown  by  increases  in  spliced-­
XBP1   (sp-­XBP1)  mRNA   in   T47D   and  MCF-­7   breast   and   PEO4   ovarian   cancer   cells  
(Figure  2.2A  and  B),  and  by  induction  of  downstream  sp-­XBP1  targets,  SERP1  and  ERDJ  
(Figure   2.3A)   (32).   The   antiestrogens   ICI   182,780/Faslodex/fulvestrant   (ICI)   and   4-­  
hydroxytamoxifen,  (4-­OHT),  which  compete  with  E2  for  binding  to  ERa,  blocked  the  E2-­  
mediated  increase  in  sp-­XBP1  (Figure  2A).  Consistent  with  E2-­ERa  activating  the  IRE1a  
arm   of   the   UPR,   RNAi   knockdown   of   ERa   blocked   E2-­induction   of   sp-­XBP1   mRNA  
(Figure  2.2C),  and  induction  of  GREB1  by  nuclear  E2-­ERa  (Figure  2.3B).  
We  next  assessed  whether  estrogen  activates  the  ATF6a  arm  of  the  UPR.  ATF6a  
is  a  90  kDa  protein  (p90-­ATF6a)  that  translocates  from  the  EnR  to  the  Golgi  in  response  
to  stress,  where  it  undergoes  proteolytic  cleavage  to  its  active  50  kDa  form  (p50-­ATF6a)  
(Figure   2.1B)   (6,   7,   33).   Increased  ATF6a   proteolysis   in   T47D   cells   and   PEO4   cells  
demonstrates  that  E2-­ERa  transiently  activates  the  ATF6a  arm  of  the  UPR  (Figure  2.2D  
and  Figure  2.3C).  Since  pretreatment  with   ICI,  abolished   the  E2-­mediated   increase   in  
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p50-­ATF6a,   this  effect   is  mediated  through  ERa  (Figure  2.2D).  Active  cleaved  ATF6a  
regulates   induction   of   BiP   and   other   EnR   chaperones   (33,   34).   Consistent   with   this,  
ATF6a  knockdown  in  T47D  cells  blocked  BiP  induction  (Figure  2.2E).  BiP  increases  EnR  
protein  folding  capacity,  contributing  to  resolution  of  the  stress,  and  helps  reverse  UPR  
activation;;   likely   preventing   the   cytotoxicity   that   would   result   if   UPR   activation   was  
sustained.  Consistent  with   its  antiapoptotic  role,   in  several  cancers,  elevated   levels  of  
BiP  are  associated  with  a  poor  prognosis   (9).  Estrogen   rapidly   induced  BiP  mRNA   in  
breast  and  ovarian  cancer  cells  (Figure  2.2F),  leading  to  a  2.3-­fold  increase  in  BiP  protein  
(Figure  2.2G).  RNAi  knockdown  of  ERa  prevented  E2-­induction  of  BiP  mRNA  (Figure  
2.2H).  
PERK  activation  leads  to  inhibition  of  protein  synthesis  (Figure  2.1C).  Surprisingly,  
E2   induces   a   rapid   and   transient   increase   in   PERK   phosphorylation   (Figure   2.4A),  
resulting   in   increased  phosphorylation  of  eIF2a   (Figure  2.4B)  and  a  modest   transient  
decline   in   overall   protein   synthesis   (Figure   2.4C).  Consistent  with   p-­PERK  catalyzing  
formation  of   p-­eIF2a,  PERK  knockdown   inhibited   formation  of   p-­eIF2a   (Figure  2.4D).  
Consistent  with  E2  acting   through  ERa,   ICI   inhibited  E2-­stimulated   phosphorylation   of  
PERK  and  eIF2a  and   largely   reversed   the  E2-­mediated   inhibition  of  protein  synthesis  
(Figure  2.4A,  B,  and  C).  PERK  activation  leads  to  ATF4  expression,  and  we  observed  a  
transient  increase  in  ATF4  expression  (Figure  2.4E).  However,  the  proapoptotic  protein  
CHOP  was  not  induced  because  mild  and  transient  activation  of  PERK  does  not  induce  
CHOP  (Figure  2.3D,  Figure  2.4F)  (35).  Together,  this  data  demonstrates  that  E2,  acting  




E2-­ERa  Rapidly  Increases  Cytosol  Ca2+  by  a  PLCg-­mediated  Opening  of  the  EnR  IP3R  
Ca2+  Channel,  Activating  the  UPR  
Rapid  UPR  activation  by  E2-­ERa  suggested  accumulation  of  unfolded  protein  was  
not   triggering   UPR   activation.   Some   UPR   activators,   such   as   thapsigargin,   rapidly  
activate  the  UPR  by  depleting  Ca2+  stores  in  the  lumen  of  the  EnR,  increasing  intracellular  
Ca2+.  To  test  whether  E2  rapidly  alters  cytosol  Ca2+,  we  monitored  cytosol  calcium  using  
the  sensor  dye  Fluo-­4  AM.  In  the  presence  or  absence  of  extracellular  Ca2+,  estrogen  
produced   a   rapid   and   transient   increase   in   fluorescence   in   T47D  breast   cancer   cells  
(Figure  2.5A  and  B).  Since  E2  increases  cytosol  Ca2+  when  there  is  no  extracellular  Ca2+,  
and  the  EnR  lumen  is  the  major  Ca2+  store  available  to  increase  cytosol  Ca2+,  E2  is  acting  
by   depleting   the   EnR   Ca2+   store.   Estrogen   also   increased   cytosol   calcium   in   PEO4  
ovarian  cancer  cells  (Figure  2.6).  Inhibition  of  the  IP3R  channel  with  2-­APB,  which  locks  
the  IP3R  Ca2+  channels  closed,  and  RNAi  knockdown  of  the  three  isoforms  of  the  IP3R  
channels  (Figure  2.5C),  abolished  the  rapid  E2-­ERa-­mediated  increase  in  cytosol  Ca2+  
(Figure  2.5A,  B,  and  D).  In  contrast,  high  concentration  ryanodine  (Ry),  which  closes  the  
ryanodine   receptor   (RyR)   Ca2+   channels,   did   not   block   the   increase   in   cytosol   Ca2+  
(Figure  2.5A  and  B).  We  next  assessed  whether  Ca2+-­release  was  necessary  for  UPR  
activation   using   2-­APB   and   ryanodine   individually,   or   in   combination.   2-­APB,   but   not  
ryanodine,   inhibited   E2-­ERa   activation   of   the   PERK   arm   of   the   UPR,   as   shown   by  
inhibition  of  formation  of  p-­eIF2a  (Figure  2.7A).  RNAi  knockdown  of  IP3R  (Figure  2.5C)  
blocked  E2-­induced  Ca2+  release  (Figure  2.5D),  activation  of  the  IRE1a  arm  of  the  UPR  
(Figure  2.7B),  and  blocked  E2-­induction  of  BiP  (Figure  2.5C),  which  is  a  commonly  used  
surrogate  readout  for  UPR  activation.  
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We  next  tested  the  possibility  that  activation  of  PLCg,  which  hydrolyzes  PIP2  to  DAG  
and  IP3,  plays  a  role  in  E2-­mediated  opening  of  the  IP3R  Ca2+  channels.  Treating  T47D  
cells  with  the  PLCg  inhibitor,  U73122,  or  siRNA  knockdown  of  PLCγ,  abolished  the  rapid  
E2-­ERa-­mediated   increase   in   cytosol   Ca2+   (Figure   2.5E   and   Figure   2.8).   Since   PLCg  
mediates  E2-­dependent  opening  of  the  IP3R  Ca2+  channels  and  calcium  release  (Figure  
2.5F),   we   examined   the   effect   of   siRNA   knockdown   of   PLCg   on   E2-­ERa-­dependent  
activation  of  the  UPR.  siRNA  knockdown  of  PLCg  blocked  E2-­ERa  activation  of  the  ATF6a  
arm  of  the  UPR,  as  shown  by  a  reduction  in  p50-­ATF6a,  and  inhibition  of  BiP   induction  
(Figure  2.5E).  
To  evaluate  the  role  of  ERa   in  the  E2-­mediated  increase  in  cytosol  calcium,  we  
performed  siRNA  knockdown.  In  T47D  cells,  RNAi  knockdown  of  ERa,  in  the  absence  of  
extracellular  Ca2+,  prevented  E2-­stimulated  calcium  release  (Figure  2.5G  and  H).  PLCg  is  
on   the   inner   leaflet   of   the   plasma   membrane   and   the   E2-­ERa-­mediated   increase   in  
cytosol  Ca2+  occurs  in  <2  min.  Thus,  the  E2-­ERa-­mediated  increase  in  intracellular  Ca2+  
that   leads   to   UPR   activation   is   a   rapid,   extranuclear   action   of   ERa   at   the   plasma  
membrane.  
  
The  UPR  and  E2-­ERa  Action  in  E2-­ERa  Stimulated  Cell  Proliferation  
We  explored  the  role  of  Ca2+-­release  from  the  EnR  in  promoting  E2-­ERa   induced  
gene   expression,   UPR   activation,   and   subsequent   cell   proliferation.   Consistent   with   a  
possible  role  for   intracellular  Ca2+  in  E2-­ERa  action  (36),  chelating  intracellular  Ca2+  with  
BAPTA-­AM  blocked  E2-­stimulated  cell  proliferation  (Figure  2.9A).  In  T47D  cells,  PLCg  or  
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IP3R  knockdown,  or  locking  IP3R  with  2-­APB,  strongly  inhibited  the  increase  in  cytosol  Ca2+  
(Figure  2.5A,  B,  D  and  F),  UPR  activation  (Figure  2.5C  and  E,  Figure  2.7),  and  E2-­ERa  
stimulated  cell  proliferation  (Figure  2.9A  and  B).  However,  IP3R  knockdown  did  not  inhibit  
E2-­dependent  down-­regulation  of  ERa  or  E2-­induction  of  GREB1  or  pS2  mRNA  (Figure  
2.9C;;  Figure  2.10B)  (37,  38).  Similarly,  2-­APB  did  not  abolish  E2-­ERa  induced  expression  
of  stably  transfected  ERE-­luciferase  in  T47D  cells,  while  2-­APB  and  Ry  together,  strongly  
inhibited   reporter   gene   expression   (Figure   2.9D).   This   suggests   there   are   different  
intracellular   Ca2+   requirements   for   E2-­ERa-­mediated   UPR   activation   and   E2-­ERa-­  
mediated   gene   expression.   Importantly,   the   IP3R   knockdown   data   uncouples   UPR  
activation  from  E2-­ERa-­mediated  gene  expression,  and  demonstrates  that  blocking  UPR  
activation  is  sufficient  to  inhibit  estrogen-­stimulated  cell  proliferation.  
We  next  evaluated  the  role  of  E2-­induction  of  EnR  chaperones  in  E2-­ERa  stimulated  
cell  proliferation.  Knockdown  of  PLCg  or  IP3R  strongly  inhibited  E2-­induction  of  BiP  and  E2-­
ERa   stimulated   cell   proliferation   (Figure   2.5C   and   E,   Figure   2.9A).   Knockdown   of   the  
primary  UPR  regulator  of  EnR  chaperones,  ATF6a,  also  strongly  inhibited  E2-­  induction  of  
BiP  and  E2-­ERa  stimulated  cell  proliferation  (Figure  2E  and  9A).  Thus,  UPR  activation  and  
subsequent   induction  of  EnR  chaperones  plays  an  important  role   in  E2-­  ERa  stimulated  
cell  proliferation.  
We  further  evaluated  the  effects  of  PLCg,  IP3R,  ATF6a,  XBP1,  and  PERK  knockdown  
on  E2-­stimulated  proliferation  of  MCF-­7  cells  (Figure  2.11).  Knockdown  of  the  ATF6a  and  
XBP1  arms  of  the  UPR  produced  40%  declines  in  E2-­stimulated  in  cell  proliferation,  while  
PERK  knockdown  had  no  effect  (Figure  2.10E).  IP3R  knockdown  produced  a  50%  decline  
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in  E2-­ERa  stimulated  MCF-­7  cell  proliferation  (Figure  2.9E).  This  is  consistent  with  the  40%  
decline  in  proliferation  following  2-­APB  treatment  (Figure  2.10C),  which  did  not  fully  abolish  
E2-­induction  of   pS2  and  GREB1  mRNA   (Figure  2.9F;;  Figure  2.10D).  Targeting   IP3R   in  
MCF-­7   cells   produced   less   dramatic   inhibition   of   E2-­ERa   stimulated   cell   proliferation  
compared  to  T47D  cells  or  BG-­1  ovarian  cancer  cells  (Figure  2.9A,  B,  E;;  Figure  2.10C  and  
E).  Knockdown  of  PLCg  in  MCF-­7  cells  nearly  abolished  E2-­ERa  stimulated  cell  proliferation  
(Figure  2.9E).  Together,   this  data  demonstrates   that  weak  anticipatory  activation  of   the  
UPR,  resulting  in  induction  of  chaperones,  plays  an  important  role  in  E2-­ERa-­stimulated  
cell  proliferation.  This  novel  E2-­ERa  pathway  leading  to  cancer  cell  proliferation  is  shown  
(Figure  2.9G).  
  
E2-­ERa  Action  Increases  Levels  of  UPR  Sensors  and  Downstream  Targets  
We  investigated  whether  E2-­ERa  facilitates  UPR  activation  by  inducing  the  sensors  
that  trigger  activation  of  the  three  UPR  arms.  E2  rapidly  induced  mRNAs  encoding  sensors  
for  all  3  UPR  arms  and  the  chaperones  BiP  and  GRP94  (Figure  2.12A).  These  were  early  
responses,   usually   visible   within   2   hours.   Although   some   responses   declined   at   later  
times,   estrogen  produced   sustained   increases   in   resident   chaperones   and   some  UPR  
components,  such  as  eIF2a  (Figure  2.12A).  
  
E2-­ERa-­regulated  Gene  Expression  and  UPR  Activation  are  Correlated  In  Vivo  
To  assess   in  vivo  relevance,  we  used  growing  MCF-­7  tumors  receiving  estrogen  
and   regressing   MCF-­7   tumors   receiving   only   cholesterol   vehicle   (Figure   2.12B)   and  
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compared   expression   of   classical   measures   of   E2-­ERa   activity   to   markers   of   UPR  
activation   (24).   In   the   +E2   tumors,   the   markers   for   E2-­ERa   activity,   pS2   and   GREB1  
mRNAs   (37,   38),   were   induced   12-­fold   and   17-­fold   and   all   three   UPR   arms   were  
moderately  activated  (Figure  2.12C  and  D).  Consistent  with  activation  of  the  IRE1a  arm  of  
the  UPR,  active  sp-­XBP1  increased  3-­fold  while  inactive  XBP1  declined  (Figure  2.12D).  
Consistent  with  E2-­activation  of  the  ATF6a  arm  of  the  UPR,  +E2  tumors  displayed  2.0  and  
1.8-­fold   increases   in   BiP   and   GRP94   mRNAs,   respectively   (Figure   2.12D).   Levels   of  
CHOP   and   GADD34   mRNA   were   2.1-­fold   and   1.4-­fold   higher   in   the   +E2   group,  
respectively,  indicating  weak  activation  of  the  PERK  arm  (Figure  2.12D).  While  levels  of  
primary  UPR  sensors  IRE1a  and  PERK  were  reduced  in  these  tamoxifen-­sensitive  tumors,  
their  immediate  targets  eIF2a  and  sp-­XBP1  were  increased  (Figure  2.12D).  
To  assess  UPR  activity  early  in  ERa+  breast  cancer  development,  we  compared  E2-­
ERa   activity   and   UPR   pathway   activity   in   samples   of   histologically   normal   breast  
epithelium  and  invasive  ductal  carcinoma  (IDC).  Compared  to  normal  epithelium  from  IDC  
patients,  IDC  samples  displayed  elevated  levels  of  ERa  mRNA  and  E2-­ERa  induced  pS2  
and  GREB1  mRNAs,  and  reduced  levels  of  E2-­ERa  downregulated  IL1-­R1  mRNA  (Figure  
2.12E).   IDC  samples  displayed  elevated  SERP1  mRNA,  a  marker   for   IRE1   activation  
(32);;  CHOP  and  GADD34,  which  are  markers  of  PERK  activation;;  and  BiP  and  GRP94  
chaperones,  which  are  markers  of  ATF6a  activation  (Figure  2.12F).  These  data  suggest  
UPR  activation  occurs  very  early  in  tumor  development.  
Using  data  from  an  independent  cohort  of  278  ERa+  breast  cancers  we  explored  whether  
expression   of   ERa   mRNA   and   protein,   or   E2-­ERa-­regulated   genes,   correlates   with  
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expression  of  UPR  genes.  Expression  of  several  UPR  genes  displayed  highly  significant  
correlation  with  expression  of  ERa  and  ERa-­target  genes  (Table  2.1).  
  
Prior  Estrogen  Activation  of  the  UPR  Protect  Cells  from  Subsequent  Exposure  to  
Cell  Stress  
Weakly   activating,   non-­toxic,   concentrations   of   the   UPR   activator,   tunicamcyin  
(TUN),  elicit  an  adaptive  stress  response   that   increases  EnR  chaperones,  and  renders  
cells  resistant  to  subsequent  exposure  to  an  otherwise  lethal  concentration  of  tunicamycin  
(35,  39).  Consistent  with  weak  E2  activation  of  the  UPR,  E2  induces  a  2.3-­fold  increase  in  
BiP  protein  compared  to  a  5.5-­fold  increase  in  BiP  following  maximal  UPR  activation  by  a  
lethal  concentration  of  tunicamycin  (Figure  2.2G  and  Figure  2.13).  We  tested  whether  prior  
exposure   of   T47D   cells   to   E2,   or   a   low   concentration   of   tunicamycin,   altered   the  
concentration  of  tunicamycin  required  to  subsequently  induce  substantial  cell  death.  Pre-­
treating  cells  with  estrogen  or  TUN  had  nearly  identical  effects;;  each  elicited  an  ~10  fold  
increase  in  the  concentration  of  tunicamycin  required  to  induce  apoptosis  (Figure  2.14A).  
Thus,  the  E2-­induced  weak  anticipatory  activation  of  the  UPR  both  facilitates  tumor  cell  
proliferation  and  is  a  potential  mechanism  by  which  estrogen  might  protect  ERa+  breast  
tumors  against  subsequent  apoptosis  due  to  hypoxia,  nutritional  deprivation  and  therapy.  
  
A  UPR  Gene  Signature  Predicts  Clinical  Outcome  in  ERa  Positive  Breast  Cancer  
To  explore  UPR  activation  as  a  potential  prognostic  marker  in  ERa+  breast  cancer,  
we  developed  a  UPR  gene  signature  consisting  of  genes  encoding  components  of   the  
UPR  pathway  and  downstream  targets  of  UPR  activation  (Table  2.2).  Using  data  from  261  
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ERa+  breast  cancer  patients,  each  assigned   to  a  high-­  or   low-­genomic  UPR  grade,  we  
observed  reduced  time  to  relapse  for  patients  overexpressing  the  UPR  signature  (hazard  
ratio  (HR)  =  5.5,  95%  CI:  3.1-­9.8)  (Figure  2.15A  and  B).  To  evaluate  the  UPR  signature  in  
patients  undergoing  tamoxifen  therapy,  samples  collected  from  474  ERa+  breast  cancer  
patients,  prior  to  starting  5-­years  of  tamoxifen  therapy,  were  assigned  to  low,  medium,  or  
high  UPR  risk  groups.  Increased  prior  expression  of  the  UPR  gene  signature  was  tightly  
correlated   with   subsequent   reduced   time   to   recurrence   (Figure   2.14B   and   D;;   Figure  
2.15C).  Hazard   ratios   increased   from   2.2   to   3.7   for   the  medium  and   high-­risk   groups,  
respectively,   suggesting   that   recurrence   risk   is   sensitive   to   levels   of   the   UPR   gene  
signature  (Figure  2.14B).  The  UPR  index  provides  prognostic  information  beyond  current  
clinical  covariates.  In  a  cohort  of  236  ERa+  breast  cancer  patients,  UPR  overexpression  
was  strongly  predictive  of  reduced  survival  (HR  2.69,  95%  CI:  1.3-­5.6),  over  and  above  
clinical   covariates   alone   (tumor   grade,   node   involvement,   tumor   size   and  ERa   status)  
(Figure  2.14C  and  D;;  Figure  2.15D).  Thus,  the  UPR  index  is  a  powerful  prognostic  gene  




In   contrast   to   the  well-­studied   “reactive  mode”   of   UPR   activation   that   occurs   in  
response  to  endoplasmic  reticulum  stress,   there  are   few  studies  of  UPR  activation   that  
anticipates  the  future  need  for  increased  capacity  to  fold  and  sort  proteins,  and  occurs  in  
the  absence  of  endoplasmic  reticulum  stress  (7).  Anticipatory  UPR  activation  is  observed  
in   B-­cell   differentiation   where   UPR   activation   in   plasma   cells   precedes   the   massive  
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production  and  secretion  of  immunoglobulins  (13,  14).  Because  the  signals  responsible  for  
anticipatory  activation  of  the  UPR  are  largely  unknown,  it  is  poorly  understood.  
In  the  absence  of  cell  stress  or  misfolded  proteins,  the  mitogen,  estrogen,  acting  via  ERa,  
triggers  anticipatory  activation  of  the  UPR  in  breast  and  ovarian  cancer  cells.  In  less  than  
2   minutes,   E2-­ERa   triggers   PLCg-­mediated   opening   of   EnR   IP3R   calcium   channels   and  
release  of  Ca2+  into  the  cytosol.  This  increase  in  cytosol  Ca2+  stimulates  activation  of  all  
three  arms  of  the  UPR  and  is  required  for  E2-­ERa-­stimulated  cell  proliferation.  
Anticipatory   activation   of   the   UPR   by   E2-­ERa   enhances   EnR   protein   folding  
capacity,  and  thereby  primes  cells  to  meet  the  higher  protein  folding  and  sorting  demands  
that  characterize  the  later  growth  phases  of  the  cell  cycle.  The  major  EnR  chaperone  BiP,  
plays  a  central  role  in  EnR  homeostasis,  protein  processing,  and  UPR  signaling.  Since  BiP  
knockdown  stimulates  UPR  activation  and  promotes  EnR  stress-­  induced  apoptosis  (10,  
40),  and  cells  undergoing  E2-­mediated  apoptosis  have  lower  levels  of  chaperones  (41),  
we   assessed   the   consequences   of   abrogating   the   expansion   of   EnR   protein-­folding  
capacity  by  blocking  anticipatory  activation  of   the  UPR.  PLCg,   IP3R  or  ATF6a  knockdown  
blocked  E2-­induction  of  BiP  and  inhibited  E2-­ERa  stimulated   proliferation   of   T47D   cells.  
While  IP3R  knockdown  nearly  abolished  E2-­ERa-­stimulated  Ca2+-­release  from  the  EnR,  
and   this   blocked  UPR  activation,   it   did   not   inhibit   E2-­ERa-­  mediated   gene   expression.  
Thus,  inhibition  of  E2-­ERa-­stimulated  UPR  activation  and  chaperone  induction  is  sufficient  
to   inhibit   E2-­ERa   stimulated   cell   proliferation.  Using   2-­APB  and   ryanodine   together,   or  
chelating   intracellular   calcium   with   BAPTA,   completely   abrogated   the   increase   in  
intracellular   calcium,   and   blocked   E2-­ERa-­regulated   gene   expression.   Based   on   the  
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inhibitor   and  knockdown  data,  we  hypothesize   that   very  small   increases   in   intracellular  
calcium  are  sufficient   to  enable  E2-­ERa-­regulated  gene  expression  and   that  somewhat  
larger   increases   in   intracellular   calcium  are   likely   required   for  E2-­ERa   activation  of   the  
UPR.  E2-­ERa  induces  a  substantial  increase  in  intracellular  calcium,  which  may  promote  
coordination  between  the  nucleus  and  endoplasmic  reticulum,  and  couple  activation  of  the  
E2-­ERa  genomic  program  with  UPR  activation  and  expansion  of  the  EnR  protein-­folding  
capacity.  
We  further  validated  the  importance  of  this  novel  extranuclear  pathway  of  E2-­  ERa  
action  using  MCF-­7  cells  to  assess  how  knockdown  of  each  pathway  component  affects  
E2-­ERa   stimulated   cell   proliferation.   PERK   knockdown   produced   a   20%   in   E2-­   ERa-­
stimulated  cell  proliferation,  and  may  be  required  to  fully  activate  the  ATF6a  arm  of  the  UPR  
(42).  Knockdown  of  the  XBP1  or  ATF6a  produced  a  40%  decline  in  E2-­ERa  stimulated  cell  
proliferation.  IP3R  knockdown  produced  an  even  larger  reduction  in  E2-­  ERa  stimulated  cell  
proliferation,  while  PLCg  knockdown  had  the  largest  effect.  Thus,  anticipatory  activation  of  
the  UPR  plays  an  important  role  in  E2-­ERa  dependent  proliferation  of  cancer  cells.  
As  expected  (1,  3),  IDC  tumor  samples  exhibited  increased  ERa  expression  and  
activation  compared  to  normal  breast  epithelial  tissue.  Consistent  with  a  role  for  the  UPR  
in   this   proliferative   phase   of   early   tumor   development,   increased  UPR  expression   and  
activation   was   observed   in   IDC   tumor   samples.   This   suggests   that   increased   UPR  
expression  occurs  early  in  tumor  development,  long  before  detection,  diagnosis,  and  the  
initiation  of  treatment.  
Activation  of  the  UPR  by  E2-­ERa  exerts  a  long-­term  impact  on  the  pathology  of  ERa  
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positive  breast  cancer.  Weak  activation  of  the  UPR  by  estrogen,  or  by  tunicamcyin,  elicits  
an  adaptive  response  that  protects  cells  from  subsequent  exposure  to  higher  levels  of  cell  
stress.  We  explored  whether   the  effects  of  E2-­ERa  on   the  UPR  correlated  with  clinical  
resistance   to   tamoxifen   therapy.   Increased  UPR  activation   and   elevated   expression   of  
UPR  components  were  predictive  of  a  poor  response  to  tamoxifen-­therapy,  shorter  time  to  
recurrence,   and   decreased   overall   survival.   If   UPR   expression   promotes   resistance   to  
tamoxifen  therapy,  some  UPR  genes  should  exhibit  differential  regulation  in  our  tamoxifen-­
sensitive  MCF-­7   tumors   (24),  compared   to   their   expression   in   the   tamoxifen-­resistance  
gene  signature.  Supporting  this  view,  several  genes  encoding  UPR  components  were  E2-­
downregulated  in  tamoxifen-­sensitive  MCF-­7  tumors,  but  elevated  in  the  human  tumors  
expressing  the  tamoxifen-­resistance  gene  signature  (PERK,  p58IPK).  
For  ERa+  breast  cancers  resistant  to  endocrine  therapies,  an  important  objective  is  
development   of   more   specific   biomarkers   that   predict   therapeutic   response   and  
identification  of  new   therapeutic   targets.  The  UPR   is  a  new  biomarker  and   therapeutic  
target  in  ERa+   breast  cancer;;  validated  through  mechanistic  studies  in  culture,  a  mouse  
xenograft,   and   bioinformatics   analysis   of   patient   tumor   samples.   Anticipatory   estrogen  
activation  of  the  UPR  is  a  novel  extranuclear  action  of  ERa,  a  previously  undescribed  early  
component  of  the  estrogen-­ERa  cell  proliferation  program  and  a  new  paradigm  by  which  
estrogens  may  influence  tumor  development  and  resistance  to  therapy.  
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FIGURES  AND  TABLES  
  
  
Figure  2.1.  Endoplasmic  reticulum  (EnR)  stress  activates  the  three  arms  of  the  UPR.  
(A)  EnR  stress   induces   the  oligomerization,   autophosphorylation,   and  activation  of   the  
transmembrane  endoribonuclease,  IRE1a.  Activated  IRE1a  removes  an  intron  from  full-­
length   XBP1   (fl-­XBP1)   mRNA,   producing   spliced-­XBP1   (sp-­XBP1)   mRNA,   which   is  
subsequently   translated   into   active   sp-­XBP1   protein.   sp-­XBP1   enhances   the   protein-­
folding  capacity  of   the  EnR,   increases   turnover  of  misfolded  proteins  by  inducing  EnR-­
associated  degradation   (ERAD)  genes,   and  alters  mRNA  decay  and   translation   (6,   7).  
ERDJ  and  SERP1  are  commonly  used  readouts  of  IRE1a  activation  (32,  43,  44).  (B)  EnR  
stress  activates  the  transmembrane  protein,  activating  transcription  factor  6  a  (ATF6a).  
Full-­length  ATF6a  (p90-­ATF6a)  translocates  from  the  EnR  to  the  Golgi  Apparatus,  where  
it   is  cleaved  by  site-­1  and  site-­2  proteases,   resulting   in   the   release  of  a  50-­kDa  ATF6a  
(p50-­ATF6a)  fragment  into  the  cytosol.  p50-­ATF6a  enters  the  nucleus  and  induces  several  
UPR  genes  including  BiP,  GRP94,  calreticulin,  and  other  EnR  chaperones  (34).  (C)  EnR  
stress   induces   the   oligomerization,   autophosphorylation,   and   activation   of   the  
transmembrane  kinase  PERK  (6,  7).  P-­PERK  phosphorylates  eukaryotic  initiation  factor  
2a   (eIF2a),   leading   to   general   inhibition   of   protein   synthesis   and   a   reduction   in   the  
endoplasmic   reticulum  protein   folding   load.  However,   increased  eIF2a   phosphorylation  
also   leads  to  preferential   translation  of  certain  mRNA,   including  the  transcription  factor,  
ATF4  (6,  7).  Increased  translation  of  ATF4  induces  the  transcription  factor  CHOP,  which  
induces   GADD34   and   several   pro-­apoptotic   genes.   Inhibition   of   protein   synthesis   is  
normally  reversed  by  inactivating  PERK  and  dephosphorylating  eIF2a.  p58IPK  binds  PERK,  
inhibiting   PERK   activation,   and   GADD34   forms   a   phosphatase   complex   with   protein  
phosphatase  1  (PP1),  which  dephosphorylates    eIF2a  (45-­47).  




Figure  2.2.  E2-­ERa  activates   the   IRE1a   and  ATF6a   arms  of   the  UPR   in  breast  and  
ovarian  cancer  cells,  resulting  in  the  induction  of  the  major  EnR  chaperone,  BiP.  (A)  
qRT-­PCR  comparing  the  effect  of  estrogen  (E2),  ICI  182,780  (ICI)  and  4-­  hydroxytamoxifen  
(4-­OHT)  on  E2-­ERa  induction  of  spliced-­XBP1  (sp-­XBP1)  in  T47D  breast  cancer  cells  (n  =  
3;;  -­E2  set  to  1).  Different  letters  indicate  a  significant  difference  among  groups  (p  <  0.05)  
using  one-­way  ANOVA  followed  by  Tukey’s  post  hoc  test.  (B)  qRT-­PCR  showing  the  effect  
of  E2-­ERa  on  sp-­XBP1  mRNA  in  MCF-­7  breast  and  PEO4  ovarian  cancer  cells  (n  =  3;;  -­E2  
set  to  1).  P-­values  testing  for  significance  between  indicated  group  and  -­E2  group.  (C)  RNAi  
knockdown  of  ERa  abolishes  E2-­induction  of  sp-­XBP1  in  MCF-­7  cells  (n  =  3).  Cells  treated  
with  100  nM  non-­coding  control  (NC)  or  ERa  siRNA  SmartPools  for  3  days,  followed  by  E2  
treatment   for   the   indicated   times   (D)  Western   blot   analysis   showing   full-­length   90   kDa  
ATF6a  (p90-­ATF6a)  and  proteolytically  cleaved  50  kDa  ATF6a  (p50-­ATF6a)  in  E2-­treated  
T47D  breast  cancer  cells.  (E)  RNAi  knockdown  of  ATF6a  blocks  E2-­induction  of  BiP  in  T47D  
cells.  Cells  treated  with  100  nM  non-­coding  control  (NC)  or  ATF6a  siRNA  SmartPool  for  3  
days,  followed  by  E2  treatment  for  4  hours.  (F)  qRT-­PCR  showing  the  effect  of  E2  on  BiP  
mRNA  in  MCF-­7  cells  and  in  PEO4  ovarian  cancer  cells  (n  =  3;;  -­E2  set  to  1).  (G)  Western  
blot  analysis  of  BiP  protein  levels  in  MCF-­7  cells  treated  with  E2.  The  fold-­  change  in  BiP  
protein  levels  is  shown  below  each  lane  and  was  determined  by  quantifying  BiP  and  β-­Actin  
signals,  and  calculating  the  ratio  of  BiP/β-­Actin  (t=0,  [-­E2],  set  to  1).  (H)  RNAi  knockdown  of  
ERa  abolishes  E2-­induction  of  BiP  in  MCF-­7  cells  (n  =  3).  Cells  treated  with  100  nM  non-­
coding  control  (NC)  or  ERa  siRNA  SmartPools  for  3  days,  followed  by  E2  treatment  for  the  
indicated  times.  Concentrations:  E2,  1  nM  (A,  D),  10  nM  (B,  C,  E-­H);;  ICI,  1  μM  (A,  D);;  4-­
OHT,  1  μM  (A).  Data  is  mean  ±  S.E.M.  *  p  <  0.05;;  **  p  <  0.01;;  ***  p  <  0.001.  




Figure  2.3.  E2-­ERa   induces   the  UPR.   (A)  E2-­ERa   stimulates   induction  of   downstream  
transcriptional   targets   of   spliced-­XBP1,   SERP1   and   ERDJ.(32,   43,   44)   The   increase   in  
SERP1  and  ERDJ  mRNA  coincides  with  increased  splicing  of  XBP1  mRNA,  which  together  
indicate  that  E2-­ERa  stimulates  activation  of  the  IRE1a-­arm  of  the  UPR.  -­E2  treatment  set  
to  1.  P-­values   testing   for   significance  between   indicated  group  and   -­E2  group.   (B)  ERa  
knockdown   abolishes   E2-­induction   of   GREB1   (growth   regulated   by   estrogen   in   breast  
cancer  1)  mRNA,  which  is  a  well-­established  transcriptional  target  of  E2-­ER   (38,  48).  (C)  
E2-­ERa  activates  the  ATF6a  arm  of  the  UPR  in  PEO4  ovarian  cancer  cells.  The  increase  in  
the  level  of  p50-­ATF6a  (p50-­ATF6a)  demonstrates  activation  of  the  ATF6a  arm  of  the  UPR.  
Ug-­ATF6a   band   represents   the   unglycosylated   or   underglyosylated   precursor   of   p90-­
ATF6a,  which  has  been  described  previously  (49).  (D)  qRT-­pCR  analysis  of  CHOP  mRNA  
following   treatment   of   MCF-­7   cells   with   E2,   or   the   UPR   activator   tunicamycin   (TUN).  
Concentrations:  E2,  10  nM;;  TUN,  10  μg/mL.  Data  is  mean  ±  SEM.  *  P  <  0.05;;  **  P  <  0.01;;  
***  P  <  0.001;;  ns,  not  significant.  




Figure  2.4.  E2-­ERa  activates  the  PERK  arm  of  the  UPR.  Western  blot  analysis  showing  
(A)  p-­PERK  and  total  PERK  levels  and  (B)  p-­eIF2a  levels  and  total  eIF2a  levels  in  T47D  
cells  treated  with  ICI  182,780  (ICI)  or  a  vehicle  control  for  2  hours,  followed  by  treatment  
with   10   nM   17b-­estradiol   (E2)   (n   =   3).   Numbers   below   each   lane   are   the   ratio   of   p-­
PERK/PERK   or   p-­eIF2a/eIF2a   normalized   to   the   vehicle-­treated   control.   (C)   Protein  
synthesis   in  ERa+  T47D  breast   cancer   cells   treated  with   ICI   182,780   (ICI)   or   a   vehicle  
control  for  2  hours,  followed  by  treatment  with  10  nM  17b-­estradiol  (E2)  (n  =  3).  P-­values  
testing  for  significance  between  indicated  groups  and  -­E2  samples.  (D)  PERK  knockdown  
inhibits  downstream  phosphorylation  of  eIF2a  in  T47D  cells.  (E)  Western  blot  analysis  of  
ATF4  following  treatment  of  T47D  cells  with  E2,  or  the  UPR  activator  tunicamycin  (TUN).  
(F)  qRT-­pCR  analysis  of  CHOP  mRNA  following  treatment  of  T47D  cells  with  E2.  Brackets  
denote  pre-­treatment  with  ICI  for  2  hours.  Concentrations:  E2,  1  nM  (A-­F);;  ICI,  1  μM  (A,  B,  





Figure   2.5.   Estrogen   stimulates   the   release   of   calcium   from   the   endoplasmic  
reticulum,  and  this  calcium  release  is  necessary  for  UPR  activation.  (A)  Effects  of  
300  nM  estrogen  (E2)  on  cytosolic  calcium  levels  in  T47D  breast  cancer  cells  conditioned  
in  the  presence  (2  mM  CaCl2)  or  absence  (0  mM  CaCl2)  of  extracellular  calcium,  or  cells  
pre-­treated  with  2-­APB  or  ryanodine  (Ry)  for  30  minutes  in  the  absence  of  extracellular  
calcium  (0  mM  CaCl2).  Visualization  of   intracellular  Ca2+  using  Fluo-­4  AM.  Colors   from  
basal   Ca2+   to   highest   Ca2+:   Blue,   green,   red,   white.   (B)   Graph   depicts   quantitation  of  
cytosolic  calcium  levels  in  ERa+  T47D  breast  cancer  cells  treated  with  E2  in  the  presence  
or  absence  of  extracellular  calcium,  and  in  cells  pre-­treated  with  2-­APB  or  ryanodine  (Ry)  
in   the   absence   of   extracellular   calcium   (n   =   10   cells).   E2   was   added   at   60   sec,   and  
fluorescence  intensity  prior  to  60  sec  was  set  to  1.  (C)  Western  blot  analysis  of  IP3R  and  
BiP  protein  levels  following  treatment  of  T47D  cells  with  either  100  nM  non-­coding  (NC)  
siRNA  or  a  IP3R  SmartPool,  followed  by  treatment  with  E2  (+E2)  or  ethanol-­vehicle  (-­E2)  
for  4  hours.  IP3R  smartpool  contained  33  nM  siRNA  directed  against  each  isoform  of  IP3R  
Ca2+-­channel.   (D)   Quantitation   of   cytosolic   Ca2+   levels   in   response   to   E2,   following  
treatment  of  T47D  cells  with  100  nM  non-­coding  (NC)  siRNA  or  IP3R  siRNA  SmartPools  
for  3  days  (n  =  10  cells)  (E)  Western  blot  analysis  of  PLCg,  BiP,  and  ATF6a  protein  levels  
after   treatment   of   T47D   cells   with   100   nM   non-­coding   (NC)   siRNA   or   PLCg    siRNA  
SmartPool,  followed  by  treatment  with  E2  (+E2)  or  ethanol-­  vehicle  (-­E2)  for  4  hours.  (F)  
Quantitation  of  cytosolic  Ca2+  levels  in  response  to  E2,  following  treatment  of  T47D  cells  
with  100  nM  non-­coding  (NC)  siRNA  or  PLCg  siRNA  SmartPool  for  3  days.  (G)  Western  blot  
analysis  of  ERa  protein  levels  after  treating  T47D  cells  with  either  100  nM  non-­coding  (NC)  
siRNA  or  ERa  siRNA  SmartPool,  followed  by  treatment  with  E2  (+E2)  or  ethanol-­vehicle  (-­
E2)  for  4  hours.  (H)  Visualization  and  quantitation  of  cytosolic  Ca2+  levels  in  response  to  
E2  after  ERa  knockdown  in  T47D  cells.  Concentrations:  E2,  300  nM  (A,  B,  D,  F,  H),  1  nM  
(C,  E,  G);;  2-­  APB,  200  µM  (A,  B);;  ryanodine,  200  µM  (A,  B).  Graphical  data  is  mean  ±  SE  
(n  =  10)).  I  designed  and  performed  research  experiments,  and  analyzed  data  for  the  




Figure  2.6.  Estrogen   increases   intracellular  calcium   levels   in  ERa+  PEO4  ovarian  
cancer  cells.  Effect  of  300  nM  E2  on  intracellular  calcium  levels  in  ERa+  PEO4  ovarian  
cells.  Cells  visualized  with  the  Ca2+  sensitive  dye  Fluor-­4.  Low  levels  of  basal  [Ca2+]  are  
blue  and  then  green,  whereas  higher   levels  of  [Ca2+]  are  seen  as  red,  with  the  highest  
levels  white.  The  trace  represents  relative  signal  intensity  averaged  from  10  cells.  E2  was  
added  at  60  sec,  and  fluorescence  intensity  prior  to  60  sec  was  set  to  1.  Data  is  mean  ±  
S.E.  ).  I  designed  and  performed  research  experiments,  and  analyzed  data  for  the  
entire  figure.  




Figure   2.7.   Blocking   Ca2+-­release   from   the   EnR   through   the   IP3R   Ca2+   channel  
prevents  estrogen-­dependent  activation  of  the  IRE1a  and  PERK  arms  of  the  UPR.  
(A)   Pre-­blocking   the   IP3R   Ca2+-­channel   with   2-­APB   prevents   estrogen-­dependent  
activation  of  the  PERK  arm  of  the  UPR  in  T47D  cells.  Western  blot  analysis  showing  p-­  
eIF2a  and  total  eIF2a  levels  in  T47D  breast  cancer  cells  pre-­treated  for  30  minutes  with  2-­
APB   and/or   ryanodine   (Ry)   or   a   vehicle   control,   followed   by   treatment   with   E2   for   30  
minutes.  Numbers  below  each  lane  are  the  ratio  of  p-­eIF2a/eIF2a  with  the  vehicle-­  treated  
control  set  at  100.  (B)  IP3R  knockdown  abolishes  E2-­induction  of  sp-­XBP1  mRNA  in  T47D  
cells.  Cells  were   treated  with  non-­coding  control   (NC)  or   IP3R  siRNA  SmartPools   for  3  
days,   followed   by   E2   treatment   for   4   hours.   Data   is   mean   ±   SEM.   Letters   indicate   a  
significant  difference  among  groups  (p  <  0.05)  using  one-­way  ANOVA  followed  by  Tukey’s  
post  hoc  test.  Concentrations:  E2,  10  nM;;  2-­APB,  200  µM;;  Ryanodine,  200  µM.  




Figure   2.8.   Treatment   of   T47D   cells   with   the   PLCg   inhibitor,   U73122,   blocks   E2-­  
stimulated   calcium   release.  Graph   depicts   quantitation   of   cytosolic   calcium   levels   in  
ERa+  T47D  breast  cancer  cells  pre-­treated  with  DMSO  vehicle  or  U73122,   followed  by  
treatment  with  300  nM  E2  in   the  absence  of  extracellular  calcium  (n  =  10  cells).  E2  was  
added  at  60  sec,  and  fluorescence  intensity  prior  to  60  sec  was  set  to  1.  Data  is  mean  ±  
S.E.   ).   I  designed  and  performed   research  experiment,  and  analyzed  data   for   the  
figure.  




Figure   2.9.   E2-­ERa   induced   calcium   release   from   the   EnR   into   the   cytosol   is  
important   for   E2-­ERa   mediated   gene   expression   and   E2-­ERa   stimulated   cell  
proliferation.  (A)  E2-­ERa  stimulated  proliferation  of  T47D  breast  cancer  cells  treated  100  
nM  non-­coding  (NC),  PLCg,  IP3R,  or  ATF6a  siRNA  SmartPools  (n  =  6).  (B)  E2-­ERa  stimulated  
proliferation   of   T47D   breast   cancer   cells   treated   with   ryanodine   (Ry),   2-­APB,   or   both  
inhibitors   (Ry   +   2-­APB)   for   4   days   (n   =   5).   (C)   qRT-­PCR   analysis   of   effects   of   IP3R  
knockdown  on  E2-­ERa   induction  of  GREB1  mRNA   in  T47D  cells   (n  =  3).  Western  blot  
shows  ERa  protein  levels  after  treatment  of  T47D  cells  with  100  nM  non-­coding  (NC)  siRNA  
or  IP3R  siRNA,  followed  by  treatment  with  E2  (+E2)  or  ethanol-­vehicle  (-­E2)  for  4  hours.  (D)  
ERE-­luciferase   activity   in   kBluc-­T47D   breast   cancer   cells   treated   with   E2   and   either  
ryanodine  (Ry),  2-­APB,  or  both  inhibitors  for  24-­hours  (Ry  +  2-­APB)  (n  =  4).  (E)  E2-­ERa  
stimulated  proliferation  of  MCF-­7  breast  cancer  cells   treated  100  nM  non-­  coding   (NC),  
PLCg,   IP3R,   ATF6a,   XBP1,   or   PERK   siRNA   (n   =   6).   (F)   qRT-­PCR   analysis   of   effects  of  
ryanodine  (Ry),  2-­APB,  or  both  inhibitors  (Ry  +  2-­APB)  on  E2-­ERa  induction  of  pS2  mRNA  
in  MCF-­7  cells  (n  =  3).  (G)  Model  of  E2-­ERa  acting  through  the  UPR  to  influence  breast  
tumorigenesis.  “•”  denotes  cell  number  at  day  0.  Concentrations:  E2,  100  pM  (A-­F);;  2-­APB,  
200  µM  (B,  D,  F);;  Ryanodine,  100  µM  (B,  D,  F).  Data   is  mean  ±  SEM.  Different   letters  
indicate  a  significant  difference  among  groups  (p  <  0.05)  using  one-­way  ANOVA  followed  
by  Tukey’s  post  hoc  test.  ns,  not  significant  (p  >  0.05).  




Figure   2.10.   E2-­ERa   induced   calcium   release   from   the   EnR   into   the   cytosol   is  
important   for   E2-­ERa   mediated   gene   expression   and   E2-­ERa   stimulated   cell  
proliferation.   (A)   Effects   of   the   intracellular   calcium   chelator   BAPTA-­AM   on   E2-­ERa  
stimulated  cell  proliferation  (n  =  5).  MCF-­7  cells  were  treated  with  10  µM  BAPTA-­AM  for  3  
days.   (B)  qRT-­PCR  analysis  of   effects  of   IP3R  knockdown  on  E2-­ERa   induction  of  pS2  
mRNA  in  T47D  cells  (n  =  3).  (C)  E2-­ERa  stimulated  proliferation  of  MCF-­7  breast  cancer  
cells  treated  with  ryanodine  (Ry),  2-­APB,  or  both  inhibitors  (Ry  +  2-­APB)  for  4  days  (n  =  5).  
(D)  qRT-­PCR  analysis  of  effects  of  ryanodine  (Ry),  2-­APB,  or  both  inhibitors  (Ry  +  2-­  APB)  
on   E2-­ERa   induction   of   GREB1  mRNA   in  MCF-­7   cells   (n   =   3).   (E)   E2-­ERa   stimulated  
proliferation   of   BG-­1   ovarian   cancer   cells   treated   with   ryanodine   (Ry),   2-­APB,   or   both  
inhibitors  (Ry  +  2-­APB)  for  4  days  (n  =  5).  “•”  denotes  cell  number  at  day  0.  Data  is  mean  
±  SEM.  Letters   indicate  a  significant  difference  among  groups  (p  <  0.05)  using  one-­way  
ANOVA  followed  by  Tukey’s  post  hoc  test.  *  P  <  0.05;;  **  P  <  0.01;;  ***  P  <  0.001;;  ns,  not  
significant.  Concentrations:  E2,  100  pM;;  2-­APB,  200  µM;;  Ryanodine,  200  µM.  
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Figure  2.11.  Western  blot  analysis  of  UPR  proteins  following  siRNA  knockdown  in  
MCF-­7  cells.  Western  blot  analysis  of  (A)  PLCg,  (B)  pan-­IP3R,  (C)  ATF6a,  (D)  XBP1,  and  (E)  
PERK  protein   levels   following   treatment  of  MCF-­7  cells  with  either  100  nM  non-­  coding  
SmartPool  siRNA  or  100  nM  SmartPool  siRNA  directed  against  the  protein  of  interest.  The  
IP3R  SmartPool  consisted  of  three  individual  siRNAs  SmartPools  targeting  each  isoform  of  
the  IP3R  Ca2+-­channel  (ITPR1,  ITPR2,  ITPR3).  




Figure   2.12.   E2-­ERa   activity   and  UPR  activity   are   correlated   in   vivo.   (A)   qRT-­PCR  
analysis  of  levels  of  mRNAs  for  each  arm  of  the  UPR  after  treatment  of  MCF-­7  cells  with  
10   nM  E2   for   the   indication   times   (n   =   3).   (B)  MCF-­7   tumor   growth   in   the   presence   or  
absence  of  estrogen  in  athymic  mice.  All  mice  were  treated  with  estrogen  to  induce  tumor  
formation.  On  “Day  0”,  E2  in  silastic  tubes  was  replaced  with  silastic  tubes  containing  only  
cholesterol  in  the  –E2  group  (n  =  15),  while  silastic  tubes  were  retained  in  the  +E2  treatment  
group  (n  =  15).  qRT-­PCR  analysis  of   (C)  classical  E2-­ERa   regulated  genes  and  (D)   the  
UPR  in  mouse  tumors  collected  after  24  days  of  exposure  to  estrogen  (+E2)  or  vehicle-­
control  (-­E2)  (n  =  15).  Relative  mRNA  levels  of  (E)  classical  E2-­ERa  regulated  genes  and  
(F)  the  UPR  pathway  in  patient  samples  of  normal  breast  epithelium  taken  from  patients  
undergoing  reduction  mammoplasty  (RM)  (n  =  18),   istologically  normal  breast  epithelium  
taken  from  patients  diagnosed  with  invasive  ductal  carcinoma  (IDC)  (n  =  9),  and  carcinoma  
epithelium  taken  from  IDC  patients  (n  =  20).  p-­values  represent  comparisons  to  –E2  groups  
(A,   C,   D)   or   to   histologically   normal   breast   epithelium   from   patients   who   underwent  
reduction  mammoplasty  (e,  f).  Data  is  mean  ±  SEM.  *  P  <  0.05;;  **  P  <  0.01;;  ***P  <  0.001;;  
ns,  not  significant.  




Figure  2.13  The  UPR  Activator,  tunicamycin,  induces  BiP.  Time  course  analysis  of  BiP  
protein  levels  following  tunicamycin  (TUN)  treatment.  Densiometric  analysis  performed  by  
normalizing  BiP  protein  levels  to  Actin.  




Figure   2.14.   Anticipatory   activation   of   the   UPR   by   estrogen   protects   cells   from  
subsequent  cell  stress,  and  expression  of  the  UPR  gene  signature  predicts  relapse-­
free  and  overall  survival  in  ERa  positive  breast  tumor  cohorts.  (A)  Weak  anticipatory  
activation  of   the  UPR  with  estrogen  or   tunicamycin  protects  cells   from  subsequent  UPR  
stress.  T47D  cells  were  maintained  in  10%  CD-­FBS  for  8  days  and  treated  with  either  250  
ng/ml  tunicamycin  (TUN),  100  pM  E2,  or  ethanol/DMSO-­vehicle  (Untreated).  E2,  TUN,  or  
the  vehicle  control  were  removed  from  medium,  and  cells  were  harvested  in  10%  CD-­calf  
serum  and  treated  with  the  indicated  concentrations  of  tunicamycin.  Data  is  mean  ±  SEM  
(n  =  6).  Different  letters  indicate  a  significant  difference  among  groups  (p  <  0.05)  using  one-­
way  ANOVA  followed  by  Fisher’s  LSD  post  hoc  test.  (B)  Relapse-­free  survival  as  a  function  
of  the  UPR  gene  signature  for  patients  with  ERa+  breast  cancer  who  subsequently  received  
tamoxifen   alone   for   5   years.   Interquartile   range   used   to   assign   tumors   to   risk   groups,  
representing  UPR  activity  from  high  to  low.  Hazard  ratios  are  between  low  and  medium  and  
low  and  high  UPR  groups  (n  =  474).  (C)  Overall  survival  as  a  function  of  the  UPR  signature  
and  clinical  covariates  (node  status,  tumor  grade,  ERa-­status,  tumor  size).  p-­value  is  testing  
for  significance  between  the  combined  model  (UPR  gene  signature  and  clinical  covariates)  
versus   the   covariates   only   model   (multivariate   analysis)   (n   =   236).   (D)   Univariate   and  
multivariate  Cox  regression  analysis  of  the  UPR  signature,  clinical  covariates,  and  classical  
estrogen-­induced  genes  for  time  to  recurrence  and  survival  (n.s.,  not  significant).  Median  
used  to  classify  tumors  into  high  and  low  risk  groups.  
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Figure  2.15.  The  UPR  genomic  index  is  a  new  biomarker  that  predicts  relapse  free  
and  overall  survival  of  breast  cancer  patients.   (A)  Relapse   rate  of  261  ERa  positive  
breast  tumors,  classified  by  expression  levels  of  the  UPR  gene  signature,  plotted  by  the  
Kaplan-­Meier  method.  Tumor  samples  were  analyzed  on  both,  U133A  and  U133B  gene  
chips.  The  table  below  denotes  univariate  and  multivariate  Cox  regression  hazard  ratios  
and  p-­values  for  the  UPR  gene  signature  and  other  clinical  covariates  (tumor  grade,  tumor  
size,  node  status).  (B)  UPR  genes  independently  predictive  of  relapse  (p  <  0.05)  in  gene  
expression   profiles   obtained   from   277  ERa+  positive   breast   cancers   (27).  Kaplan-­Meier  
plots  and  Cox  regression  hazard  analysis  for  this  tumor  cohort  is  displayed  in  Figure  15A.  
(C)  UPR  genes   independently  predictive  of   relapse   in  474  gene  expression  microarrays  
taken  from  ERa-­positive  breast  cancer  patients  prior  to  the  initiation  of  tamoxifen-­therapy  
(27,  28).  Kaplan-­Meier  analysis  and  Cox  regression  hazard  analysis  for  this  tumor  cohort  
are  displayed  in  Figure  2.14B  and  Figure  2.14D,  respectively.  (D)  UPR  genes  predictive  of  
survival  in  236  gene  expression  microarrays  from  breast  cancer  patients  (29).  All  Kaplan-­
Meier   plots   assessing   UPR   risk   prediction   were   computed   using   leave-­one-­   out   cross-­
validation.   UPR   signature   genes   shown   in   the   tables   are   listed   with   their   respective  
univariate  Cox  hazard  ratio  and  p-­value  test  the  hypothesis  if  expression  data  is  predictive  
of  relapse  or  overall  survival.  
  











Table  2.1.  Expression  of  UPR  genes  is  positively  correlated  with  expression  of  ERa  
and  ERa-­regulated  target-­genes.  Correlations  between  the  UPR  and  ERa  protein  levels  
(ERa),  ERa  mRNA  levels  (ESR1),  or  transcriptional  activity  of  E2-­ERa.  E2-­ERa  transcriptional  
activity  was  assessed  using  downstream  target  genes  of  E2-­ERa   (pS2,   GREB1)   (38,   48,   50).  
Analysis  carried  out  on  a  cohort  of  278  breast  cancer  patients  (GSE20194)  (26),  which  consisted  
of  164  ERa  positive  tumors  and  114  ERa  negative  tumors.  Quantitation  of  ERa  protein  was  by  
IHC.   Pearson   correlation   coefficients   and   parametric   p-­values   are   shown   in   the   table.   “n.s.”  
indicates  that  no  significant  correlation  was  observed.  While  expression  of  UPR  genes  is  correlated  
with  ERa  levels  and  expression  of  ERa-­regulated  genes,  the  UPR  index  is  not  simply  a  surrogate  
marker  for  ERa  activity.  In  multivariate  analysis,  the  UPR  index,  but  not  ERa,   or   classical   ERa-­
regulated  genes,  exhibits  a  statistically  significant  increase  in  hazard  ratio  (Figure  14D).  Also,  UPR  
index  exhibits  predictive  power  to  stratify  patients  into  high  and  low  risk  groups  above  ERa  status  
(Figure  14C).  Thus,  while  active  ERa  is  important  for  expression  of  the  UPR  signature,  it’s  the  UPR  
signature  not  ERa   level  or  activity  that   is  predictive  of   reduced   time   to   recurrence  and   reduced  
survival.  
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Table  2.2.  UPR  gene  signature.  The  table  shows  the  genes  used  to  construct  the  UPR  
gene  signature.  HUGO  Gene  Nomenclature  Committee   (HGNC)  approved  names   for  
each   gene   are   shown   in   parenthesis.   UPR   genes   independently   predictive   either   of  
relapse  free  or  overall  survival  (p  <  0.05)  were  used  to  construct  the  UPR  gene  signature,  
which  was  then  used  to  carry  out  risk  prediction  analysis.  
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CHAPTER  3    
AN  ESTROGEN  RECEPTOR  a  INHIBITOR  ACTIVATES  THE  UNFOLDED  PROTEIN  




Recurrent  estrogen  receptor  a  (ERa)  positive  breast  and  ovarian  cancers  are  often  
therapy-­resistant.  Using  screening  and  functional  validation,  we  identified  BHPI,  a  potent  
non-­competitive  small  molecule  ERa  biomodulator  that  selectively  blocks  proliferation  of  
drug-­resistant  ERa  positive  breast  and  ovarian  cancer  cells.  In  a  mouse  xenograft  model  
of   breast   cancer,   BHPI   induced   rapid   and   substantial   tumor   regression.   While   BHPI  
potently   inhibits   nuclear   estrogen-­ERa-­regulated   gene   expression,   BHPI   is   effective  
because  it  elicits  sustained  ERa-­dependent  activation  of  the  endoplasmic  reticulum  (EnR)  
stress  sensor,  the  unfolded  protein  response  (UPR)  and  persistent   inhibition  of  protein  
synthesis.  BHPI  distorts  a  newly  described  action  of  estrogen-­ERa,  mild  and   transient  
UPR   activation.   In   contrast,   BHPI   elicits   massive   and   sustained   UPR   activation,  
converting   the   UPR   from   protective   to   toxic.   In   ERa+   cancer   cells,   BHPI   rapidly  
hyperactivates  plasma  membrane  PLCg,  generating  IP3,  which  opens  EnR  IP3R  calcium  
channels,  rapidly  depleting  EnR  Ca2+  stores.  This  leads  to  activation  of  all  three  arms  of  
the  UPR.  Activation  of  the  PERK  arm,  stimulates  phosphorylation  of  eukaryotic  initiation  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2  This  chapter  appeared  in  its  entirety  in  the  Proceedings  of  the  National  Academy  of  Sciences.  Neal  D  
Andruska,  Xiaobin  Zheng,  Xujuan  Yang,  Chengjian  Mao,  Mathew  M  Cherian,  Lily  Mahapatra,  William  G  
Helferich,  David  J  Shapiro.  (2015)  Estrogen  receptor  α  inhibitor  activates  the  unfolded  protein  response,  
blocks  protein  synthesis,  and  induces  tumor  regression.  PNAS.  DOI:  10.1073/pnas.1403685112.  My  
contributions  to  the  research  are  denoted  under  the  figure  legends.    
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factor  2a  (eIF2a),  resulting  in  rapid   inhibition  of  protein  synthesis.  The  cell  attempts  to  
restore   EnR   Ca2+   levels,   but   the   open   EnR   IP3R   calcium   channel   leads   to   an   ATP-­
depleting   futile   cycle,   resulting   in   activation   of   the   energy   sensor   AMPK   and  
phosphorylation  of  eukaryotic  elongation  factor  2  (eEF2).  eEF2  phosphorylation  inhibits  
protein   synthesis   at   a   second   site.   BHPI’s   novel   mode   of   action,   high   potency,   and  
effectiveness  in  therapy-­resistant  tumor  cells,  make  it  an  exceptional  candidate  for  further  
mechanistic  and  therapeutic  exploration.  
  
SIGNIFICANCE  
Late-­stage  estrogen  receptor  a  (ERa)-­positive  breast  and  ovarian  cancers  exhibit  
many  regulatory  alterations  and  therefore  resist  therapy.  Our  novel  ERa  inhibitor,  BHPI,  
stops   growth   and   often   kills   drug-­resistant   ERa+   cancer   cells   and   induces   rapid   and  
substantial  tumor  regression  in  a  mouse  model  of  human  breast  cancer.  BHPI  distorts  a  
normally  protective  estrogen-­ERa-­mediated  activation  of  the  unfolded  protein  response  
(UPR)  and  elicits  sustained  UPR  activation.  The  UPR  cannot  be  deactivated  because  
BHPI,  acting  at  a  second  site,  inhibits  production  of  proteins  that  normally  help  turn  it  off.  
This  persistent  activation  converts  the  UPR  from  protective  to  lethal.  Targeting  therapy-­
resistant  ERa  positive  cancer  cells  by  converting  the  UPR  from  cytoprotective  to  cytotoxic  
may  hold  significant  therapeutic  promise.  
  
INTRODUCTION  
Estrogens,   acting   via   estrogen   receptor  a   (ERa),   stimulate   tumor  growth   (1-­3).  
Approximately  70%  of  breast  cancers  are  ERa  positive  and  most  deaths  due  to  breast  
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cancer   are   in   patients   with   ERa+   tumors   (2,   4).   Endocrine   therapy   using   aromatase  
inhibitors  to  block  estrogen  production,  or  tamoxifen  and  other  competitor  antiestrogens,  
often  results  in  selection  and  outgrowth  of  resistant  tumors.    Although  30-­70%  of  epithelial  
ovarian  tumors  are  ERa  positive  (1),  endocrine  therapy  is  largely  ineffective  (5-­7).  After  
several  cycles  of  chemotherapy,  tumors  recur  as  resistant  ovarian  cancer  (5),  and  most  
patients  die  within  5  years  (8).  
Non-­competitive  ERa   inhibitors   targeting   this   unmet   therapeutic   need   including  
DIBA,  TPBM,  TPSF,  and  LRH-­1  inhibitors  that  reduce  ERa  levels,  show  limited  specificity,  
require  high  concentrations  (>5  µM)  and  usually  have  not  advanced  through  preclinical  
development  (9-­12).  These  non-­competitive  ERa  inhibitors  and  competitor  antiestrogens  
are  primarily  cytostatic  and  act  by  preventing  estrogen-­ERa  action;;   therefore,   they  are  
largely  ineffective  in  therapy-­resistant  ERa  containing  cancer  cells  that  no  longer  require  
estrogens  and  ERa  for  growth.  
To  target  the  estrogen-­ERa  axis  in  therapy-­resistant  cancer  cells,  we  developed  
(13)   and   implemented   an   unbiased   pathway-­directed   screen   of   ~150,000   small  
molecules.  We  identified  ~2,000  small  molecule  biomodulators  of  17b-­estradiol  (E2)-­ERa  
induced  gene  expression,  evaluated  these  biomodulators  for  inhibition  of  E2-­ERa-­induced  
cell  proliferation  and  performed  simple  follow-­on  assays  to  identify  inhibitors  with  a  novel  
mode   of   action.   Here,   we   describe   BHPI,   our   most   promising   small   molecule   ERa  
biomodulator.  
In  response  to  stress  cancer  cells  often  activate  the  endoplasmic  reticulum  (EnR)  
stress   sensor,   the   unfolded   protein   response   (UPR).  We   recently   showed   that   as   an  
essential  component  of   the  E2-­ERa  proliferation  program,  estrogen   induces  a  different  
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mode  of  UPR  activation,  a  weak  anticipatory  activation  of   the  UPR  prior   to   increased  
protein  folding  loads  that  accompany  cell  proliferation.  This  weak  and  transient  E2-­ERa-­
mediated  UPR  activation  is  protective  (14).  BHPI  distorts  this  normal  action  of  E2-­ERa  
and  induces  a  massive  and  sustained  ERa-­dependent  activation  of  the  UPR,  converting  
UPR  activation  from  cytoprotective  to  cytotoxic.  Moreover,   independent  of   its  effect  on  




BHPI  IS  EFFECTIVE  IN  DRUG-­RESISTANT  ERa+  BREAST  AND  OVARIAN  CANCER  
CELLS.    
We   investigated  BHPI’s  effect  on  proliferation   in   therapy-­sensitive  and   therapy-­
resistant  cancer  cells.  BHPI  (Figure  3.1A  and  B)  completely  inhibited  proliferation  of  ERa+  
breast  (Figure  3.2  A,  E,  F  and  G),  endometrial  (Figure  3.2C)  and  ovarian  (Figure  3.2B,  H,  
and  I)  cancer  cells,  and  had  no  effect  in  counterpart  ERa-­  cell  lines  (Figure  3.2D).  At  100-­
1,000  nM,  BHPI  completely  blocked  proliferation  in  diverse  drug-­resistant  cell  lines:    4-­
hydroxytamoxifen  (4-­OHT)-­resistant  ZR-­75-­1  breast  cancer  cells  (Figure  3.2E);;  tamoxifen  
and   fulvestrant/ICI   182,780   (ICI)-­resistant   BT-­474   cells   (Figure   3.2F)   (15);;   epidermal  
growth  factor  (EGF)  stimulated  T47D  breast  cancer  cells,  which  are  resistant  to  4-­OHT,  
ICI  and  raloxifene  (RAL)  (Figure  3.2G);;    Caov-­3  ovarian  cancer  cells,  which  are  resistant  
to  4-­OHT,  ICI  and  cisplatin  (Figure  3.2H)  (16),  and  multidrug  resistant  OVCAR-­3  ovarian  
cancer  cells,  which  are  resistant  to  5  µM  ICI  (Figure  3.2I)  and  to  paclitaxel,  cisplatin  and  
other  anticancer  drugs  (17,  18).  BHPI  blocked  proliferation  in  all  15  ERa+  cell  lines  and  at  
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10   µM   had   no   effect   on   proliferation   in   all   12   ERa-­   cell   lines   tested   (Figure   3.3).  
Furthermore,  BHPI  blocked  anchorage-­independent  growth  of  MCF-­7  cells  in  soft  agar  
(Figure  3.4).  
  
BHPI  INDUCES  TUMOR  REGRESSION.  
We  next  evaluated  BHPI   in  a  mouse  xenograft  model  using  MCF-­7  cell   tumors  
(19).   For   each   tumor,   cross-­sectional   area   at  Day   0   (~45  mm2)   is   set   to   0%.  Control  
(vehicle  injected)  and  BHPI  treated  mice  were  continuously  exposed  to  estrogen.  After  
daily  IP  injections  for  10  days,  the  tumors  in  the  vehicle  treated  mice  exhibited  continued  
robust   growth   (Figure   3.5,   red   bars).   While   BHPI   at   1   mg/kg   every   other   day   was  
ineffective   (Figure   3.6A),   initiation   of   15  mg/kg   daily   BHPI   treatment   resulted   in   rapid  
regression  of  48/52   tumors   (Figure  3.5,  blue  bars).  BHPI  easily  exceeded   the  goal  of  
>60%   tumor  growth   inhibition  proposed  as  a  benchmark  more   likely   to   lead   to  clinical  
response  (20).  Furthermore,  BHPI,  at  10  mg/kg  every  other  day,  ultimately  stopped  tumor  
growth  and  final  tumor  weight  was  reduced  ~60%  compared  to  controls  (Figure  3.6A  and  
B).  BHPI  was  well  tolerated;;  BHPI-­treated  and  control  mice  exhibited  similar  food  intake  
and  weight  gain  (Figure  3.6C  and  D).  
  
BHPI  IS  AN  ERa-­DEPENDENT  INHIBITOR  OF  PROTEIN  SYNTHESIS.  
Surprisingly,  BHPI  greatly  reduced  protein  synthesis  in  ERa+  cancer  cells  (Figure  
3.7A  and  Figure  3.8).  If  BHPI  inhibits  protein  synthesis  through  ERa,  it  should  only  work  
in  ERa+  cells,  and  ERa  overexpression  should  increase  its  effectiveness.  BHPI  inhibited  
protein  synthesis   in  all  14  ERa+  cell   lines,  with  no  effect  on  protein  synthesis   in  all  12  
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ERa-­   cell   lines   (Figure   3.7A   and   Figure   3.8A   and   B).   BHPI   does   not   inhibit   protein  
synthesis  in  ERa  negative  MCF-­10A  breast  cells,  but  gains  the  ability  to  inhibit  protein  
synthesis  when  ERa   is  stably  expressed   in   isogenic  MCF10AER   In9   cells   (Figure  3.7B)  
(21).  Notably,  BHPI  loses  the  ability  to  inhibit  protein  synthesis  when  ERa  in  the  stably  
transfected   cells   is   knocked   down   with   siRNA   (Figure   3.7C   and   Figure   3.9A),   or   is  
degraded  by  ICI  (Figure  3.7D).  Furthermore,  increasing  the  ERa  level  in  MCF7ERaHA  
cells   (22),   stably   transfected   to   express   doxycycline-­inducible   ERa,   progressively  
increased   BHPI   inhibition   of   protein   synthesis   (Figure   3.7E).  BHPI   does   not   work   by  
activating  the  estrogen  binding  protein  GPR30.  BHPI  has  no  effect  on  cell  proliferation  
(Figure   3.3)   or   protein   synthesis   (Figure   3.8A)   in   HepG2   cells   that   contain   functional  
GPR30  (23)  and  activating  GPR30  with  G1,  did  not  inhibit  protein  synthesis  (Figure  3.9B  
and  C).  Thus,  ERa  is  necessary  and  sufficient  for  BHPI  to  inhibit  protein  synthesis.  
  
BHPI  RAPIDLY   INHIBITS  PROTEIN  SYNTHESIS  BY  A  PLCg-­MEDIATED  OPENING  
OF   THE   INOSITOL   TRIPHOSPHATE   RECEPTOR   (IP3R)   CA2+   CHANNEL,  
ACTIVATING  THE  PERK  ARM  OF  THE  UPR.    
Inhibiting  mechanistic  target  of  rapamycin  (mTOR)  signaling  did  not  strongly  inhibit  
protein  synthesis  (Figure  3.9D),  suggesting  BHPI  is  unlikely  to  work  through  mTOR.  We  
next  investigated  whether  initial  inhibition  of  protein  synthesis  by  BHPI  is  due  to  activation  
of  the  UPR.  There  are  three  UPR  arms.  The  transmembrane  kinase  PERK  is  activated  
by  autophosphorylation.  P-­PERK  phosphorylates  eukaryotic  initiation  factor  2a  (eIF2a),  
inhibiting  translation  of  most  mRNAs  (Figure  3.10A)  (24,  25).  The  other  arms  of  the  UPR  
initiate  with  ATF6a  activation  (Figure  3.10B),  leading  to  increased  protein  folding  capacity  
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and  activation  of  IRE1a,  which  alternatively  splices  XBP1,  producing  active  spliced  (sp)-­
XBP1  (Figure  3.10C)  (24,  25).  In  ERa+  MCF-­7  and  T47D  cells,  but  not  in  ERa-­  MDA-­MB-­
231  cells,  BHPI  rapidly  inhibited  protein  synthesis  (Figure  3.11A)  and  in  parallel  increased  
eIF2a  phosphorylation  (Figure  3.7F  and  Figure  3.11B  and  C).  Downstream  readouts  of  
eIF2a   phosphorylation,   CHOP   and   GADD34   mRNAs,   were   rapidly   induced   by   BHPI  
(Figure  3.11D  and  E).  Consistent  with  BHPI  inhibiting  protein  synthesis  through  eIF2a-­
Ser51  phosphorylation,  transfecting  cells  with  a  dominant-­negative  eIF2a-­S51A  mutant  
largely   prevented   BHPI   from   inhibiting   protein   synthesis   (Figure   3.11F).   We   next  
evaluated   whether   increases   in   eIF2a   phosphorylation   and   rapid   inhibition   of   protein  
synthesis   occur   through  activation  of  PERK.   p-­PERK  was   increased  30  minutes  after  
BHPI   treatment   (Figure   3.7F   and   Figure   3.11G),   and   pre-­treating   cells   with   a   PERK  
inhibitor  (PERKi)  abolished  rapid  BHPI  inhibition  of  protein  synthesis  (Figure  3.12A).  RNAi  
knockdown  of  PERK  abolished  BHPI   inhibition  of  protein  synthesis  at  30  minutes  and  
strongly   inhibited   BHPI-­stimulated   eIF2a   phosphorylation   (Figure   3.7G   and   Figure  
3.12B).   Since   PERK   knockdown   blocks   rapid   eIF2a   phosphorylation,   BHPI   is   not  
inhibiting   translation   by   activating   other   upstream   kinases   that   phosphorylate   eIF2a.  
Furthermore,  BHPI  rapidly  activates  the  ATF6a  and  IRE1a  arms  of  the  UPR,  as  shown  
by  increased  cleaved  p50-­ATF6a  and  sp-­XBP1  (Figure  3.7H).  
To   explore   how   BHPI   activates   the   UPR,   we   examined   inhibition   of   protein  
synthesis  by  known  UPR  activators.  Thapsigargin  and  Ionomycin,  which  activate  the  UPR  
by   release  of  Ca2+   from   the   lumen  of   the  EnR   into   the   cytosol   (24,   25),   but   not  UPR  
activators   that   work   by   other   mechanisms,   elicited   the   rapid   and   near   quantitative  
inhibition  of  protein  synthesis  seen  with  BHPI  (Figure  3.13A).  
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To  test  whether  BHPI  alters  intracellular  Ca2+,  we  monitored  intracellular  Ca2+  with  
the   calcium   sensitive   dye   Fluo-­4   AM.   In   MCF-­7   cells,   BHPI   produced   a   large   and  
sustained  increase  in  intracellular  Ca2+  in  the  presence  of  extracellular  Ca2+,  and  a  large  
transient  increase  in  intracellular  Ca2+  in  the  absence  of  extracellular  calcium  (Figure  3.7I  
and  Figure  3.13B).  Time-­dependent  changes  in  cytosol  calcium  in  BHPI-­treated  MCF-­7  
cells  were  quantitated  (Figure  3.13B).  Since  BHPI  elicits  a  large  increase  in  cytosol  Ca2+  
when  there  is  no  extracellular  Ca2+,  BHPI  is  acting  by  depleting  the  Ca2+  store  in  the  EnR.  
BHPI  had  no  effect  on  intracellular  Ca2+  in  ERa-­  HeLa  cells  (Figure  3.13C).  
We  next   identified   the  EnR  Ca2+  channel   that  opens  after  BHPI   treatment.  The  
inositol  triphosphate  receptor  (IP3R)  and  ryanodine  (RyR)  receptors  are  the  major  EnR  
Ca2+  channels.  Treatment  with  2-­APB,  which   locks  the  IP3R  Ca2+  channels  closed,  but  
not  closing  the  RyR  Ca2+  channels  with  high  concentration  ryanodine  (Ry),  abolished  the  
rapid  BHPI-­ERa-­mediated   increase   in   cytosol  Ca2+   and   inhibition   of   protein   synthesis  
(Figure  3.7I  and  J).  Furthermore,  RNAi  knockdown  of  IP3R  (Figure  3.14A)  abolished  the  
BHPI-­mediated  increase  in  cytosol  Ca2+  and  inhibition  of  protein  synthesis  (Figure  3.7K  
and  L).  IP3R  Ca2+  channels  are  also  modulated  through  protein  kinase  A  (PKA),  but  BHPI  
did  not  induce  PKA-­dependent  IP3R-­Ser1756  phosphorylation  (26)  (Figure  3.14B).  
  
BHPI  STRONGLY  ACTIVATES  PHOSPHOLIPASE  C  g,  PRODUCING  INOSITOL  1,4,5-­
TRIPHOSPHATE.  
Inositol   1,4,5-­triphosphate   (IP3)   is  produced  when   the  activated  phosphorylated  
plasma   membrane   enzyme,   PLCg,   hydrolyzes   PIP2   to   diacylglycerol   (DAG)   and   IP3.  
Supporting   a   role   for   PLCg,   siRNA   knockdown   of   PLCg   (Figure   3.14C)   abolished   the  
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BHPI-­mediated   increase   in   cytosol  Ca2+   (Figure  3.14C)   and  BHPI   inhibition  of  protein  
synthesis  (Figure  3.7L),  and  the  PLCg  inhibitor  U73122  abolished  the  BHPI-­ERa  increase  
in  cytosol  Ca2+  (Figure  3.14C).  Confirming  PLCg’s  role,  BHPI  induces  rapid  PLCg-­Tyr783  
phosphorylation   (Figure   3.14D),   and   strongly   increased   IP3   levels   (Figure   3.7M).  
Supporting   the   idea   that   BHPI   acts   by   distorting   the   newly   described   weak   E2-­ERa  
activation  of   the  UPR  (14),  BHPI   induced  a  much  larger   increase  in  IP3   levels  than  E2  
(Figure  3.7M).  
Rapid  BHPI  activation  of  plasma  membrane  PLCg  indicates  UPR  activation  is  an  
extranuclear   action   of   BHPI-­ERa.   PLCg   and   ERa   coimmunoprecipitate   (27),   and  
overexpression  of  ERa  in  MCF7ERaHA  cells  further  increased  IP3  levels  in  response  to  
BHPI  (Figure  3.14E).  Consistent  with  extranuclear  ERa-­dependent  activation  of  the  UPR,  
an  estrogen-­dendrimer  conjugate  (EDC)  that  cannot  enter  the  nucleus  (28),  induced  sp-­
XBP1,  but  not  nuclear  estrogen-­regulated  genes  (Figure  3.15).  A  model  depicting  BHPI  
action  is  presented  in  Figure  3.7N.  
  
BHPI  INHIBITS  E2-­ERa-­REGULATED  GENE  EXPRESSION  AND  LIKELY  INTERACTS  
WITH  ERa.    
Consistent  with  BHPI  binding  to  E2-­ERa,  BHPI,  but  not  an  inactive  close  relative,  
Compound  8  (Figure  3.1B),  significantly  altered  the  fluorescence  emission  spectrum  of  
purified  ERa  (Figure  3.16A).  We  also  tested  whether  BHPI  alters  the  sensitivity  of  purified  
ERa   ligand-­binding  domain   (LBD)   to  protease  digestion.  Addition  of  BHPI   followed  by  
cleavage  with  proteinase  K  revealed  a  15  kDa  band  in  BHPI  treated  ERa  LBD  that  was  
nearly  absent  in  the  LBD  treated  with  DMSO  or  Compound  8  (Figure  3.16B).  
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Because  BHPI  interacts  with  ERa  and  distorts  an  extranuclear  action  of  E2-­ERa,  
we  tested  whether,  independent  of  its  ability  to  inhibit  protein  synthesis  and  activate  the  
UPR,  BHPI  would  also  modulate  nuclear  E2-­ERa-­regulated  gene  expression.  At  early  
times  when   BHPI   inhibited   E2-­ERa   induction   of   pS2  mRNA,   neither   inhibiting   protein  
synthesis  with  CHX,  nor  activating  the  UPR  with  TUN  or  THG  (Figure  3.17A),  inhibited  
induction  of  pS2  mRNA  (Figure  3.16C).  BHPI  inhibited  E2-­ERa  induction  of  pS2,  GREB1,  
XBP1,  CXCL2,  and  ERE-­luciferase  in  ERa+  MCF-­7  and  T47D  cells  (Figure  3.17B-­F),  and  
blocked  E2-­ERa  down-­regulation  of  IL1-­R1  and  EFNA  mRNA  (Figure  3.17E  and  G).    BHPI  
is  not  a  competitive  ERa  inhibitor.  Increasing  the  concentration  of  E2  by  1,000-­fold  had  
no  effect  on  BHPI  inhibition  of  E2  induction  of  pS2  mRNA  (Figure  3.16D).  Moreover,  BHPI  
did  not  compete  with  E2  for  binding  to  ERa  (Figure  3.18A).  Since  BHPI  inhibits  E2-­ERa  
induction  and  repression  of  gene  expression,  BHPI  acts  at  the  level  of  ERa  and  not  by  a  
general  inhibition  or  activation  of  transcription.  
BHPI  did  not  alter  ERa  protein  levels  or  nuclear  localization  (Figure  3.18B  and  C).  
Chromatin  immunoprecipitation  (ChIP)  showed  that  BHPI  strongly  inhibited  E2-­stimulated  
recruitment  of  ERa   and  RNA  polymerase   II   to   the  pS2  and  GREB1  promoter   regions  
(Figure  3.16E  and  Figure  3.18D).  Consistent  with  BHPI  inducing  an  ERa  conformation  
exhibiting  reduced  affinity  for  gene  regulatory  regions,  ten-­fold  overexpression  of  ERa  in  
MCF7ERaHA   cells   abolished   BHPI   inhibition   of   induction   of   GREB1   mRNA   (Figure  
3.16F).  BHPI  still  kills  these  cells  because  ERa  overexpression  enhances  BHPI  inhibition  
of  protein  synthesis  (Figure  3.7E).  Taken  together,  our  data  provides  compelling  evidence  
BHPI   is  a  new   type  of  biomodulator,  altering  both  nuclear  and  extranuclear  actions  of  
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ERa.  
  
BHPI   RAPIDLY   DEPLETES   INTRACELLULAR   ATP   STORES   AND   ACTIVATES  
AMPK.    
BHPI  treatment  results  in  rapid  depletion  of  EnR  Ca2+.  To  restore  EnR  Ca2+,  the  
cell   activates   SERCA   (Sarco/Endoplasmic   Reticulum   Ca2+-­ATPase)   pumps,   which  
catalyze  ATP-­dependent   transfer   of  Ca2+   from   the   cytosol   into   the   lumen  of   the  EnR.  
Since  BHPI  opens   the   IP3R  Ca2+   channel,  Ca2+  pumped  back   into   the  EnR   lumen  by  
SERCA   flows   back   into   the   cytosol   (model   in   Figure   3.7N).   This   futile   cycle   rapidly  
depletes  intracellular  ATP,  resulting  in  activation  of  AMP-­activated  protein  kinase  (AMPK)  
by  AMPKa-­Thr172   phosphorylation   (Figure  3.19A   and  B).  Moreover,   the  AMPK   target,  
acetyl   CoA-­carboxylase   (ACC)   is   rapidly   phosphorylated   (Figure   3.19B).   Since  
Thapsigargin,  which  depletes  EnR  Ca2+  by   inhibiting  SERCA  pumps,  had  no  effect  on  
ATP  levels  (Figure  3.19A)  and  did  not  increase  levels  of  p-­AMPKa  and  p-­ACC  (Figure  
3.20A),   ATP   depletion,   rather   than   increased   cytosol   Ca2+   is   responsible   for   AMPK  
activation.   Importantly,   pre-­blocking   SERCA-­pumps   with   Thapsigargin,   abolished   the  
BHPI-­induced  decline  in  ATP  levels  and  phosphorylation  of  AMPKa  (Figure  3.19A).  
  
BHPI  BLOCKS  UPR  INACTIVATION  BY  TARGETING  A  SECOND  SITE  OF  PROTEIN  
SYNTHESIS  INHIBITION.  
In  ERa+,  but  not  ERa-­  cells,  after  ~2  hours,  BHPI  phosphorylates  and  inactivates  
eukaryotic   elongation   factor   2,   (eEF2)   (Figure   3.19C   and  Figure   3.20B   and  C).   eEF2  
phosphorylation  is  regulated  by  a  single  Ca2+/calmodulin-­dependent  kinase,  eukaryotic  
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elongation  factor  2  kinase  (CAMKIII/eEF2K).  eEF2K  is  inhibited  by  mTORC1-­p70S6K  and  
ERK-­p90RSK   through   eEF2K-­Ser366   phosphorylation   and   activated   by   Ca2+/calmodulin  
and  AMPK   (29,   30).   BHPI   increases   cytosol   Ca2+   and   activates   AMPK,   but   inhibiting  
AMPK  did  not  inhibit  eEF2  phosphorylation  (Figure  3.20D).  BHPI  also  rapidly  induces  a  
transient   increase   in   ERK1/2   activation   (Figure   3.20E  and   F),   which   stimulates   ERK-­
p90RSK  and  mTORC1-­p70S6K  activation  (31).  Together,  these  pathways  induce  eEF2K-­
Ser366  phosphorylation  (Figure  3.19D),  and  prevent  increases  in  p-­eEF2  for  ~1  hour  after  
BHPI   treatment   (Figure   3.19C  and  Figure   3.20G).  Consistent  with   this,   blocking  ERK  
activation   with   U0126   prevented   BHPI   from   producing   transient   declines   in   eEF2  
phosphorylation  through  inactivation  of  eEF2K  (Figure  3.20G).  
UPR   activation   with   conventional   UPR   activators   produces   transient   eIF2a  
phosphorylation  and  inhibition  of  protein  synthesis  (Figs.  3.20A,  3.21A,  and  3.21B)  in  part  
because  they  induce  BiP  and  p58IPK  chaperones  (Figure  3.21C  and  D).  The  chaperones  
help  resolve  UPR  stress  and  inactivate  the  UPR.  In  contrast,  BHPI  blocks  induction  and  
reduces   levels   of   BiP   and   p58IPK   protein   (Figure   3.19E),   leading   to   sustained   eIF2a  
phosphorylation  and  inhibition  of  protein  synthesis  (Figure  3.8  and  3.11B).  BHPI  failed  to  
increase  p58  protein  despite  inducing  p58  mRNA  (Figure  3.19E),  and  at  later  times  PERK  
inhibition  failed  to  prevent  BHPI  from  inhibiting  protein  synthesis  (Figure  3.12A).  This  is  
consistent  with  BHPI  targeting  protein  synthesis  at  a  second  site  at  later  times.  
  
DISCUSSION  
BHPI  and  estrogen  share  the  same  ERa-­dependent  pathway  for  UPR  activation:  
Activation  of  PLCg   producing   IP3,  opening  of   the   IP3R  Ca2+   channels,   release  of  EnR  
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Ca2+,  and  activation  of  the  PERK,  IRE1a  and  ATF6a  arms  of  the  UPR  (model  in  Figure  
3.7N).  We  recently  reported  that  as  an  early  component  of  the  proliferation  program,  E2-­
ERa  weakly  and  transiently  activates  the  UPR.  We  showed  that  E2-­ERa  elicits  a  mild  and  
transient   activation   of   the   PERK   arm   of   the   UPR,   while   simultaneously   increasing  
chaperone  levels  and  protein  folding  capacity  by  activating  the  IRE1a  and  ATF6a  arms  
of  the  UPR  (14).  BHPI  distorts  this  normal  action  of  E2-­ERa  by  increasing  the  amplitude  
and  duration  of  UPR  activation.  Compared  to  E2,  BHPI  hyperactivates  PLCg,  producing  
much  higher   IP3   levels,  Ca2+-­release   from   the  EnR,  and  UPR  activation.  BHPI   initially  
inhibits  protein  synthesis  by  strongly  activating  the  PERK  arm  of  the  UPR.  Knockdown  of  
ERa,  PLCg,   IP3R  and  PERK  blocked   rapid  BHPI   inhibition  of  protein  synthesis.  While  
BHPI  activates  the  IRE1a  and  ATF6a  UPR  arms,  by  acting  at  later  times  to  inhibit  protein  
synthesis   at   a   second   site,   BHPI   prevents   the   synthesis   of   chaperones   required   to  
inactivate  the  UPR.  Because  the  cell  attempts  to  restore  EnR  Ca2+  while  the  IP3R  Ca2+  
channels  remain  open,  BHPI  rapidly  depletes  ATP  (Figure  3.7N),  resulting  in  activation  
of   AMPK.  Several   actions   of   BHPI,   including   strong   elevation   of   intracellular   calcium,  
sustained  UPR  activation,   long-­term   inhibition  of  protein  synthesis,  ATP  depletion  and  
AMPK  activation  can  potentially  contribute  to  BHPI’s  ability  to  block  cell  proliferation.  How  
the  cascade  of  events  initiated  by  BHPI  enables  BHPI  to  block  cell  proliferation,  and  often  
kill,  ERa+  cancer  cells  requires  further  exploration.  Supporting  BHPI  targeting  PLCg  and  
the  UPR   through  ERa,   independent   of   its   effects   on   the  UPR,  BHPI   inhibits  E2-­ERa-­
mediated  induction  and  repression  of  gene  expression.  
BHPI  and  E2  activation  of  plasma  membrane-­bound  PLCg,  resulting  in  increased  
IP3,  is  an  extranuclear  action  of  ERa.  Increasing  the  level  of  ERa,  increased  IP3  levels.  
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Consistent  with  ERa  and  PLCg  interaction,  they  coimmunoprecipitate  (27).  BHPI  and  E2  
induce  Ca2+  release  in  1  min.,  too  rapidly  for  action  by  regulating  nuclear  gene  expression  
(14).   Furthermore,   a   membrane-­impermeable   estrogen-­dendrimer   induces   the   UPR  
marker  sp-­XBP1,  but  not  nuclear  E2-­ERa-­regulated  genes.  
The  UPR  plays  important  roles  in  tumorigenesis,  therapy  resistance,  and  cancer  
progression  (14,  32).  Moderate  and  transient  UPR  activation  by  E2  and  other  activators  
promotes  an  adaptive   stress   response,  which   increases  UPR  expression  and   confers  
protection  from  subsequent  exposure  to  higher  levels  of  cell  stress  (14,  33).  In  contrast,  
sustained  UPR  activation  triggers  cell  death.  Since  most  current  anticancer  drugs  inhibit  
a   pathway   or   protein   important   for   tumor   growth   or  metastases,  most   UPR   targeting  
efforts  focus  on  inactivating  a  protective  stress  response  by  inhibiting  UPR  components  
(34).  UPR  overexpression  in  cancer  is  associated  with  a  poor  prognosis  (14),  suggesting  
that  sustained  lethal  hyperactivation  of  the  UPR  by  BHPI  represents  a  novel  alternative  
anticancer  strategy.  
BHPI  can  selectively  target  cancer  cells,  because  its  targets,  ERa  and  the  UPR,  
are  both  overexpressed  in  breast  and  ovarian  cancers  (14,  22,  32,  35).  Cells  expressing  
low  levels  of  ERa,  more  typical  of  non-­transformed  ERa  containing  cells,  such  as  PC-­3  
prostate  cancer  cells,  were  less  sensitive  to  BHPI  inhibition  of  protein  synthesis  (Figure  
3.3),  while  doxycycline-­treated  MCF7ERaHA  cells  expressing  very  high   levels  of  ERa  
exhibited  near  complete  inhibition  of  protein  synthesis  (Figure  3.7E).  Consistent  with  low  
toxicity,  in  the  xenograft  study,  BHPI-­treated  mice  showed  no  evidence  of  gross  toxicity.  
Most  gynecological  cancers  show  little  dependence  on  estrogens  for  growth  and  other  
non-­competitive  ERa  inhibitors  have  not  demonstrated  effectiveness  in  these  cells.  BHPI  
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is   highly   effective   in   several   breast   and   ovarian   cancer   drug-­resistance   models   and  
extends  the  reach  of  ERa  biomodulators  to  gynecologic  cancers  that  do  not  respond  to  
current  endocrine  therapies.  BHPI’s  effectiveness  in  ERa-­containing  breast,  ovarian  and  
endometrial  cancer  cells  is  consistent  with  the  finding  that  female  reproductive  cancers  
exhibit  common  genetic  alterations  and  might  respond  to  the  same  drugs  (36),  and  with  
our  finding  that  E2-­ERa  weakly  activates  the  UPR  in  breast  and  ovarian  cancer  cells  (14).  
With  its  submicromolar  potency,  effectiveness  in  a  broad  range  of  therapy  resistant  
cancer  cells,  ability  to   induce  substantial   tumor  regression  and  unique  mode  of  action,  
BHPI  is  a  promising  small  molecule  for  therapeutic  evaluation  and  mechanistic  studies.  
  
MATERIALS  AND  METHODS  
Cell  Culture  and  Reagents  
MCF-­7,   T47D,   T47D-­kBluc,   HCC-­1500,   ZR-­75-­1,   MCF10A,   MDA   MB-­231,   CAOV-­3,  
OVCAR-­3,  IGROV-­1,  ES2,  ECC-­1,  HeLa,  PC-­3,  DU145,  H1793,  A549,  MEF,  and  HepG2  
cells   wereobtained   from   the   ATCC.   Dr.   E.   Wilson   provided   HeLa-­AR13   cells,   Dr.   K.  
Korach  provided  BG-­1/MCF-­7  cells,  Dr.  B.H.  Park  provided  MCF10AER  IN9  cells,  Dr.  R.  
Schiff   provided   BT-­474   cells,   and   E.   Alarid   provided   MCF7ERaHA   cells.   Prior   to  
experiments,  to  deplete  cells  of  estrogens  in  the  serum  and  medium,  ERa  positive  cell  lines  
were   maintained   for   4   days   in   medium   supplemented   with   phenol   red-­free   charcoal-­
dextran  (CD)  treated  serum.  
  
Chemical  Libraries  and  Screening  
The  small  molecule  libraries  screened  were:  The  ~150,000  small  molecule  Chembridge  
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MicroFormat   small   molecule   library,   the   ~10,000   small   molecule   University   of   Illinois  
Marvel  library  developed  by  Drs.  K.  Putt  and  P.  Hergenrother  (37),  and  the  ~2,000  small  
molecule   NCI   diversity   set   obtained   from   NIH.   High   throughput   screening   for   small  
molecule  inhibitors  of  endogenous  E2-­ERa  induced  expression  of  the  stably  transfected  
(ERE)3-­luciferase   reporter   in   T47D-­KBluc   cells,   was   carried   out   using   the   assay   we  
recently  described  (38).  
  
Cell  Proliferation  Assays  
Cells  were  resuspended  in  the  following  media  and  plated  in  96  well  plates  at  the  indicated  
densities:  MCF-­7  (10%  CD-­calf,  1,000  cells);;  MCF7ERaHA  (10%  CD-­calf,  1,000);;  T47D  
(10%  CD-­calf,   2,000);;   T47D-­   kBluc   (10%  CD-­FBS,   1,000);;  HCC-­1500   (10%  CD-­FBS,  
1,000);;  BT-­474   (10%  CD-­calf,   2,000);;   ZR-­75-­1   (10%  CD-­calf   2,000);;  MCF10AER   IN9    
(2%  CD-­FBS,  1,000);;  MCF10A  (2%  CD-­FBS,  1,000);;  MDA  MB-­231  (10%  FBS,  1,000);;  
BG-­1/MCF-­7  (5%  FBS,  250);;  CaOV-­3  (10%  CD-­CALF,  2,000);;  OVCAR-­3  (10%  CD-­FBS,  
2,000);;  IGROV-­1  (10%  FBS,  1,000);;  ES2  (10%  FBS,  1,000);;  ECC-­1  (5%  CD-­FBS,  1,000);;  
Ishikawa  (10%  CD-­calf,  2,000);;  HeLa  (10%  FBS,  1,000);;  PC-­3   (10%  CD-­FBS,  1,000);;  
DU145  (10%  FBS,  1,000);;  201T  (10%  FBS,  2,000);;  273T  (10%  FBS,  1,000);;  H1793  (5%  
FBS,  2,000);;  A549  (10%  FBS,  1,000);;  HepG2  (10%  CD-­FBS,  1,000),  MEF  (10%  FBS,  
2,000).  The  medium  was  replaced  with  treatment  medium  the  following  day,  and  plates  
were   incubated  at  37o  C   in  5%  CO2   for  4  days  except   for  BT-­474,  BG-­1/MCF-­7  and  
Ishikawa  which  were  incubated  for  6  days  and  ZR-­75-­1  cells  which  were  incubated  for  7  
days.  Treatment  solutions  were  replaced  every  two  days.  Cell  number  was  determined  
from  MTS  assays  using  CellTiter  96  Aqueous  One  Solution  Reagent  (Promega).  For  each  
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To  measure  ATP  levels,  cells  were  lysed  and  ATP  luminescence  levels  were  measured  
using  an  ATPlite  Luminesence  Assay  kit  (PerkinElmer,  MA).  ATP  released  from  cells  was  
quantified  from  a  standard  curve  of  ATP  standards  versus  luminescence.  
  
Luciferase  Assays  
Reporter  gene  assays  were  carried  out,  as  previously  described  (38,  39).  Briefly,  cells  
were  switched  to  10%  CD-­FBS  for  four  days  prior  to  experiments,  and  plated  at  a  density  
of  50,000  cells/well  in  24-­well  plates.  The  medium  was  replaced  the  next  day  with  medium  
containing   the   test   compounds,  with   or  without   hormone,   incubated   for   24   hours   and  
luciferase  assays  were  performed  using  Bright  Glow  reagent  (Promega,  WI).  
  
qRT-­PCR  
RNA  was  extracted  using  a  QiaShredder  kit  (Qiagen)  for  cell  homogenization,  and  purified  
with   the  RNAeasy  mini-­kit   (Qiagen,  CA).   cDNA  was  prepared   from  0.5  µg  of  RNA  by  
reverse   transcription   using   a   DyNAmo   cDNA   synthesis   kit   (Finnzymes,   Finland).  
Quantitative  PCR  assays  were  performed  on  samples  from  3  independent  sets  of  cells  
(biological  triplicate).  Reactions  contained  10  ng  of  cDNA  and  50  nM  forward  and  reverse  
primers  in  15  µl  and  were  carried  out  using  Power  SYBR  Green  PCR  Mastermix  (Applied  
Biosystems).  The  fold  change  in  expression  of  each  gene  was  calculated  using  the  ∆∆Ct  
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method   with   the   ribosomal   protein   36B4   used   as   the   internal   control,   as   described  
previously  (38,  40,  41).  
  
Chromatin  Immunoprecipitation  
MCF-­7  cells  were  stripped  of  estrogens  for  3  days  in  5%  CD-­FBS.  Cells  were  pretreated  
with  1  µM  BHPI  or  DMSO  (0.1%)  as  a  control  for  105  minutes,  and  then  were  treated  with  
either  10  nM  E2  or  an  ethanol-­vehicle  control  (0.1%)  for  45  minutes.  ChIP  was  carried  
out  essentially,  as  previously  described  (39).  
  
Transfections  
siRNA   knockdowns  were   performed   using  DharmaFECT1   Transfection  Reagent   and  
100  nM  ON-­TARGETplus  non-­targeting  pool   or  SMARTpools   for   ERa   (ESR1),   PLCg   
(PLCG1),   PERK   (EIF2AK3),   or   pan-­IP3R   (Dharmacon).   The   pan-­IP3R   SmartPool  
consisted  of  three  individual  SmartPools,  each  at  33  nM,  directed  against  each  isoform  
of   the   IP3R  (ITPR1,   ITPR2,  and   ITPR3).  To  knockdown  ERa,  MCF10AERa   IN9  cells  
were  treated  for  16  hours  with  either  human  ERa    SMARTpool  (ESR1)  siRNA  or  Non-­
targeting  Control  Pool  siRNA.  Cells  were  treated  with  transfection  complex  for  16  hours,  
and   medium   was   replaced   with   DMEM/F12,   supplemented   with   2%   CD-­FBS.   ERa  
knockdown   at   the   mRNA   and   protein   level   was   assessed   every   24   hours   following  
transfection.  The  effects  of  BHPI  on  protein  synthesis  following  ERa  knockdown  were  
assessed   3-­days   post-­knockdown   by   treating   cells   with   either   0.1%   DMSO   loading  
control  or  100  nM  BHPI  for  the  indicated  times  and  protein  synthesis  was  then  assessed  
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by  measuring   35S-­Methionine   incorporation.   Knockdowns   of   PERK,   IP3R,   and   PLCg  
were  performed  by  maintaining  MCF-­7  cells  in  MEM  containing  5%  CD-­FBS  for  4  days  
prior  to  plating  cells  in  serum-­free  MEM.  Cells  were  treated  with  transfection  complexes  
for   16   hours   and  medium  was   replaced  with  MEM,   supplemented  with   10%  CD-­calf  
serum.  The  effects  of  BHPI  on  protein  synthesis  or  calcium  signaling  were  assessed  3-­
days  post-­knockdown.  The  eIF2a  S51A  plasmid  was  a  gift  from  Dr.  David  Ron  (Addgene  
plasmid  #  21808).  ECC-­1  cells  (4  ×  103)  were  transfected  with  either  0.2  μg  of  eIF2a    
S51A  plasmid  DNA  or  empty  expression  vector.  Transfections  were  performed  using  
Lipofectamine  3000,  according  to  manufacture  instructions.  Cells  were  treated  with  100  





Western   blotting  was   carried   out   as   previously   described   (38,   40,   42).   The   following  
antibodies   were   used:   ERa   [6F11]   antibody   (Biocare   Medical,   CA),   Phospho-­eIF2a    
(Ser51)  (#3398;;  Cell  Signaling  Technology),  eIF2a    (#5324;;  Cell  Signaling  Technologies,  
MA),   Phospho-­eEF2   (#2331;;   Cell   Signaling   Technology,   MA),   eEF2   (#2332;;   Cell  
Signaling  Technology,  MA),  Phospho-­p44/42  MAPK  (#4370;;  Cell  Signaling  Technology,  
MA),  p44/42  MAPK  (#4695;;  Cell  Signaling  Technology,  MA),  Phospho-­PERK  (#3179;;  
Cell  Signaling  Technology,  MA),  PERK  (#5683;;  Cell  Signaling  Technology,  MA),  ATF6a  
(Imgenex,   CA),   Phospho-­AMPKa   (#2535;;   Cell   Signaling   Technology,   MA),   AMPKa  
(#2603;;   Cell   Signaling   Technology,   MA),   Phospho-­AMPKβ1   (#4181;;   Cell   Signaling  
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Technology,  MA),  AMPKβ1/2  (#4150,  Cell  Signaling  Technology,  MA),  Phospho-­Acetyl-­
CoA   Carboxylase   (#3661;;   Cell   Signaling   Technology,   MA),   Acetyl-­CoA   Carboxylate  
(#3676;;   Cell   Signaling   Technology,   MA),   Phospho-­IP3R   (#8548;;   Cell   Signaling  
Technology,  MA),  IP3R  (#8568;;  Cell  Signaling  Technology,  MA),  Pan-­IP3R  (sc-­28613;;  
Santa  Cruz,  CA),  Phospho-­PLCg  (#2821;;  Cell  Signaling  Technology,  MA),  PLCg  (#5690;;  
Cell  Signaling  Technology,  MA),  BiP  (#3177;;  Cell  Signaling  Technology,  MA),  p58IPK  
(#2940;;  Cell  Signaling  Technology,  MA),  laminin  A/C  (Santa  Cruz,  CA),  β-­Actin  (Sigma,  
MO),  and  a-­  Tubulin  (Sigma,  MO).  Bound  antibodies  were  detected  using  horseradish  
peroxidase-­conjugated  secondary  antibodies  and  chemiluminescent   immunodetection  
with   an   ECL   Detection   Kit   (GE   Healthcare,   NJ),   and   were   visualized   using   a  
PhosphorImager.  
  
Nuclear-­cytoplasmic  Distribution  of  ER   
MCF-­7  cells  were  pre-­treated  with  1  µM  BHPI  or  DMSO  (0.1%)  for  30  minutes,  followed  
by  2  hours  with  or  without  E2.  Nuclear  and  cytoplasmic  extraction  was  carried  out  on  ~6  
million  cells/treatment  using  a  NE-­PER  Nuclear  and  Cytoplasmic  Extraction  Reagents  




Protein  synthesis  rates  were  evaluated  by  measuring  incorporation  of  35S-­Methionine  
into  newly  synthesized  protein.  Cells  were  plated  at  a  density  of  10,000  cells/well  in  96-­
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well   plates.   Cells   were   incubated   for   30   minutes   with   3   µCi   of   35S   methionine  
(PerkinElmer,  MA)  per  well  at  37o  C.  Cells  were  washed  two  times  with  PBS,  and  lysed  
using  30  µL  of  RIPA  buffer.  Cell  lysates  were  collected  in  microfuge  tubes  and  clarified  
by  centrifugation  at  13,000  x  g   for  10  min  at  4o  C.  Samples  were  normalized   to   total  
protein,   and   the   appropriate   volume  of   sample  was   spotted   onto  Whatman  540   filter  
paper  discs  and  immersed  in  cold  10%  TCA.  The  filters  were  washed  once  in  10%  TCA  




Cytoplasmic  Ca2+  concentrations  were  measured  using  the  calcium-­sensitive  dye,  Fluo-­
4  AM.  The  cells  were  grown  on  35  mm-­fluorodish  cell  culture  plates  (#FD35-­100,  World  
Precision  Instruments)  for  two  days  prior  to  imaging  experiments.  The  cells  were  loaded  
with  5  µM  Fluo-­4  AM  (Life  Technologies,  CA)  in  HEPES-­based  buffer  (140  mM  NaCl,  4.7  
mM  KCl,  1.13  mM  MgCl2,  10  mM  HEPES,  10  mM  Glucose,  pH  =  7.4)  for  30  minutes  at  
37
o  C  before  measurement  of  intracellular  calcium.  The  cells  were  washed  three  times  
with  HEPES  buffer   to  remove  extracellular  Fluo4-­AM  dye  and   incubated  with  either  2  
mM   CaCl2   or   0   mM   CaCl2   for   10   minutes   to   complete   de-­esterification   of   the   dye.  
Confocal  images  were  obtained  for  one  minute  to  determine  basal  fluorescence  intensity,  
and  then  the  appropriate  treatment  was  added.  Confocal  images  were  captured  using  a  
Zeiss  LSM  700  confocal  system,  Plan-­Four  20X  objective  (N.A.  =  0.8)  and  scanned  at  a  
resolution   of   512x512   pixels   (780ms/min).   To   minimize   photo-­bleaching   and   photo-­
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toxicity   of   samples,   the   laser   power   was   reduced   to   7%.   For   fluorescence  
measurements,  the  cells  were  excited  at  488  nm,  and  the  emission  was  collected  at  525  
nm.   Images   were   acquired   and   analyzed   with   AxioVision   and   Zen   software   (Zeiss).  
Calcium   traces   were   generated   by   normalizing   fluorescence   to   basal   fluorescence  
intensity.  Data  presented  as  mean  ±  standard  error  (n  =  10  individual  cells).  
  
Protease  Sensitivity  Assays  
ERa  LBD  (N304-­S554)  containing  an  N-­terminal  6-­His  tag,  was  expressed  and  purified  
as  described  previously  (43),  and  stored  in  Tris-­HCl  buffer  (50  mM  Tris-­HCl  pH  8.0,  10%  
glycerol,  2  mM  DTT,  1  mM  EDTA,  and  1  mM  Na3VO4).  Purified  ERa  LBD  protein  (10  
µg)  was  incubated  with  500  nM  E2  for  20  min  at  37o  C.  Samples  were  then  treated  with  
either  DMSO  vehicle,  BHPI  (1  µM)  or  inactive  Compound  8  (1  µM)  and  incubated  for  20  
min  at  37o  C.  For  partial  protease  cleavage,  the  binding  mixture  was  added  with/without  
protease  K  at  a  concentration  of  7.5  ng  protease  K  per  µg  protein.  After  incubation  for  
10  min  at  22o  C,  the  digestions  were  terminated  by  addition  of  SDS  sample  buffer  buffer.  
The   denatured   samples  were   analyzed   on   a   15%  SDS-­PAGE   gel   and   visualized   by  
coomassie  blue  staining.  
  
Intrinsic  Fluorescence  Spectroscopy  
The  stock  solution  of   full-­length  ERa  was  diluted   to  400  nM   in  a  Tris-­  Buffer   (50  mM  
Tris/HCl  pH8.0,  150  mM  KCl,  2  mM  DTT,  1  mM  EDTA,  and  10%  glycerol).  The  intrinsic  
fluorescence  measurements  were  carried  out  in  a  10  mm  quartz  cuvette  using  a  Varian  
	   78	  
Cary  Eclipse  Fluorescence  Spectrophotometer.  The  excitation  and  emission  slits  were  
set  at  5  nm.  Tryptophan  fluorescence  was  measured  using  an  excitation  wavelength  of  
295  nm.  Emission  spectra  were  collected  from  310-­380  nm.  All  spectra  were  collected  
at  37  oC    E2  (500  nM),  BHPI  (500  nM),  or  inactive  compound  88  (500  nM)  was  added  
and  incubated  at  37  oC  for  10  min,  and  then  the  ERα  emission  spectra  were  recorded.  
All  the  spectra  were  corrected  for  baseline  in  the  absence  of  E2.  
  
Colony  Formation  Assays  
Assays  to  assess  anchorage-­independent  cell  proliferation  in  soft  agar  were  carried  out  
as   previously   described   (39).   Each   treatment   condition   was   evaluated   on   five  
independent  sets  of  cells.  Culture  medium  was  changed  every  3  days.  Colonies  were  
visible   after   2  weeks,   and   total   colonies  were   counted   at   Day   21   using   a   dissecting  
microscope.  Photographs  of  colonies  were   taken  using  a  Zeiss  AxioImager2   imaging  
system  at  5X  magnification.  
  
Mouse  xenograft  
All  experiments  were  approved  by  the  Institutional  Animal  Care  Committee  (IACUC)  of  
the  University  of  Illinois  at  Urbana-­Champaign.  The  MCF-­7  cell  mouse  xenograft  model  
has  been  described  previously   (44).  At   least  12  animals,  with  2-­4   tumors  per  mouse,  
were  required  per  experimental  group  to  maintain  significant  statistical  power  to  detect  
>25%   difference   in   tumor   growth   rates.   Briefly,   estrogen   pellets   (1   mg:19   mg  
estrogen:cholesterol)  were  implanted  into  60  athymic  female  OVX  mice,  which  were  7  
weeks  of  age.  Three  days  after  E2  pellet   implantation  1  million  MCF-­7,  human  breast  
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cancer  cells  per  site  in  matrigel  were  subcutaneously  injected  at  2  sites  in  each  flank  for  
a  total  of  4  potential  tumors  per  mouse.  When  the  average  tumor  size  reached  17.6  mm2  
(4.7  by  4.7  mm),  E2  pellets  were  removed  and  a  lower  dose  of  E2  in  sealed  silastic  tubing  
(1:31  estrogen:cholesterol,  3  mg  total  weight)  was  implanted  in  the  same  site.  When  the  
average  tumor  size  reached  23.5  mm2  (5.5  by  5.5  mm),  mice  were  divided  into  4  groups  
with  tumor  size  normalized:  E2  group,  no  treatment  control  (NC)  group,  B_10  group  and  
B_1/B_15  group.  E2  silastic  tubes  in  the  NC  group  were  removed,  while  E2  silastic  tubes  
in  the  E2,  B_10,  and  B_1/B_15  groups  were  retained.  The  E2  and  NC  group  received  
intraperitoneal  injection  every  other  day  with  10  ml/kg  vehicle  (2%  DMSO,  10%  Tween-­
20,  and  88%  PBS).  The  B_10  group  received  10  mg/kg  BHPI  by  intraperitoneal  injection  
every  other  day.  The  B_1/B_15  group  received  1  mg/kg  BHPI  by  intraperitoneal  injection  
every  other  day  for  14  days.  Since  this  extremely  low  BHPI  dose  had  no  effect,  (average  
tumor  cross-­sectional  area  ~45  mm2)  they  then  received  15  mg/kg  BHPI  every  day  for  
another  10  days.  Food  intake  and  body  weight  were  measured  every  4  days  and  food  
intake  is  presented  as  grams/day.  Tumors  were  measured  every  4  days  with  a  caliper.  
Tumor  cross  sectional  area  was  calculated  as  (a/2)*(b/2)*3.14,  where  a  and  b  were  the  
measured   diameters   of   each   tumor.   On   termination   of   the   experiments   mice   were  
euthanized  and  the  tumors  were  excised  and  weighed.  2  of  60  mice  were  removed  during  
the  course  of  the  study,  one  that  failed  to  form  tumors  and  the  other  due  to  unrelated  
illness.  No  tumors  were  excluded  from  analysis,  and  blinding  was  not  performed.  
  
IP3  Quantitation  
MCF-­7   cells   were   incubated   for   10   minutes   in   100   nM   E2,   10   µM   BHPI   or   vehicle.  
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Intracellular   IP3   levels  were   determined   by   extracting   the   cells,   and   determining   IP3  
levels   in   an   assay   based   on   competition   with   radiolabeled   IP3   for   binding   to   a  
recombinant  fragment  of  IP3R  containing  the  IP3  binding  site.  Unlabeled  IP3    provided  
a  standard  for  the  competition  assays.  1.5x106  MCF-­7  cells  were  incubated  with  ice-­  cold  
1   M   trichloroacetic   acid   (TCA)   containing   1   mM   EDTA   on   ice   for   15   min.   After  
centrifugation,   the   supernatant   was   collected   and   incubated   for   15   min.   at   room  
temperature.  The  TCA  solution  was  removed  by  adding  two  volumes  of  1,1,2-­Trichloro-­
1,2,2-­trifluoroethane  (TCTFE)-­triocylamine  solution.  The  TCTFE-­solution  was  prepared  
by  mixing  3:1  (v/v)  of  TCTFE  and  trioctylamine  (Sigma).  Unlabeled  IP3,  labeled,  IP3  and  
the  unlabeled   IP3R   fragment  were   from  Perkin  Elmer   (Waltham,  MA)  and  were  used  
largely   according   to   the   supplier’s   directions.  Briefly,   unlabeled   IP3   standards   or   cell  
extracts  were  incubated  with  the  working  receptor/tracer  solution  at  1:4  (v/v)  for  1  hr.  at  
4oC.   The   samples  were   sedimented   by   centrifugation   at   2,000xg   for   20  min   and   the  
supernatant  was  discarded.  The  pellet  was  suspended  in  0.15  M  NaOH.  After  15  min.  at  
room  temperature,  the  samples  were  mixed  with  5  ml  of  Pico-­Fluor  Plus  scintillation  fluid  
(Perkin  Elmer,  Watham,  MA)  and  radioactivity  determined  by  scintillation  counting.  IP3  
levels  in  biological  samples  were  calculated  from  the  standard  curve  generated  using  a  
range  of  unlabeled  IP3  concentrations.  
  
EDC  Dendrimer  
The  EDC  dendrimer  was  prepared  and  used  as  previously  described  (45).  
  
Statistical  Analysis  
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Calcium  measurements   reported  as  mean  ±  S.E.  All   other   pooled  measurements   are  
represented  as  mean  ±  S.E.M.  Two-­tailed  student  t-­tests  or  one-­way  ANOVA  with  post-­
hoc  Fisher’s  LSD  tests  were  used  to  test  for  statistical  significance  (p  <  0.05).  
     




Figure  3.1.  BHPI  and  structurally  related  compounds  selectively  inhibit  estrogen-­
dependent  cell  proliferation.  (A)  Structure  of  BHPI  (3,3-­bis(4-­hydroxyphenyl)-­7-­methyl-­
1,3,dihydro-­2Hindol-­2-­one).  (B)  Inhibition  of  the  proliferation  of  T47D  cells  by  BHPI  and  
by  structurally  related  compounds  (n  =  6).  
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Figure  3.2.  BHPI  selectively  inhibits  proliferation  of  ERa+  cancer  cells  sensitive  or  
resistant   to  drug   therapy.   BHPI   inhibits   proliferation   of  ERa+   (A)  MCF-­7   breast,   (B)  
PEO4  ovarian,  and  (C)  ECC-­1  endometrial  cancer  cells  with  no  effects  on  (D)  counterpart  
ERa-­  cancer  cells.  Effects  of  BHPI  on  proliferation  of  drug-­resistant  cells:  Tamoxifen-­  and  
ICI-­resistant  (E)  ZR-­75-­1  cells  and  (F)  BT-­474  breast  cancer  cells.  (G)  T47D  cells  treated  
with  1  µM  BHPI  or  competitor  antiestrogens  (4-­OHT,  RAL,  ICI)  in  the  presence  or  absence  
of  E2  and/or  EGF.  Proliferation  of  (H)  cisplatin  resistant  Caov-­3  ovarian  cancer  cells  and  
(I)   multi-­drug   resistant   OVCAR-­3   ovarian   cancer   cells   treated   with   BHPI,   or   the  
antiestrogens  4-­OHT  or  ICI.  Concentrations:  E2,  1  nM  (E,  G,  H)  or  10  nM  (A-­C,  F,  I);;  EGF,  
50  ng/mL  (G);;  ICI,  1  μM  (E,  G,  H),  5  μM  (I);;  4-­OHT,  1  μM  (E,  G,  H);;  RAL,  1  μM  (G)  “•”  
denotes  cell  number  at  day  0.  Hatched  bars  denote  antiestrogens  (4-­OHT,  RAL,  or  ICI).  
Cell  proliferation  is  expressed  as  mean  ±  SEM  (n  =  6).  
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Figure   3.3.   BHPI   selectively   inhibits   cell   proliferation   in   ERa positive   cancer  
cells.  Effects  of  BHPI  on  cell  proliferation  in  15  ERa positive  (colored  bars)  and  12  
ERa negative  (black  bars)  cell  lines.  Cell  lines  are  grouped  by  tissue  of  origin  (breast,  
ovary,  cervix,  prostate,  lung  and  liver).  “•”  on  each  graph  denotes  the  number  of  cells  
at  the  start  of  the  experiment.  Most  cell  proliferation  studies  were  for  3  or  4  days  in  10  
nM  E2.  Since  we  recently  found  that  our  BG-­1  cells  are  genetically  identical  to  MCF-­
7  cells,  that  data  is  presented  as  BG-­1/MCF-­7.  Data  is  the  mean  ±  SEM  (n  =  6).  
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Figure  3.4.  BHPI  inhibits  anchorage-­independent  growth  of  MCF-­7  cells  in  soft  agar.  
5,000  MCF-­7  cells  were  plated  into  top  agar.  Cells  were  treated  with  medium  containing  
DMSO  (vehicle)  and  either,  10  nM  E2  (+E2)  or  Ethanol  (vehicle)  (-­E2),  or  1  µM  BHPI  and  
10  nM  E2  (+E2,  BHPI).  Medium  was  changed  every  3  days.  After  21  days,  colonies  were  
counted   and   photographed   at   5x   magnification.   For   each   treatment,   the   bar   graph  
represents  the  average  of  the  total  number  colonies  per  well  with  a  diameter  >0.5  mm.  
Data  is  the  mean  ±  SEM  (n  =  6).  
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Figure  3.5.  BHPI  induces  tumor  regression  in  a  mouse  xenograft.  Change  in  tumor  
cross  sectional  area  in  mouse  MCF-­7  xenografts  after  10  days  of  daily  IP  injections  of  
either  15  mg/kg  BHPI   (blue)  or   vehicle   control   (red).  Tumors  had  an  average  starting  
cross-­sectional  area  of  ~45  mm2.  For  each  tumor,  area  at  day  0  was  set  to  0%  change.  
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Figure   3.6.   BHPI   inhibits   tumor   growth   in   a  mouse   xenograft   model   of   breast  
cancer  and  is  not  toxic.  (A)  MCF-­7  tumor  growth  in  athymic  mice  was  monitored  every  
4  days  by  measuring   tumor  diameter  with  a  caliper.  The  E2  and  –E2  group  received  
vehicle   injection,  while   the  B_10  group  was   injected  with  10  mg/kg  BHPI  every  other  
day.  The  B_1/B_15  group  received  the  extremely  low  dose  of  1  mg/kg  BHPI  every  other  
day  for  14  days.  This  very  low  dose  of  BHPI  had  no  effect  on  tumor  growth.  They  then  
received   15  mg/kg   BHPI   every   day   until   the   end   of   the   study   (*   denotes   change   in  
dosage).  Tumor  size  was  represented  as  tumor  cross  sectional  area  (mm2).  Each  tumor  
was  analyzed  individually,  and  data  are  expressed  as  mean  ±  SEM  (n  =  52).  (B)  Mice  
were  sacrificed  and  tumor  weights  were  recorded.  Data  is  expressed  as  mean  ±  SEM  (n  
=  52)  and  analyzed  using  one  way  ANOVA  with  post  hoc  Fisher’s  LSD  test.  Different  
letters  indicate  significant  differences  between  groups  (p  <0.05).  (C)  Mouse  body  weight  
was  measured  every  4  days  after  initiation  of  drug  injection.  Data  is  expressed  as  mean  
±  SEM  (n  =  13).  (D)  Mouse  food  intake  was  measured  every  4  days  after  initiation  of  
drug  injection.  Data  expressed  as  mean  ±  SEM  (n  =  13).  BHPI  treatment  had  no  effect  
on  body  weight  or  food  intake  and  was  therefore  not  overtly  toxic.  
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Figure  3.7.  BHPI  selectively  inhibits  protein  synthesis  in  ERa  positive  cancer  cells  
by  activating  PLCg,  depleting  endoplasmic  reticulum  Ca2+,  and  activating  the  UPR.  
(A)  Protein  synthesis  in  BHPI-­treated  ERa+  and  ERa-­  cells  (n  =  4).  CHX,  cycloheximide.  
(B)  ERa  is  sufficient  to  make  a  cell  sensitive  to  BHPI  inhibition  of  protein  synthesis.  Protein  
synthesis  in  parental  ERa-­  MCF10A  cells  and  ERa  expressing  MCF10AER  IN9  cells  (n  =  
4).  (C)  RNAi  knockdown  of  ERa  abolishes  BHPI  inhibition  of  protein  synthesis.  Protein  
synthesis   in   MCF10AER   IN9   cells   treated   with   non-­coding   (NC)   siRNA   or   ERa   siRNA  
SmartPool   followed   by   100   nM   BHPI   (n   =   4).   (D)   Protein   synthesis   and   immunoblot  
analysis  of  ERa  protein  levels  in  MCF10AER  IN9  cells  pre-­treated  with  1  µM  ICI  for  24  hours  
to  degrade  ERa,  followed  by  treatment  with  100  nM  BHPI  (n  =  4).  (E)  Residual  protein  
synthesis  (untreated  cells  are  set  to  100%)  after  treatment  with  1  µM  BHPI  in  Doxycycline-­
treated  MCF7ERaHA  cells   expressing   increasing   levels  of  ERa   (n  =  6).  Western  blot  
shows  ERa   levels   in   each   sample.   (F)   Time   course   of   phosphorylation   of  PERK  and  
eIF2a  following  BHPI  treatment  of  MCF-­7  cells.  (G)  eIF2a  phosphorylation  and  protein  
synthesis  after  4-­day  treatment  of  MCF-­7  cells  with  either  50  nM  non-­coding  (NC)  siRNA  
or   PERK   siRNA,   followed   by   treatment   with   BHPI   (n   =   4).   (H)  Western   blot   analysis  
showing  full-­length  (p90-­ATF6a)  and  cleaved  p50-­ATF6a  in  BHPI-­treated  cells  and  effect  
of   BHPI   on   levels   of   spliced-­XBP1  mRNA   (sp-­XBP1).   (I)   BHPI   increases   intracellular  
calcium   levels.   Visualization   of   intracellular   Ca2+   using   Fluo-­4   AM;;   BHPI   (1   µM)   was  
added  to  MCF-­7  cells  at  30  sec.  Color  scale  from  basal  Ca2+  to  highest  Ca2+:  blue,  green,  
red,   white.   (J)   Inhibiting   opening   of   the   endoplasmic   reticulum   IP3R   Ca2+   channel  
abolishes  BHPI   inhibition  of  protein  synthesis.  The   ryanodine  and   IP3R  Ca2+  channels  
were  pre-­blocked  with  100  µM  ryanodine  (RyR)  and  100  μM  2-­amino  propyl-­benzoate  (2-­
APB),   respectively,   followed   by   70   nM   BHPI   for   3   hours   (n   =   4).   (K)   Quantitation   of  
cytosolic  Ca2+  levels  after  treating  MCF-­7  cells  with  either  50  nM  non-­coding  (NC)  siRNA,    
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Figure  3.7  (cont.)  
  
pan  IP3R  siRNA  SmartPool,  followed  by  treatment  with  BHPI  (n  =  10).  IP3R  SmartPool  
contained  equal  amounts  of  three  individual  SmartPools  directed  against  each  isoform  of  
IP3R.  (L)  Effects  of  BHPI  on  protein  synthesis  in  MCF-­7  cells  treated  with  either  100  nM  
NC   siRNA,   pan-­IP3R   siRNA,   or   PLCg   siRNA   SmartPool   (n   =   4).   (M)   Quantitation   of  
intracellular  IP3  levels  following  treatment  of  MCF-­7  cells  for  10  min.  with  E2  or  BHPI  (n=3)  
(N)  Model  of  BHPI  acting  through  the  UPR,  eEF2  and  AMPK  to  kill  ERa+  cancer  cells.  
Data  is  mean  ±  S.E.M.  Different  letters  indicate  a  significant  difference  among  groups  (p  
<  0.05)  using  one-­way  ANOVA  followed  by  Tukey’s  post  hoc  test.  ns,  not  significant.  ***P  
<   0.001,   compared   with   NC   control.   ns,   not   significant.   I   designed   and   performed  
research  experiments,  and  analyzed  data  for  the  panel  I,  J,  K,  and  M.  
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Figure  3.8.  BHPI  selectively  inhibits  protein  synthesis  in  ERa positive  cells  in  26  
cells  lines.  (A)  Comparison  of  ERa protein  levels  and  the  effects  of  BHPI  treatment  on  
protein  synthesis  in  23  cell  lines.  The  number  of  samples  was  too  large  to  run  on  a  single  
gel   and   the   data   is   from   3   identically   processed   gels.   (B)   Effects   of   BHPI   on   protein  
synthesis   in  ERa-­  Mouse  Embryo  Fibroblast   (MEF)  cells.   Incorporation  with  no  added  
BHPI  was  set  to  100%.  In  general,  protein  synthesis  in  cells  expressing  moderate  or  high  
levels  of  ERa was  robustly  inhibited  by  100  nM  BHPI  (yellow  bars),  while  10,000  nM  BHPI  
(orange  bars),   the  highest   concentration   tested,   had   very   little   or   no  effect   on  protein  
synthesis  in  ERa negative  cells.  Cells  expressing  low  levels  of  ERa,  more  typical  of  non-­
transformed  ERa containing  cells,  such  as  PC-­3  prostate  cancer  cells,  were  much  less    
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Figure  3.8  (cont.)  
  
sensitive   to  BHPI   inhibition  of  protein  synthesis.  Western  blot  of  ERa protein   levels   in  
MEF   cells.   (C)   Dose-­response   curve,   which   shows   the   effects   of   increasing  
concentrations  of  BHPI  on  protein  synthesis  in  MCF-­7  cells  following  24-­hour  treatment.  
The  narrow  dose-­response  curve  is  consistent  with  either  activation  of  the  autoactivated  
kinase  PERK,  or  with  a  threshold  level  of  calcium  required  for  PERK  activation  (D)  Time  
course  showing  the  effect  of  100  nM  BHPI  on  protein  synthesis  in  MCF-­7  cells.  Data  is  
the   mean   ±   SEM   (n   =   4).   I   designed   and   performed   research   experiment,   and  
analyzed  data  for  the  panel  B.  
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Figure   3.9.   Activation   of   the   estrogen   binding   protein,   GPR30,   or   inhibition   of  
mTOR,   have   minimal   effects   on   protein   synthesis.   (A)   Western   blot   analysis   of  
ERa levels   after   treatment   of   MCF-­7   cells   with   either   100   nM   non-­coding   SmartPool  
siRNA  or  100  nM  SmartPool  ERa siRNA.  Effects  of  the  GPR30  activator,  G1,  on  (B)  MCF-­
7   and   (C)   BG-­1/MCF-­7   cells.   Cells   were   plated   at   10,000   cells/well,   the   indicated  
concentrations  of  G1  (0-­  100  nM)  were  added  for  the  times  indicated,  and  35S-­Methionine  
incorporation  was  used  to  assess  rates  of  protein  synthesis.  Protein  synthesis  with  no  
added  G1  was  set  to  100%.  (D)  The  effects  of  rapamycin  (RAP)  on  protein  synthesis  in  
MCF-­7  cells  in  the  absence  of  growth  factors  (blue  bars),  or  in  the  presence  of  10  nM  E2  
(red  bars)  or  10  μg/ml  Insulin  (green  bars).  Inhibition  of  mTORC1  with  rapamycin  blocks  
insulin-­dependent   increases   in  protein  synthesis   (green  bars)  and  substantially  blocks  
estrogen-­dependent   increases   in   protein   synthesis   (red   bars).   In   contrast,   BHPI   and  
cycloheximide  (CHX)  treatment  elicit  near-­quantitative  inhibition  of  protein  synthesis,  far  
below  baseline  levels  of  protein  synthesis  (blue  bars).  Data  is  mean  ±  SEM  (n  =  4).  
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Figure  3.10.  Endoplasmic  reticulum  (EnR)  stress  activates   the   three  arms  of   the  
UPR.   (A)   EnR   stress   induces   the   oligomerization   and   phospho-­activation   of   the  
transmembrane   kinase   PERK.   P-­PERK   phosphorylates   eukaryotic   initiation   factor  
2a (eIF2a),  leading  to  inhibition  of  protein  synthesis  and  a  reduction  in  the  endoplasmic  
reticulum  protein  folding  load  (46,  47).  Reduced  protein  synthesis  increases  levels  of  the  
transcription  factor,  ATF4.  ATF4  induces  the  transcription  factor  CHOP,  which  induces  
GADD34  and  several  pro-­apoptotic  genes.  (B)  EnR  stress  promotes  the  translocation  of  
the  transmembrane  protein,  p90-­ATF6α,  from  the  EnR  to  the  Golgi  Apparatus,  where  it  
encounters  proteases  that  liberate  the  N-­terminal  fragment  of  ATF6α  (p50-­ATF6).  p50-­
ATF6   increases   the   protein-­folding   capacity   of   the   EnR   by   inducing   EnR-­resident  
chaperones,   including   BiP   and   GRP94   (47-­48).   (C)   EnR   stress   induces   the  
oligomerization  and  phospho-­  activation  of   the   transmembrane  protein,   IRE1a (46,  47,  
49).   Activated   IRE1a removes   an   intron   from   full-­   length   XBP1   (fl-­XBP1)   mRNA,  
producing   spliced   (sp)-­XBP1  mRNA,   which   is   subsequently   translated   into   sp-­   XBP1  
protein   (sp-­XBP1).   sp-­XBP1   increases   the   protein-­folding   capacity   of   the   EnR   and  
turnover  of  misfolded  proteins  by  inducing  EnR  resident-­chaperone  protein  genes  (BiP,  
HEDJ,  SERP1),  EnR-­associated  degradation  (ERAD)  genes  and  alters  mRNA  decay  and  
translation  (36,  47).  
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Figure  3.11.   In  ERa positive  cell   lines,  BHPI  rapidly   inhibits  protein  synthesis  by  
activating   the  PERK  arm  of   the  UPR.   (A)   Time  course  of  BHPI   inhibition  of   protein  
synthesis.   ERa positive  MCF-­7,   T47D,   and   BG-­1/MCF-­7   cells   were   incubated   for   the  
indicated  times  with  1  µM  BHPI.  Set  to  100%  was  incorporation  of  35S-­methionine  into  
protein  at  time  =  0.  Data  is  mean  ±  SEM  (n  =  4).  At  30  min.  with  BHPI,  35S-­methionine  
incorporated   into   protein   was   reduced   by   ~50%.   (B)   In   the   presence   [+E2],   BHPI  
increases  p-­eIF2α  (Ser-­51)  in  ERa+  MCF-­7,  BG-­1/MCF-­7,  and  T47D  cells.  In  the  absence  
of  estrogen  (-­E2),  BHPI  increases  eIF2a phosphorylation  in  ERa+  MCF-­7  cells.  (C)  BHPI  
does  not  increase  p-­eIF2α  in  ERa negative  MDA  MB-­231  cells.  Since  the  UPR  activator  
Tunicamycin   (TUN)   increased   p-­eIF2a in   these   cells,   the   absence   of   BHPI   induced  
phosphorylation  of  eIF2a in  the  MDA-­MB-­231  cells  was  not  due  to  the  inability  of  UPR  
activation  to  induce  eIF2a phosphorylation.  (D)  Induction  of  CHOP  and  GADD34  mRNA  
in  MCF-­7   cells   following   treatment  with   1  µM  BHPI,   as   determined   by   qRT-­PCR.   (E)  
Induction   of   CHOP  mRNA   in   BG-­1/MCF-­7   cells   following   treatment   with   1  µM  BHPI.  
Increased   levels   of   ATF4   induce   the   transcription   factor,   CHOP,   which   then   induces  
GADD34.  Increased  phosphorylation  of  eIF2a results  in  translational  upregulation  of  the    
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Figure  3.11  (cont.)  
  
transcription  factor,  ATF4.  ATF4  contains  short,  inhibitory  upstream  open  reading  frames  
(uORFs),   which   normally   inhibit   translation   of   ATF4  mRNA   (46).  Under   conditions   of  
reduced  eIF2a availability,  the  inhibitory  uORFs  are  skipped,  allowing  ATF4  translation.  
(F)   Effects   of   100   nM   BHPI   on   protein   synthesis   following   transfection   of   ECC-­1  
endometrial   cells  with  either  a  dominant-­negative  eIF2aS51A  mutant  or  empty  vector.  
Data  is  the  mean  ±  SEM  (n  =  4).  ***  p  <0.001.  (G)  Time  course  of  phosphorylation  of  PERK  
(Thr-­980)  and   total  PERK  protein   levels   following   treatment  with  BHPI   in  MCF-­7  cells.  
PERK-­Thr980  phosphorylation  serves  as  a  marker  of  PERK  activation.  
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Figure   3.12.   Blocking   PERK   activation   or   PERK   knockdown   largely   blocks  
inhibition  of  protein  synthesis  at  early   times  after  BHPI   treatment,  but  does  not  
prevent  BHPI   from   inhibiting  protein  synthesis  at   later   times.   (A)   Inhibiting  PERK  
activation  with   the  PERK   inhibitor,  GSK2606414   (PERKi)   (50,   51),   blocks   rapid  BHPI  
inhibition  of  protein  synthesis  in  MCF-­7  and  T47D  cells  (n  =  4).  Cells  were  pre-­treated  for  
1  hour  with  DMSO-­vehicle  or  1  μM  GSK2606414,   followed  by   treatment  with  100  nM  
BHPI  for  the  indicated  times.  (B)  RNAi  knockdown  of  PERK  mRNA  and  protein.  MCF-­7  
cells  were  transfected  with  either  50  nM  PERK  siRNA  SmartPool  (PERK)  or  with  50  nM  
of  a  control  non-­coding  SmartPool  (NC).  PERK  mRNA  levels  were  determined  by  qRT-­
PCR  with  36B4  as  internal  standard.  Set  to  1  at  each  time  was  the  level  of  PERK  mRNA  
in  cells  transfected  with  the  Non-­coding  control  (NC)  siRNA.  Shown  is  a  Western  blot  of  
PERK  protein  levels  after  transfection  with  PERK  siRNA  and  control  siRNA  (NC).  Null:  
control  cells,  no  transfection;;  Lip:  liposome  only  no  siRNA.  Data  is  the  mean  ±  SEM.  ***  
p   <   0.001;;   ns,   not   significant   (p   >   0.05).   I   designed   and   performed   research  
experiment,  and  analyzed  data  for  the  panel  A.  
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Figure  3.13.  BHPI  activates  the  UPR  through  depletion  of  endoplasmic  reticulum  
calcium  stores  in  ERa+  MCF-­7  breast  cancer  cells,  but  not  in  ERa-­  HeLa  cervical  
cancer  cells.  (A)  Protein  synthesis  in  MCF-­7  cells  treated  for  2  hours  with  UPR  activators  
(n  =  6).  Effect  of  BHPI  and  Thapsigargin  (THG)  on  intracellular  calcium  levels  in  (B)  ERa+  
MCF-­7  breast  cancer  cells  and  (C)  ERa-­  HeLa  cervical  cells.  Although  BHPI  has  no  effect,  
HeLa  cells  remain  sensitive  to  Thapsigargin.  Cells  visualized  with  the  Ca2+sensitive  dye  
Fluo-­4  AM.  Low  levels  of  basal  [Ca2+]  are  blue  and  then  green,  whereas  higher  levels  of  
[Ca2+]  are  seen  as  red,  with  the  highest  levels  white.  Trace  represents  calcium  following  
treatment  with  Thapsigargin  or  BHPI.  Intensity  was  normalized  to  the  basal  signal,  which  
was   set   to   1.   Data   is   mean   ±   SEM   (n   =   10).   I   designed   and   performed   research  
experiments,  and  analyzed  data  for  the  entire  figure.  
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Figure  3.14.  Effects  of  BHPI  on  IP3R,  IP3,  and  PLCg.  (A)  Western  blot  analysis  of  pan-­
IP3R  protein  levels  after  treatment  of  MCF-­7  cells  with  either  100  nM  non-­coding  (NC)  
SmartPool  siRNA  or  100  nM  SmartPool  IP3R  siRNA.  Data  in  panel  A  is  from  ([40]).  (B)  
Time   course   of   phosphorylation   of   the   IP3R   Ca2+-­channel   and   total   IP3R   following  
treatment  with  BHPI.  Phosphorylation  of   IP3R  at  Ser-­1756  by  cyclic  AMP-­  dependent  
protein  kinase  A  (PKA)  regulates  the  activity  of  the  IP3R  Ca2+  channel.  While  BHPI  had  
no  effect,  the  MCF-­7  cells  contain  a  functional  protein  kinase  A  pathway  since  the  protein  
kinase  A  activators,  IBMX  and  Forskolin,  increased  phosphorylation  of  IP3R.  (C)  Effects  
of  BHPI  on  cytosol  Ca2+  following  either  PLCg knockdown  or  blocking  PLCg activation  with  
U73122.  Western  blot  shows  PLCg protein  levels  following  treatment  of  MCF-­7  cells  with  
either   100   nM   non-­coding   SmartPool   siRNA   or   100   nM   SmartPool   PLCg  siRNA.   (D)  
Effects  of  BHPI  on  phosphorylation  and  activation  of  PLCg.  Phosphorylation  of  PLCg at  Tyr-­
1756  regulates  the  activity  of  PLCg.  MCF-­7  cells  were  treated  for  10  min.  with  1  µM  BHPI.  
(E)   Effects   of   overexpressing   ERa on   BHPI-­induced   increases   in   IP3   levels.   ERa in  
MCF7ERaHA  cells  was   induced  with  DOX  as  described   in  Figure  3E.   IP3   levels  were  
determined   10   min.   after   treatment   with   1   µM   BHPI.   Data   is   mean   ±   SEM   (n=3).   I  
designed  and  performed  research  experiments,  and  analyzed  data  for  the  panel  C  
and  E.  
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Figure  3.15.  Comparison  of  effects  of  17b-­estradiol  (E2)  and  estrogen-­dendrimer-­
conjugate  (EDC)  on  the  ability  of  ERa to  activate  (A)  GREB1,  (B)  PI-­9,  and  (C)  Fos  
expression.  These  are  classical  estrogen-­regulated  genes.  (D)  Comparison  of  the  effects  
of  E2  and  EDC  on  the  ability  to  induce  spliced-­XBP1  (sp-­XBP1),  which  is  a  widely  used  
marker   of   UPR   activation.   I   designed   and   performed   research   experiments,   and  
analyzed  data  for  the  entire  figure.  
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Figure   3.16.   BHPI   interacts   with   ERa   and   inhibits   E2-­ERa   regulated   gene  
expression.  (A)  Fluorescence  emission  spectra  of  full-­length  ERa  in  the  presence  of  E2  
and  either  DMSO,  500  nM  BHPI,  or  500  nM  of  the  BHPI-­related  inactive  Compound  8  
(C8).  (B)  ERa  LBD  was  subjected  to  proteinase  K  digestion  in  the  presence  of  DMSO  
vehicle,   C8,   or   BHPI.   Bands   were   visualized   by   Coomassie-­staining.   (C)   qRT-­PCR  
showing  pS2  mRNA  in  MCF-­7  cells  pre-­treated  for  0.5  hours  with  BHPI,  cycloheximide  
(CHX),  Tunicamycin  (TUN),  Thapsigargin  (THG),  or  DMSO,  followed  by  treatment  with  or  
without  E2  for  2  hours.  (D)  BHPI  is  a  non-­competitive  ERa  inhibitor.  qRT-­PCR  showing  
pS2  mRNA  in  MCF-­7  cells  treated  with  BHPI  or  the  competitive  inhibitor  ICI,  and  low  (1  
nM)  or  high  (1,000  nM)  E2.  (E)  ChIP  showing  effect  of  BHPI  on  recruitment  of  E2-­ERa  
(green  bars)  and  RNA  polymerase  II  (RNAP,  yellow  hatched  bars)  to  the  promoter  region  
of  pS2.  (F)  qRT-­PCR  showing  GREB1  mRNA  levels  in  MCF7ERaHA  cells  after  1  day  +  
or  –  doxycycline  (DOX),  pre-­treated  for  30  minutes  with  BHPI  or  DMSO,  followed  by  4  
hours  with  or  without  E2.  Concentrations:  E2,  500  nM  (A  and  B),  10  nM  (C-­F);;  BHPI,  500  
nM  (A)  or  1  μM  (B-­F);;  C8,  500  nM  (A)  or  1  μM  (B);;  CHX,  10  μM;;  THG,  1  μM;;  TUN,  10  
μg/ml.  Data  is  mean  ±  SEM  (n  =  3).  *  P  <  0.05,  **  P  <  0.01,  ***P  <  0.001,  compared  with  
+E2  samples.  n.s.,  not  significant.   I  designed  and  performed  research  experiments,  
and  analyzed  data  for  the  panel  A  and  B.     
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Figure  3.17.  BHPI  inhibits  E2-­ERa regulated  gene  expression.  (A)  Comparison  of  the  
effects   of   BHPI,   the   protein   synthesis   inhibitor   cycloheximide   (CHX),   and   the   UPR  
activators  Tunicamycin  (TUN)  or  thapsigargin  (THG)  on  protein  synthesis.  Since  protein  
synthesis  was  robustly  inhibited  by  CHX  after  120  minutes,  this  time  was  used  in  the  gene  
expression  studies.  Effects  of  BHPI  on  E2-­ERa induction  of  (B)  pS2,  (C)  GREB1  and  (D)  
CXL2   mRNAs   and   (E)   XBP1   in   MCF-­7,   T47D   and   BG-­1/MCF-­7   cells.   Cells   were  
pretreated  with  either  1  µM  BHPI  (+E2,  BHPI),  10  µM  cycloheximide  (+E2,  CHX),  or  0.1%  
DMSO  (+E2;;  -­E2)  for  30  minutes,  followed  by  treatment  with  either  10  nM  E2  (+E2;;  +E2,  
BHPI;;  +E2,  CHX)  or  0.1%  ethanol-­vehicle  control  (-­E2)  for  2  hours.  (F)  Dose  response  
studies  of  the  effect  of  BHPI  on  E2-­ERa induction  of  ERE-­luciferase  activity  in  ERa positive  
T47D-­kBluc   breast   cancer   cells   (black   bars)   and   for   dihydrotestosterone-­androgen  
receptor   (DHT-­AR)   induction   of   prostate   specific   antigen   (PSA)-­luciferase   in  
ERa negative  HeLaA6  cells  (open  bars).  HeLaA6  cells  are  stably  transfected  to  express  
AR  and  a  PSA-­luciferase  reporter.  Supporting  specificity  of  BHPI,  it  did  not  inhibit  DHT-­
AR  induction  of  ARE-­luciferase.  BHPI  blocks  E2-­ERa down-­regulation  of  EFNA1  in  MCF-­
7  cells(E)  and  IL1-­R1  in  T47D  cells  (G).  Data  is  mean  ±  SEM  (n  =  3).  
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Figure  3.18.  BHPI  is  a  non-­competitive  inhibitor  that  reduces  binding  of  E2-­ERa to  
gene  regulatory  regions.  BHPI  does  not  compete  with  estrogens  for  binding  to  ERa.  
(A)   Competitive   radioligand   binding   assay   comparing   the   ability   of   E2   and   BHPI   to  
compete  with  [3H]  estradiol  (E2)  for  binding  to  ERa.  The  relative  binding  affinity  (RBA)  of  
BHPI  for  the  estrogen-­binding  pocket  of  ERa was  determined  using  0.2  nM  [3H]  E2  and  
a   range   of   BHPI   concentrations.   RBA   values   were   determined   from   the   competitive  
radiometric  binding  assay  (43,  52).  Values  are  expressed  as  percentages  relative  to  the  
affinity  of  the  standard,  E2  =  100%.  (B)  Western  blots  showing  that  at  early  times  after  
treatment  with  1  µM  BHPI,  ERa protein   levels  are  nearly  unchanged.  (C)  Western  blot  
showing  that  treatment  of  MCF-­7  cells  with  1  µM  BHPI  does  not  inhibit  nuclear  localization  
of  ERa.  a-­Tubulin  and  lamin  A/C  were  controls  for  the  cytoplasmic  and  nuclear  fractions,  
respectively.  ERa protein   levels   and  nuclear   localization  were   assessed  2   hours   after  
treatment,  which  was  the  same  time  used  to  assess  endogenous  mRNA  levels  of  E2-­
ERa regulated   genes   via   qRT-­PCR.   (D)   ChIP   shows   that   1   µM   BHPI   BHPI   inhibits  
recruitment  of  E2-­ERa (black  bars)  and  RNA  polymerase  II  (RNAP,  hatched  bars)  to  the  
GREB1  promoter  region.  Data  is  mean  ±  SEM  (n  =  3).  *  Significant  at  (p  <0.05).  
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Figure  3.19.  BHPI  depletes  intracellular  ATP  stores,  activates  AMPK,  and  inhibits  
protein   synthesis   at   a   second   site.   (A)   Inhibiting  SERCA  pumps  with   Thapsigargin  
(THG)  prevents  BHPI  from  reducing  intracellular  ATP  levels.  Western  blot  showing  effect  
of   THG   (1   μM)   or   BHPI   (1   μM)   treatment   of   MCF-­7   cells   on   AMPKα-­Thr172  
phosphorylation.  ATP  levels  in  MCF-­7  cells  treated  with  1  μM  BHPI,  or  1  μM  BHPI  and  1  
μM   THG   (n   =   5).   (B)  Western   blot   analysis   of   the   time   course   of   AMPKa   (Thr-­172),  
AMPKβ   (Ser-­108),   acetyl   CoA   carboxylase   (ACC)   (Ser-­79)   phosphorylation   in   BHPI-­
treated  MCF-­7  cells.  AMPKa-­Thr172  and  AMPKβ-­Ser108  phosphorylation  are  required  for  
AMPK  activation.  (C)  Western  blot  analysis  of  eEF2  phosphorylation  (Thr-­56)  over  time  
in  BHPI-­treated  ERa+  MCF-­7  cells.  (D)  Western  blot  analysis  showing  the  time  course  of  
decreasing   eEF2K   (Ser-­366)   phosphorylation   in   BHPI-­treated   MCF-­7   cells.   Ser-­366  
dephosphorylation  activates  eEF2K.  (E)  qRT-­PCR  analysis  showing  changes  in  p58IPK  
mRNA  and  Western  blot  analysis  showing  p58IPK  and  BiP  protein  after   treatment  with  
BHPI  (n  =  3).    -­E2  set  to  1.  
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Figure  3.20.  Conventional  UPR  activators  do  not  induce  phosphorylation  of  eEF2,  
but   induces   transient   eIF2a phosphorylation,   transient   inhibition   of   protein  
synthesis,   and   induction   of   chaperones.   (A)   Analysis   of   the   time   course   of  
Thapsigargin  (THG)  effects  on  phosphorylation  of  eIF2a (Ser-­51),  AMPKa (Thr-­172),  ACC  
(Ser-­79),  and  eEF2  (Thr-­56).  Unlike  BHPI,  Thapisgargin  does  not  induce  phosphorylation  
of  eEF2  but  induces  transient  phosphorylation  of  eIF2a.  Western  blots  of  the  time  course  
of  BHPI  effects  on  phosphorylation  of  eEF2  (Thr-­56)  in  (B)  ERa positive  T47D  and  (C)  
ERa negative  HeLa  cells.  T47D  Cells  were  pre-­treated  with  10  nM  E2  for  24-­hours.  eEF2  
is   essential   for   protein   synthesis,   and   eEF2-­Ser56   phosphorylation   inactivates   eEF2,  
blocking  the  elongation  step  of  protein  synthesis.  The  positive  controls,  Forskolin  (FOR)  
and  Rottlerin  (ROT)  induce  robust  eEF2  phosphorylation,  demonstrating  eEF2  retains  the  
capacity   for   phosphorylation   in   HeLa   cells.   (D)   Inhibiting   AMPK   phosphorylation   and  
activation  with  ST-­609  did  not  block  BHPI-­stimulated  phosphorylation  of  eEF2.  Effects  of  
BHPI  on  Thr-­202/Thr-­204  phosphorylation  of  p44/p42  MAPK  (p-­ERK)  in  ERa positive  (E)  
MCF-­7  cells  and  (F)  T47D  cells.  Activation  of  p44/p42  MAPK  promotes  the    
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Figure  3.20  (cont.)  
  
phosphorylation  and  inactivation  of  eEF2K.  The  classical  ERK  activator,  EGF  (20  ng/ml),  
served  as  a  positive  control  for  ERK1/2  phosphorylation.  As  a  control,  cells  were  treated  
with  10  μM  UO126  for  the  indicated  times.  U0126  inhibits  the  upstream  kinase  MEK1/2,  
inhibiting  ERK1/2  phosphorylation.  UO126  pre-­treatment  was  for  2  hours.  (G)  Effects  of  
blocking   ERK   activation   with   U0126   on   BHPI-­induced   phosphorylation   of   eEF2.   By  
inhibiting  the  ERK  pathway,  UO126  allows  eEF2K  to  be  active  and  the  reduced  activation  
seen  at  0.5  and  1  hours  due  to  BHPI-­induced  ERK  activation  is  abolished.  
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Figure  3.21.  The  UPR  activators,  Thapsigargin  and  Tunicamycin,  reversibly  activate  
the   UPR.   Induction   of   BiP   and   p58IPK   normally   helps   resolve   UPR   stress   and  
reverses   UPR   activation.   (A)   Time   course   of   THG   inhibition   of   protein   synthesis.  
Consistent   with   transient   phosphorylation   of   eIF2a by   THG   (see   Figure   S15A)   and  
resolution  of  UPR  stress,  protein  synthesis  begins  to  recover  at  4  hours  after  treatment  
with  THG.  (B)  Western  blot  analysis  of  phosphorylation  of  eIF2a following  TUN  treatment.  
TUN  induces  transient  phosphorylation  of  eIF2a.  Western  blot  analysis  showing  the  time  
course  of  Tunicamycin  (TUN)  induction  of  BiP  (C)  and  p58IPK  (D)  in  MCF-­7  cells.  Data  in  
panel  C  is  from  ([40],  supplementary  figures).  Data  is  mean  ±  SEM  (n  =  3).  (A-­D)  24-­hour  
pre-­treatment  with  10  nM  E2.  
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CHAPTER  4  
TARGETING  MULTIDRUG-­RESISTANT  OVARIAN  CANCER  THROUGH  ESTROGEN  
RECEPTOR  a  DEPENDENT  ATP  DEPLETION  CAUSED  BY  HYPERACTIVATION  OF  
THE  UNFOLDED  PROTEIN  RESPONSE  3  
  
ABSTRACT  
Ovarian  cancers  often  recur  and  tumors  acquire  resistance  to  chemotherapy  due  
to   overexpression   of   the   ATP-­dependent   efflux   pump,   multidrug   resistance   protein   1  
(MDR1/P-­glycoprotein/ABCB1).  Nontoxic  small  molecule  inhibitors  targeting  MDR1  have  
remained   largely   elusive.   Instead,   in   a   novel   application   of   our   recently   described  
estrogen   receptor  a   (ERa)   biomodulator,   BHPI,  we   targeted  MDR1’s   substrate,   ATP.  
BHPI  depletes  intracellular  ATP  and  nearly  blocks  MDR1-­mediated  drug  efflux  in  ovarian  
cancer  cells  by  inducing  toxic  hyperactivation  of  the  endoplasmic  reticulum  stress  sensor,  
the  unfolded  protein  response  (UPR).  BHPI  increased  sensitivity  of  MDR1  overexpressing  
multidrug  resistant  OVCAR-­3  ovarian  cancer  cells  to  killing  by  paclitaxel  by  >1,000  fold.  
BHPI  also  restored  doxorubicin  sensitivity  in  OVCAR-­3  cells  and  in  MDR1  overexpressing  
breast  cancer  cells.  In  an  orthotopic  OVCAR-­3  xenograft  model,  paclitaxel  was  ineffective  
and  the  paclitaxel-­treated  group  was  uniquely  prone  to  form  large  secondary  tumors  in  
adjacent   tissue.   BHPI   alone   strongly   reduced   tumor   growth.   Notably,   tumors   were  
undetectable   in   mice   treated   with   BHPI   plus   paclitaxel.   Compared   to   control   ovarian  
tumors,   after   the   combination   therapy,   levels  of   the  plasma  ovarian   cancer  biomarker  
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CA125  were  at  least  several  hundred  folds  lower;;  moreover,  CA125  levels  progressively  
declined   to   undetectable.   Targeting   MDR1   through   UPR-­dependent   ATP   depletion  
represents  a  promising  therapeutic  strategy.  
  
INTRODUCTION  
Ovarian   cancer   usually   presents   at   an   advanced   stage   and  more   than   half   of  
ovarian  cancer  patients  die  within  5  years  [1-­3].  Although  30-­70%  of  ovarian  tumors  are  
estrogen   receptor   a   (ERa)   positive,   endocrine   therapy   is   largely   ineffective   [4-­6].  
Recurrent   ovarian   tumors   are   therefore   treated   with   chemotherapy.   Although   initially  
responsive,   after   several   cycles   of   treatment   tumors   often   recur   as   resistant   ovarian  
cancer,  with  few  therapeutic  options  [7].  In  ovarian  cancer,  the  most  common  mechanism  
for  resistance  to  paclitaxel  and  other  chemotherapeutic  agents  is  overexpression  of  ATP-­
dependent  membrane  efflux  pumps  of  the  ABC  transporter  family,  especially  Multidrug  
Resistance   Protein   1   (MDR1)/P-­glycoprotein/ABCB1   [8-­13].   MDR1-­mediated   efflux  
reduces   intracellular   drug   concentrations   to   levels   at   which   the   drugs   are   no   longer  
effective   at   doses  patients   can   tolerate   [8,   12,   13].  Despite   intensive   efforts,   clinically  
effective  non-­toxic  small  molecule  MDR1  inhibitors  have  not  been  described  [14].  Instead  
of  inhibition  of  MDR1  we  target  its  substrate,  ATP.  MDR1-­mediated  efflux  is  exquisitely  
sensitive   to   reductions   in   ATP   levels   [15-­17].   However,   selective   depletion   of   ATP   in  
cancer  cells  has  been  little  studied  and  is  difficult  to  achieve.  
We   recently   described   the   novel   non-­competitive   estrogen   receptor   α   (ERα)  
biomodulator,  BHPI,  which  is  effective  in  models  of  ERa+  breast  cancer  [18].  In  cancer  
cells,  BHPI,  acting  via  ERa,  induces  sustained  toxic  hyperactivation  of  the  endoplasmic  
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reticulum   (EnR)   stress   sensor,   the   unfolded   protein   response   (UPR)   [18].   The   UPR  
consists  of  three  main  branches  that  together  balance  the  synthesis  of  new  proteins  with  
the  availability  of  chaperones  and  other  proteins  to  help  fold  and  transport  proteins  within  
cells  [19,  20].  In  the  classical  reactive  mode,  EnR  stress  resulting  from  accumulation  of  
unfolded  or  misfolded  protein,  or  other  stresses,  triggers  UPR  activation  [19-­21].  In  the  
recently   unveiled   anticipatory   mode   of   UPR   activation,   estrogen   or   other   mitogenic  
hormones  pre-­activate  the  UPR  and  anticipate  a  future  need  for  increased  protein  folding  
capacity  [22,  23].  BHPI  distorts  this  normal  anticipatory  pathway  by  binding  to  a  different  
site  on  ERα  than  estrogens  and  inducing  a  different  ERα  conformation  [18].  This  enables  
BHPI  to  act  through  ERα  to  hyperactivate  the  UPR,  converting  it  from  protective  to  toxic  
[18].  BHPI  strongly  activates  phospholipase  C  g  (PLCg),  producing  inositol  triphosphate  
(IP3),   which   binds   to   and   opens   endoplasmic   reticulum   IP3   Receptor   (IP3R)   calcium  
channels  allowing  rapid  efflux  of  calcium  from  the  lumen  of  the  EnR  into  the  cytosol.  
Intracellular   calcium   levels  are   tightly   regulated  by  EnR   transport   channels  and  
pumps   [24,   25].   Opening   the   IP3Rs   and   ryanodine   receptor   (RyR)   calcium   channels  
allows  efflux  of  the  high  concentrations  of  Ca2+  stored  in  the  lumen  of  the  EnR  into  the  
cytosol   [26-­28].   To   produce   this   concentration   gradient,   powerful   ATP-­dependent  
sarcoplasmic/endoplasmic   reticulum   calcium-­ATPase   (SERCA)   pumps   in   the   EnR  
membrane  pump  calcium   from   the  cytosol   into   the  EnR   lumen   [29-­31].  We  show   that  
BHPI  elicits  a  sustained,  IP3R  dependent,  increase  in  cytosol  calcium  in  ovarian  cancer  
cells.  Since  the  IP3R  calcium  channels  remain  open  after  BHPI   treatment,   the  calcium  
pumped  into  the  EnR  by  the  ATP-­dependent  SERCA  pumps  rapidly  leaks  back  out.  We  
hypothesized   that   sustained   BHPI   hyperactivation   of   the   UPR   creates   a   futile   cycle  
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depleting  intracellular  ATP,  and  this  ATP  depletion  might  provide  a  novel  way  to  inactivate  
MDR1.  
Using   cell-­based   and   in   vivo   studies   we   evaluated   the   potential   of   this   novel  
approach  to  restoring  chemosensitivity  of  multidrug  resistant  ovarian  tumors.  Notably,  in  
OVCAR-­3   ovarian   cancer   cells,   which   are   resistant   to   micromolar   paclitaxel,   BHPI  
restored  sensitivity  to  therapeutically  relevant  low  nanomolar  concentrations  of  paclitaxel.  
We  preformed  what  is  perhaps  the  first  orthotopic  intra-­ovarian  mouse  xenograft  study  
using  multidrug  resistant  OVCAR-­3  cells.  Surprisingly,  paclitaxel  was  both  ineffective  and  
actually  appeared  to  promote  metastases,  a  result  not  seen  in  the  other  treatment  groups.  
Notably,   no   ovarian   tumors  were   detected   in   any   of   the  mice   treated  with   BHPI   plus  
paclitaxel.  Moreover,   levels  of   the  circulating  ovarian  cancer  marker,  CA125/mucin  16,  
declined  from  ~700  units/ml  in  control  vehicle-­treated  mice  to  undetectable  in  all  of  the  
BHPI  plus  paclitaxel  treated  mice.  
  
RESULTS  
BHPI   induces  a  sustained   increase   in   intracellular  calcium  through  activation  of  
the  ERα-­PLCg-­IP3R  pathway  
Using  breast  cancer  cells,  we  previously  showed  E2-­ERα  activates  a  PLCg-­IP3R  
pathway  to  release  calcium  from  EnR  stores  into  the  cytosol  [32].  Activated  PLCg  cleaves  
its  substrate  to  produce  IP3.  The  non-­competitive  ERα  biomodulator  BHPI,  that  works  by  
hyperactivating  the  UPR,  produces  much  higher  levels  of  IP3  than  E2  [18].  If  we  were  to  
use  this  pathway  to  target  multidrug  resistant  ovarian  cancer,  we  had  to  first  show  that  
the  pathway  functions  in  ovarian  cancer  cells.  We  initially  quantitated  IP3  levels  in  ERα+  
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PEO-­4  ovarian  cancer  cells  treated  with  E2  or  BHPI.  E2  induced  a  modest  increase  in  IP3  
levels,  while  BHPI  induced  a  much  more  robust  6-­fold  increase  (Figure  4.1A).  
To  test  whether  E2  and  BHPI  rapidly  increase  cytosolic  Ca2+,  we  monitored  calcium  
levels   using   the   fluorescent   calcium   sensor   dye  Fluo-­4  AM.   In   <1  min.,   E2   and  BHPI  
increased   cytosol   Ca2+   in   PEO-­4   cells   (Figure   4.1B,   C).   Notably,   in   the   absence   of  
extracellular  calcium,  E2  elicited  a  transient  ~3.5  fold  increase  in  cytosolic  Ca2+  with  the  
Ca2+  signal  rapidly  returning  to  the  basal  level  (Figure  4.1B).  In  contrast,  BHPI  elicited  a  
sustained  ~7  fold   increase  in  cytosolic  Ca2+  (Figure  4.1C).  Since  pretreatment  with  the  
PLCg   inhibitor  U73122  abolished  the  calcium  release  observed  with  E2  or  BHPI,  PLCg  
activation  was  required  for  the  increase  in  cytosolic  Ca2+  (Figure  4.1B,  C).  BHPI  induced  
a  large  increase  in  cytosolic  Ca2+  even  in  the  absence  of  extracellular  Ca2+,  indicating  that  
BHPI   increases  cytosolic  Ca2+  by  depleting   the  Ca2+  store   in   the  EnR.  Supporting   this  
idea   is  our  observation   that   inhibiting   the   IP3R  Ca2+  channel  with  2-­APB  abolished   the  
rapid  E2  and  BHPI  stimulated  Ca2+  release  (Figure  4.1B,  C  and  Figure  4.2).  In  contrast,  
inhibition  of  RyR  calcium  channels  with  high  concentration  ryanodine  (Ry)  did  not  block  
E2  or  BHPI  stimulated  Ca2+  release  in  PEO-­4  cells  (Figure  4.1B,  C).  Confirming  BHPI’s  
structural   specificity   and   the   requirement   for   ERα,   a   control   compound,   C8,   that   is  
structurally  related  to  BHPI,  but  does  not  bind  ERα  in  vitro  [18],  failed  to  increase  cytosolic  
Ca2+   (Figure   4.1C).   These   results   demonstrate   that  BHPI   strongly   activates   the  ERα-­
PLCg-­IP3R  pathway  in  ovarian  cancer  cells,  resulting  in  a  sustained  increase  in  cytosolic  
Ca2+.  
  
BHPI  activates  the  UPR  in  ovarian  cancer  cells  
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Efflux  of  calcium  stored  in  the  lumen  of  the  EnR  into  the  cell  body  activates  the  
UPR.   The   core   UPR   signaling   cascade   consists   of   3   EnR   sensors   whose   activation  
increases  protein-­folding  capacity  and  temporarily  reduces  protein  production  (Figure  4.2).  
Activation  of  IRE1α,  which  alternatively  splices  the  transcription  factor  XBP1,  produces  
the  widely  used  UPR  marker,  active  spliced  XBP1  (sp-­XBP1)  [33].  Supporting  activation  
of  the  IRE1α  branch  of  the  UPR,  in  PEO-­4  ovarian  cancer  cells,  BHPI  and  E2  robustly  
induced   sp-­XBP1   (Figure   4.3A   and   Figure   4.4A).   Protein   synthesis   is   regulated   by  
autophosphorylation  of  PERK  [34].  Phosphorylated  PERK  (p-­PERK)  phosphorylates  of  
eukaryotic   initiation   factor   2   α   (eIF2α),   which   leads   to   transient   inhibition   of   protein  
synthesis   (Figure   4.2).   E2   induced   a   weak   and   transient   phosphorylation   of   eIF2α   in  
ovarian  cells  (Figure  4.4B),  while  BHPI  elicited  robust  phosphorylation  of  PERK  and  eIF2α  
(Figure  4.3B，  C),  resulting   in   inhibition  of  most  protein  synthesis  (Figure  4.3D)  and  a  
decline  in  total  PERK  and  eIF2α  protein  (Figure  4.3B,  C).  Consistent  with  their  inhibitors’  
ability  to  block  calcium  efflux  (Figure  4.1B，C),  inhibition  of  PLCg  with  U73122  and  locking  
the  IP3R  calcium  channels  with  2-­APB,  but  not  inhibition  of  the  RyR  calcium  channels,  
reversed  BHPI  inhibition  of  protein  synthesis  (Figure  4.3E).  EnR  stress  leads  to  proteolytic  
cleavage  of  ATF6α  to  active  50  kDa  ATF6α  (p50-­ATF6α)  (Figure  4.2)  [35].  Demonstrating  
BHPI  and  E2  activate  the  ATF6α  arm  of  UPR,  E2  and  BHPI  increased  p50-­ATF6α  levels  
in  PEO-­4  cells  (Figure  4.3F  and  Figure  4.4C).  Active  p50-­ATF6α  increases  production  of  
BiP/GRP78/HSPA5  and  other  EnR  chaperones  [35].  BHPI  and  E2  increased  production  
of  BiP  mRNA  in  PEO-­4  ovarian  cancer  cells  (Figure  4.3G  and  Figure  4.4D).  However,  
since   BHPI   inhibited   protein   synthesis   (Figure   4.3D   and   E),   BiP   protein   levels   were  
reduced  in  BHPI-­treated  PEO-­4  cells  (Figure  4.3H).  
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Collectively,  our  findings  in  ovarian  cancer  cells  indicate  that  E2-­ERα  induces  weak  
and  transient  anticipatory  activation  of  the  UPR  and  that  BHPI  distorts  this  UPR  pathway  
resulting   in   strong   and   sustained   UPR   activation.   These   data   provide   a   potential  
mechanism  for  inactivating  MDR1  in  ovarian  cancer  cells.  
  
BHPI  depletes  intracellular  ATP  inactivating  MDR1-­mediated  efflux  
We   hypothesize:   (i)   In   response   to   the   BHPI-­mediated   loss   of   EnR   calcium,  
SERCA  pumps  will  carry  out  ATP-­dependent  transport  of  Ca2+  from  the  cytosol  back  into  
the  lumen  of  the  EnR.  (ii)  Since  BHPI  elicits  sustained  increases  in  cytosolic  Ca2+  (Figure  
4.1C),   indicating   the   IP3R   calcium   channels   remain   open,   calcium   pumped   from   the  
cytosol  into  the  lumen  of  the  EnR  leaks  back  out  through  the  open  IP3R  channels,  creating  
a  futile  cycle  that  depletes  ATP  (Figure  4.5A).  To  test  our  hypothesis  we  investigated  the  
effect  of  BHPI  on  ATP   levels   in  ovarian  cancer   cells.  BHPI   treatment   rapidly   reduced  
intracellular  ATP  levels  in  ERα+  PEO-­4  and  OVCAR-­3  ovarian  cancer  cells  (Figure  4.5B,  
C).  Supporting  the  role  of  the  EnR  SERCA  pumps  in  ATP  depletion,  the  SERCA  pump  
inhibitor,  thapsigargin  (THG)  blocked  the  decline  in  ATP  levels  seen  after  BHPI  treatment  
(Figure  4.5B,  C).  
ERa+,  multidrug   resistant,   OVCAR-­3   ovarian   cancer   cells   were   derived   from   a  
patient  whose  cancer  recurred  after  surgery  and  multiple  rounds  of  chemotherapy  [36].  
OVCAR-­3  cells  have  been  propagated  without  cloning  and  therefore  retain  much  of  the  
diversity   of   a   patient   derived   xenograft   [36,   37].  ERa+  MCF-­7  breast   cancer   cells   are  
normally  MDR1  negative  and  sensitive  to  the  chemotherapy  agent  doxorubicin.  MCF-­7  
doxorubicin   (MCF-­7dox)   resistant   breast   cancer   cells   were   generated   by   selection   in  
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increasing  doxorubicin  concentrations  [38,  39].  Confirming  that  upregulation  of  MDR1  is  
a  common  mechanism  in  cancer  cells  resistant  to  cytotoxic  chemotherapy,  both  the  MCF-­
7dox  and  OVCAR-­3  cells  overexpress  MDR1  (Figure  4.5D).  Notably,  while  50  nM  BHPI  
blocked  MCF-­7  proliferation,  500  nM  BHPI  was  required  to  block  proliferation  of  the  MCF-­
7dox  breast  cancer  cells  (Figure  4.6A,  B).  This  is  consistent  with  the  possibility  that  BHPI  
may  be  an  MDR1  substrate.  
The   fluorescent   MDR1   substrate   Rhodamine   123   (Rho-­123)   is   widely   used   to  
quantitate  MDR1-­mediated   efflux   from   cells   into   the  medium   [14,   40].   OVCAR-­3   and  
MCF-­7dox  cells   that  overexpress  MDR1,  and  control  MDR1  negative  PEO-­4  cells  were  
preloaded  with  Rho-­123  and  Rho-­123  efflux  into  the  medium  was  quantitated.  Rho-­123  
efflux  from  the  MDR1  negative  PEO-­4  cells  was  negligible  (Figure  4.7).  OVCAR-­3  and  
MCF-­7dox  cells  exhibited  robust  time-­dependent  efflux  of  Rho-­123  (Figure  4.7).  We  tested  
whether  BHPI-­treatment,  which  reduces  intracellular  ATP  levels,  inhibits  MDR1-­mediated  
Rho-­123  efflux.  In  OVCAR-­3  and  MCF-­7Dox  cells  BHPI  nearly  abolished  Rho-­123  efflux  
(Figure   4.5E,   F).   Consistent   with   the   proposed   futile   cycle   leading   to   ATP   depletion  
causing  inhibition  of  MDR1-­mediated  efflux  (Figure  4.5A),  inhibiting  the  rise  in  intracellular  
Ca2+  by  either  inhibiting  PLCg  with  U73122,  or  by  locking  the  EnR  IP3R  calcium  channels  
closed   with   2-­APB   (Figure   4.1C),   reversed   BHPI   inhibition   of   MDR1-­mediated   efflux  
(Figure  4.5E,  F).  We  next  explored  whether  other  actions  of  BHPI  might  complement  ATP  
depletion  and  contribute  to  the  near  abolition  of  MDR1-­mediated  efflux.  
In  OVCAR-­3  cells,  BHPI  elicited  strong  and  sustained  activation  of  the  PERK  arm  
of   the   UPR   inhibiting   protein   synthesis   cells   by   ~60%   (Figure   4.8A).   This   reduced  
production  of  protein  led  to  an  ~2  fold  decline  in  MDR1  levels  (Figure  4.8B).  Therefore,  
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the  reduced  level  of  MDR1  and  the  decline  in  the  level  of  its  substrate  ATP,  work  together  
to  enable  BHPI   to  nearly  abolish  MDR1-­mediated  efflux.  We   therefore   tested  whether  
BHPI  could  restore  sensitivity  of  OVCAR-­3  and  MCF-­7dox  cells  to  therapeutically  relevant  
concentrations  of  chemotherapy  drugs.  
  
BHPI  resensitizes  resistant  cancer  cells  to  paclitaxel  and  doxorubicin  
OVCAR-­3  cells  were  highly   resistant   to  paclitaxel,   and  were  not   killed,  even  at  
10,000  nM  paclitaxel  (Figure  4.9A).  While  BHPI  alone  blocked  OVCAR-­3  cell  growth,  it  
was  not  cytotoxic.  BHPI  restored  the  cytotoxicity  of  paclitaxel  at  10  nM  paclitaxel,  reducing  
the   number   of   OVCAR-­3   cells   by   ~70%   in   two   days   (Figure   4.9A).   This   represents  
an  >1,000  fold  increase  in  sensitivity  to  paclitaxel.  Furthermore,  OVCAR-­3  cells  were  also  
resistant  to  1,000  nM  doxorubicin;;  BHPI  also  restored  sensitivity  to  doxorubicin  (Figure  
4.9B).  MCF-­7dox  breast  cancer  cells  were  resistant  to  250  nM  doxorubicin.  BHPI  restores  
sensitivity  of  the  MCF-­7dox  cells,  to  the  lowest  dose  of  doxorubicin  tested  (15  nM)  (Figure  
4.9C).   Importantly,   since   the   therapeutic   range   of   concentrations   is   ~15-­20   nM   for  
paclitaxel   and   100-­150   nM   for   doxorubicin   [37,   41,   42],   BHPI   restored   sensitivity   of  
multidrug   resistant   ovarian   and   breast   cancer   cells   to   therapeutically   relevant  
concentrations  of  paclitaxel  and  doxorubicin.  
We  propose  that  BHPI  restores  drug  sensitivity  because  it  strongly  activates  the  
ERa-­PLCg-­IP3R  pathway  leading  to  ATP  depletion  and  a  moderate  reduction  in  MDR1  
expression.   A   testable   alternative   is   that   the   BHPI-­mediated   >1,000   fold   increase   in  
sensitivity  of  OVACR-­3  cells  to  killing  by  paclitaxel  is  simply  due  to  combinatorial  actions  
of   two   toxic  drugs,  BHPI  and  paclitaxel.  OVCAR-­3  cells  are  also   resistant   to  cisplatin,  
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which  is  not  a  substrate  of  MDR1  and  is  therefore  not  pumped  out  by  MDR1  [43].  BHPI  
treatment  did  not  restore  sensitivity  of  OVCAR-­3  cells  to  killing  by  cisplatin  (Figure  4.10A).  
Thus,  BHPI’s  ability  to  abolish  multidrug  resistance  is  due  to   its  ability  to   interfere  with  
MDR1,  and  not  to  the  additive  effects  of  BHPI  in  combination  with  a  chemotherapeutic.  
Consistent  with  BHPI  acting   through  ERa,  BHPI  did  not   inhibit   proliferation  or   restore  
paclitaxel  sensitivity  in  ERa  negative  MDR1  overexpressing  NIH/ADRes  ovarian  cancer  
cells  (Figure  4.10B).  In  addition,  the  inactive  structural  relative  of  BHPI,  C8,  did  not  restore  
paclitaxel  or  doxorubicin  sensitivity  in  OVCAR-­3  cells  (Figure  4.10C).  
We  next  sought  to  confirm  that  the  ability  of  BHPI  to  resensitize  OVCAR-­3  cells  to  
paclitaxel  was  mediated  by  the  PLCg  pathway.  Although  useful  in  short-­term  studies,  the  
long-­term  use  of  PLCg  and  IP3R  inhibitors  U73122  and  2-­APB  may  result  in  secondary  
effects.  Since  simultaneous  knockdown  of  the  three  IP3R  channels  is  somewhat  toxic  [18],  
it   cannot  be  combined  with   the   two  other  drugs.  We   therefore  evaluated   the  effect   of  
siRNA   knockdown   of   PLCg   on   paclitaxel   sensitivity   in   BHPI-­treated   OVCAR-­3   cells.  
siRNA  knockdown  of  PLCg,  but  not  a  control  siRNA,  abolished  BHPI-­mediated  restoration  
of  paclitaxel  sensitivity  (Figure  4.9D,  E).  Thus,  BHPI’s  novel  mechanism  of  action  leads  
to   inactivation  of  MDR1   in  multiple  cell  models,   resulting   in   restoration  of  sensitivity   to  
therapeutically  relevant  concentrations  of  paclitaxel  and  doxorubicin.  
  
BHPI  restores  paclitaxel  sensitivity  and  eliminates  tumors  in  a  multidrug  resistant  
ovarian  tumor  model  
To   assess   in   vivo   effectiveness   of   BHPI   in   restoring   drug   sensitivity,   we   used  
OVCAR-­3   cells,   which   are   resistant   to   therapeutically   relevant   concentrations   of   all  
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common  anticancer  drugs  [36].  We  used  an  orthotopic  model   in  which  OVCAR-­3  cells  
were  grafted  into  the  bursa  of  one  ovary,  the  other  ovary  serving  as  a  control.  At  the  end  
of  the  10  week  study,  ovarian  tumors  were  evident  in  each  of  the  vehicle-­treated  mice,  
with   an   average  weight   of   ~200  mg   (Figure   4.11A,   B).   Surprisingly,   in   the   paclitaxel-­
treated   group   there   were   large   secondary   tumors   in   adjacent   tissue   (Figure   4.11A).  
Increased  metastasis   of   paclitaxel-­treated   OVCAR-­3   tumors   has   not   been   previously  
described  because  this  is  perhaps  the  first  use  of  OVCAR-­3  cells  in  an  orthotopic  ovarian  
model   [44].  BHPI  alone  significantly  reduced  tumor  size  and  weight  (Figure  4.11A,  B).  
Notably,   there   were   no   visible   OVCAR-­3   ovarian   tumors   in   the   combined   BHPI   and  
paclitaxel  treatment  group  and  no  secondary  tumors  were  detected  (Figure  4.11A,  B).  In  
the  BHPI  plus  paclitaxel  group,   the  ovary   injected  with  OVCAR-­3  cancer  cells  and  the  
control  ovary  appeared  identical.  
Although   tumors   were   not   visible   in   the   BHPI   plus   paclitaxel   group,   to   more  
sensitively  assess  whether   tumor  cells  were  still   present,  we  quantified   the  circulating  
level  of  serum  CA125  tumor  antigen.  In  ovarian  cancer,  the  circulating  level  of  CA125  is  
a  widely  used  biomarker  for  therapeutic  progress  and  tumor  recurrence  [45-­47].  Although  
the  basal  level  of  CA125  in  normal  human  serum  is  ~35  U/ml  (Figure  4.11C,  dashed  line),  
the  human  CA125  antibody  does  not  cross-­react  with  control  mouse  serum.  Thus,   the  
level  of  serum  CA125  is  a  sensitive  marker  for  the  survival  of  human  OVCAR-­3  cancer  
cells   in  the  mice.  Serum  samples  were  taken  in  weeks  7-­10  of   the  study  and  assayed  
after  completion  of  the  study.  CA125  levels  in  the  control  vehicle-­treated  group  and  in  the  
paclitaxel-­treated   group   increased   dramatically   in   weeks   7-­10.   Confirming   that   the  
OVCAR-­3  tumors  are  highly  paclitaxel-­resistant,  CA125  levels  were  similar  in  the  control  
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vehicle-­treated   and   paclitaxel-­treated   mice   (Figure   4.11C).   BHPI   strongly   reduced  
circulating  CA125  levels  compared  to  vehicle  or  paclitaxel  alone,  but  CA125  levels  rise  
slightly  from  weeks  7-­10  (Figure  4.11C,  green  line).  Strikingly,  in  the  BHPI  plus  paclitaxel  
treated  mice,  CA125  levels  declined  from  a  low  starting  level  of  ~30  U/ml  at  week  7  to  
concentrations  below  the  detection  limits  for  all  five  mice  at  week  10  (Figure  4.11C,  purple  
line).  Since  the  detection  limit  of  the  assay  is  ±  5  U/ml  and  the  vehicle-­treated  group  had  
circulating  CA125  levels  of  ~700  U/ml,  tumor  burden  was  reduced  by  200  fold  or  more  in  
mice  to  undetectable  levels  after  combined  BHPI  and  paclitaxel  treatment.  Measurement  
of  mouse  body  weights  throughout  the  study  suggested  that  BHPI  alone  and  BHPI  plus  




Although  30-­70%  of  ovarian  cancers  are  ERa+  at  diagnosis,  endocrine  therapy  is  
largely   ineffective   [1-­3].  The   failure  of  endocrine   therapy   raises   the  possibility   that   the  
presence  or  absence  of  ERa  has  little  effect  on  ovarian  tumors  and  there  is  no  selection  
pressure  to  maintain  ERa  in  recurrent  multidrug  resistant  tumors.  However,  recent  studies  
show  that  estrogens,  acting  through  ERa,  enhance  ovarian  tumor  growth  and  increase  
risk  of  lymphovascular  space  invasion  [48,  49].  Moreover,  ERa  expression  correlates  with  
poor   clinical   outcome   in   ovarian   cancer   [50].   The   association   of   ERa   with   late-­stage  
therapy-­resistant   tumors   strongly   suggests   that   ERa   is   maintained   in   many   of   these  
tumors,  making  them  targetable  with  our  small  molecular  biomodulator.  
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Therapeutic   options   are   limited   for   patients   with   recurrent   multidrug   resistant  
ovarian  cancer.  Overexpression  of  MDR1  is  a  major  resistance  mechanism  [8,  13,  14].  
Selective   non-­toxic   inhibitors   of   MDR1   have   proven   difficult   to   identify.   For   MDR1  
inhibitors,  toxicity  due  to  inhibition  of  ABC  transporter  family  members  in  normal  cells  has  
been   a   serious   concern   [8].   BHPI   is   effective   because   it   uses   a   therapeutic   strategy  
different  from  classic  MDR1  inhibitors  and  most  other  cytotoxic  chemotherapeutic  drugs  
[8,  14].  It  works  by  hyperactivating  the  UPR,  a  pathway  that  is  already  partially  activated  
as  a  protective  mechanism  in  tumor  cells.  We  recently  reported  that  elevated  expression  
of  a  UPR  gene  signature  consisting  of  UPR  sensors  and  downstream   targets  of  UPR  
activation   is   tightly   correlated   with   therapy   resistance,   tumor   recurrence   and   a   poor  
prognosis  in  ERa+  breast  cancer  [32].  In  contrast,  the  UPR  is  nearly  off  in  normal  healthy  
cells  and  its  components  are  not  overexpressed  [32].  Consistent  with  this,  BHPI  was  well  
tolerated   in   the   xenograft   study.   While   BHPI   and   estrogen   share   a   common   ERα-­
dependent  pathway  for  UPR  activation  (Figure  4.2),  the  weak  estrogen-­ERα  activation  of  
the  UPR  induces  protective  chaperones  and  is  important  for  subsequent  estrogen-­ERα  
activation   of   gene   expression   and   induction   of   cell   proliferation   [32].   Notably,   BHPI  
binding  to  ERα  is  not  competitive  with  estrogen  binding,  indicating  that  they  bind  ERα  at  
different  sites  [18].  Moreover,  BHPI  induces  conformational  changes  in  ERα  not  seen  with  
estrogen  [18].  Thus,  unlike  estrogen,  BHPI  hyperactivates  the  UPR,  leading  to  persistent  
inhibition  of  protein  synthesis  in  ERα  positive  cancer  cells  [18].  
Strong  and  sustained  activation  of  the  UPR  by  BHPI  creates  a  futile  cycle  leading  
to  depletion  of  intracellular  ATP  and  inactivation  of  MDR1-­mediated  efflux  (Figure  4.5A).  
Supporting  the  proposed  pathway  is  our  observation  that  BHPI  is  only  effective  in  ERa+  
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cells.  Furthermore,  inhibitor  and  knockdown  studies  demonstrate  the  critical  roles  of  PLCg,  
IP3R  calcium  channels  and  SERCA  pumps.  BHPI-­ERα  hyperactivation  of  the  UPR  results  
in  rapid  depletion  of  ATP  leading  to  activation  of  AMPK  [18].  Activated  AMPK  reportedly  
inhibits  MDR1  gene  expression   [51,  52].  Since   together   the  potential  AMPK-­mediated  
reduction  in  MDR1  gene  expression  and  the  UPR  mediated  inhibition  of  protein  synthesis  
only  reduce  MDR1  protein  levels  ~2  fold,  they  are  likely  to  be  complementary,  rather  than  
central,  to  the  dramatic  and  rapid  reduction  in  MDR1  mediated  efflux  and  to  the  restoration  
of  drug  sensitivity.  
Despite  MDR1’s  acute  sensitivity  to  reduction  in  ATP  levels  therapeutic  reduction  
of   ATP   levels   has   been   an   elusive   target.   The   glyceraldehyde-­3-­phosphate  
dehydrogenase  inhibitor,  3-­bromopyruvate  inhibits  glycolysis,  leading  to  loss  of  ATP  and  
MDR1   inactivation   [53].  However,   lack  of  specificity,  and   toxicity   in  normal  cells,  have  
hindered  therapeutic  application  of  3-­bromopyruvate.  
Ovarian   cancers   originate   in   the   fallopian   tubes   or   ovaries   [5].   We   used   an  
orthotopic  mouse  xenograft  model  in  which  OVCAR-­3  cells  were  grafted  into  the  bursa  of  
one  ovary.  Because   these   internal   tumors  cannot  be  directly  measured  until   the  study  
ends,   serum   levels   of  CA125   over   the   last   4  weeks   of   the   study   provide   a   surrogate  
marker  for  tumor  progression.  Serum  CA125  levels  in  the  paclitaxel  and  vehicle-­treated  
mice  increased  rapidly  in  weeks  7-­10.  Tumor  weight  and  CA125  levels  indicated  that  the  
overall  tumor  burden  was  similar  in  the  paclitaxel  and  vehicle-­treated  mice.    Although  the  
primary  ovarian  tumors  were  small  in  the  paclitaxel-­treated  mice,  these  tumor-­harboring  
mice  were  prone   to  developing   large  secondary   (extra-­ovarian)  growths.   Interestingly,  
increased   metastasis   following   therapy   has   also   been   reported   in   prostate   cancer  
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xenografts   treated   with   abiraterone   [54]   and   breast   cancer   xenografts   treated   with  
sunitinib  or  bevacizumab  [55].  CA125  levels  and  tumor  weight  were  reduced  60-­80%  in  
the  BHPI  treated  mice.  The  slight  increase  in  CA125  levels  in  week  7-­10  suggests  BHPI  
strongly  inhibited,  but  did  not  completely  block,  tumor  progression.  In  contrast,  in  the  BHPI  
plus  paclitaxel   treatment  group,   the  already  extremely   low   levels  of  CA125  at  week  7  
declined  progressively  to  undetectable  levels  at  week  10.  This  suggests  ongoing  tumor  
regression  in  this  treatment  group  during  the  last  4  weeks  of  the  study.  Although  there  
was  substantial  individual  variation  in  tumor  size  and  weight,  and  in  CA125  levels,  in  the  
combined  treatment  group,  both  tumors  and  plasma  CA125  were  undetectable   in  all  5  
mice.  Absence  of  visible  tumors,  or  complete  loss  of  circulating  tumor  markers,  has  not  
been  reported   in  other  xenograft  studies  using  highly  drug-­resistant  OVCAR-­3  ovarian  
cells  [53,  56,  57].  
De   novo   and   acquired   multidrug   resistance   is   a   core   problem   in   cancer  
chemotherapy.   In   ovarian   cancer,   the   primary   driver   of   multidrug   resistance   is  
overexpression  of  MDR1.  BHPI  alone  has  emerged  as  a  promising  and  well-­tolerated  
therapeutic   candidate   for   multidrug   resistant   ovarian   cancer.   Central   to   BHPI’s  
therapeutic   potential   is   its   novel  mechanism  of   action  based  on   strong  and   sustained  
hyperactivation  of  the  anticipatory  UPR  pathway,  resulting  in  ATP  depletion  and  MDR1  
inactivation.   This   enables   BHPI   to   resensitize   multidrug   resistant   tumors   to  
chemotherapeutic  intervention  and  reduce  ovarian  tumor  burden  to  undetectable  levels.  
Thus,  BHPI   is   a   unique   candidate   for   further  mechanistic   exploration   and   therapeutic  
development.  
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MATERIALS  AND  METHODS  
Cell  culture  and  reagents  
Cell   culture   medium   and   conditions   were   as   previously   described   [18,   32].   Dr.   S.  
Kaufmann   provided   PEO-­4   ovarian   cells.   Dr.   A.   Parissenti   provided   MCF-­7   and  
doxorubicin   resistant   MCF-­7   (MCF-­7dox)   breast   cancer   cells.   OVCAR-­3   cells   were  
obtained   from   the   ATCC.   E2,   U73122,   Rhodamine-­123   (Rho-­123)   dye   and   2-­amino  
propyl-­benzoate  (2-­APB)  were  from  Sigma  Aldrich  (St  Louis,  MO,  USA).  Ryanodine  (Ry)  
was  from  Santa  Cruz  Biotechnology  (Danvers,  MA,  USA).  BHPI  was  synthesized  on  gram  




Western   blotting   was   carried   out   as   previously   described   [18,   32,   58].   The   following  
antibodies   were   used:   Phospho-­eIF2a      (Ser51)   (#3398;;   Cell   Signaling   Technology),  
eIF2a  (#5324;;  Cell  Signaling  Technologies,  MA),  Phospho-­PERK  (#3179;;  Cell  Signaling  
Technology,  MA),  PERK  (#5683;;  Cell  Signaling  Technology,  MA),  ATF6a  (Imgenex,  CA),  
PLCg  (#5690;;  Cell  Signaling  Technology,  MA),  BiP  (#3177;;  Cell  Signaling  Technology,  
MA),  MDR1/ABCB1  (#12683;;  Cell  Signaling  Technology,  MA)  and  β-­Actin  (Sigma,  MO).  
The   protein   and   antibody   complexes   were   detected   using   horseradish   peroxidase-­
conjugated  secondary  antibodies  and  chemiluminescent  immunodetection  with  an  ECL  
Detection  Kit  (GE  Healthcare,  NJ),  and  were  visualized  using  a  PhosphorImager.  
  
Cell  proliferation  assays  
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Cells  were  plated  in  growth  media  with  10%  CD-­FBS  for  three  days.  Subsequently,  cells  
were  resuspended  in  growth  media  with  10%  CD-­calf  serum  and  plated  in  96  well  plates.  
The   medium   was   replaced   with   treatment   media   the   following   day,   and   plates   were  
incubated  at  37oC  in  5%  CO2  for  2-­4  days.  During  experiments,  the  medium  was  replaced  
every  two  days.  Cell  number  was  determined  using  MTS  and  CellTiter  96  Aqueous  One  
Solution   Reagent   (Promega).   For   each   cell   line,   cell   number   was   calculated   from   a  
standard  curve  of  the  number  of  plated  cells  at  A490.  
  
Assaying  MDR1  efflux  activity  
Cells  were  plated  in  6-­well  plates  and  allowed  to  reach  80%  confluence.  Subsequently,  
cells  were  loaded  with  10  μM  of  Rho-­123  (1%  methanol,  HBSS)  for  10  minutes  at  37  oC.  
Then,  cells  were  washed  three  times  with  cold  PBS  to  remove  residual  Rho-­123  and  efflux  
started  by  addition  of  pre-­warmed  HBSS  buffer.  At  the  end  of  the  measured  time  points,  
cells  were  lysed  with  2%  (v/v)  triton-­x100  in  HBSS  with  proteinase  inhibitor  cocktail.  Total  
protein  was  determined  and  Rho-­123  concentration  was  normalized  to  total  protein.  
  
Mouse  xenografts  
All  experiments  were  approved  by  the  Institutional  Animal  Care  Committee  (IACUC)  of  
the  University  of  Illinois  at  Urbana-­Champaign.  The  immunodeficient  NSG  mice  (Jackson  
Laboratory)   were   obtained   from   in-­house   breeding.   1   million   OVCAR-­3   cells   were  
orthotopically  grafted  into  the  bursa  of  one  ovary.  Subsequently,  the  mice  were  randomly  
divided  into  four  treatment  groups.  Starting  one  week  after  injecting  the  tumor  cells  each  
group   received   vehicle   plus   vehicle,   paclitaxel   plus   vehicle,   vehicle   plus   BHPI,   or  
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paclitaxel  plus  BHPI.  The  paclitaxel  was  dissolved   in  Polysorbate-­80  and  ethanol  (1:1,  
vol/vol)   and   further   diluted   with   saline   to   reach   final   concentration.   Stock   BHPI   was  
dissolved   in  DMSO  and   further  diluted  with  10%  Tween-­20  with  88%  PBS   to  working  
concentration.   Doses   were   10   mg/kg   of   paclitaxel   IP   injected   every   other   day,   and  
50mg/kg  of  BHPI  injected  IP  daily.  
  
Measuring  levels  of  serum  CA125  
Plasma   CA125   concentrations   were   determined   by   ELISA   according   to   the  
manufacturer’s  protocol  (#KA0205;;  Abnova,  CA).  The  final  serum  CA125  concentrations  
were  calculated  based  on  a  standard  curve.  
  
qRT-­PCR,  IP3  quantitation,  PLCg  siRNA  knockdown,  calcium  imaging,  and  protein  
synthesis  measurements  
Carried  out  as  we  recently  described  [18,  32,  59].  
  
Statistical  analysis  
R  was   used   for   the   statistical   analysis.   For   terminal   tumor  weights,   one-­way  ANOVA  
followed   by   the  Kruskal-­Wallis  post   hoc   test  was   used   (P   <   0.05).   For  CA125   serum  
analysis,  two-­way  ANOVA  followed  by  Bonferroni’s  post  hoc  t-­test  was  used  (P  <  0.05).  
Other  analyses  were  conducted  either  with   two-­tailed  Student   t   tests  or  with  one-­way  
ANOVA  followed  by  Tukey  post  hoc  tests  (P  <  0.05).  Data  are  reported  as  mean  ±  SEM.  
     




Figure  4.1.  BHPI  and  estrogen  stimulate  release  of  calcium  from  the  endoplasmic  
reticulum   into   the   cytosol.      (A)   Quantitation   of   intracellular   IP3   levels   after   10   min  
treatment  with  DMSO,  17b-­estradiol  (E2),  or  BHPI  in  PEO-­4  ovarian  cells  (n  =  3).  (B,  C)  
Estrogen  and  BHPI  increase  cytosol  calcium  levels.  Visualization  of  cytosolic  Ca2+  using  
Fluo-­4  AM;;  estrogen  or  BHPI  was  added  to  PEO-­4  cells  at  50  s.  Color  scale  from  basal  
Ca2+  to  highest  Ca2+:  purple,  blue,  green,  yellow,  red,  white.  Quantitation  of  cytosolic  Ca2+  
levels  after  pre-­treating  PEO-­4  cells  with  U73122,  2-­APB,  or  Ry  followed  by   treatment  
with  estrogen  or  BHPI  (n  =  12-­20).  Concentrations:  U73122,  1  μM;;  2-­APB,  100  μM;;  Ry,  
C8,  10  μM;;  E2,  200  nM;;  BHPI,  10  μM.  *P  <  0.05,  ***P  <  0.001.  
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Figure  4.3.   In  PEO-­4  ovarian  cells,  BHPI  activates  the  three  branches  of  the  UPR  
and  inhibits  protein  synthesis.  (A)  qRT-­PCR  analysis  showing  the  increased  level  of  
spliced   XBP1   (sp-­XBP1)   mRNA   (n   =   3).   (B,   C)   Western   blot   analysis   showing   time  
dependent  phosphorylation  of  PERK  and  eIF2a.  (D)  Protein  synthesis  after  treating  the  
cells   with   increasing   concentrations   of   BHPI   (n   =   4).   CHX,   cycloheximide.   Protein  
synthesis   from  DMSO   treated   control   cells  was   set   to   100%.   (E)   The   level   of   protein  
synthesis   after   pretreating   the   cells   with   either   the   inhibitors   U73122,   2-­APB,   or   Ry  
followed  by  BHPI   treatment   (n  =  4).   (F)  Western  blot   analysis   shows   full-­length   (p90-­
ATF6α)  and  cleaved  p50-­ATF6α  in  BHPI  treated  cells.  Effect  of  BHPI  on  the  level  of  BiP  
mRNA  level  (G)  and  protein  (H).  Concentrations:  U73122,  1  μM;;  2-­APB,  100  μM;;  BHPI,  
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Figure  4.4.  Estrogen  weakly  activates  the  three  arms  of  the  UPR  in  PEO-­4  cells.  (A)  
qRT-­PCR   analysis   shows   increasing   sp-­XBP1   mRNA   after   treatment   with   the   17b-­
estradiol  (E2).  (B)  Western  blot  showing  phosphorylated  eIF2a  and  total  eIF2a  proteins.  
(C)  Effect  of  estrogen  on  the  level  of  full-­length  (p90-­ATF6α)  and  cleaved  p50-­ATF6α.  (D)  
qRT-­PCT  quantitation  of  BiP  mRNA  at  indicated  time  points  (n  =  3).  The  concentration  of  
E2  is  10  nM.  ***P  <  0.001.  
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Figure   4.5.   In   MDR1   overexpressing   cells,   BHPI   depletes   intracellular   ATP   and  
inhibits   MDR1   efflux   activity.   (A)   Proposed   model   of   the   pathway   by   which   BHPI  
inactivates  MDR1.  (B,  C)  Intracellular  ATP  quantitation  showing  effect  of  BHPI  on  cellular  
ATP   level   after   pretreating   cells  with  either  DMSO  or   thapsigargin   (THG)   (n  =  6).   (D)  
Western  blot  analysis  showing  MDR1  protein   level   from  the   indicated  cell   lines.   (E,  F)  
Rhodamine-­123   (Rho-­123)   quantitation   showing   the   effect   of   BHPI   on   Rho-­123  
concentration  in  the  media  after  pretreating  cells  with  either  DMSO,  U73122,  or  2-­APB  (n  
=  6).  Concentrations:  U73122,  1  μM;;  2-­APB,  100  μM;;  BHPI,  1  μM  (B,  C)  or  500  nM  (E,  
F).  Data  is  the  mean  ±  SEM.  ***P  <  0.001.  
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Figure  4.6.  BHPI  blocks  proliferation  of  MCF-­7  and  doxorubicin   resistant  MCF-­7  
(MCF-­7dox)  breast  cancer  cells.  (A,  B)  MTS  assays  showing  the  effect  of  BHPI  on  cell  
proliferation.  “•”  on  each  graph  denotes  the  number  of  cells  at  the  start  of  the  experiment.  
The  cells  were  grown  in  medium  containing  10  nM  E2  and  the  indicated  concentrations  of  
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Figure   4.7.  MDR1   overexpressing   cells   exhibit   higher  MDR1   efflux   activity   than  
MDR1  negative  cells.  For  each  cell  line,  the  Rho-­123  fluorescence  activity  in  the  medium  
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Figure  4.8.  BHPI  inhibits  protein  synthesis  and  reduces  the  level  of  MDR1  protein  
in  OVCAR-­3  cells.  (A)  Protein  synthesis  was  measured  using  the  incorporation  of  35S  
methionine  into  protein  at  the  indicated  times  after  pretreating  cells  for  20  min.  with  either  
DMSO,  U73122,  or  2-­APB  (n  =  4).  (B)  Western  blot  indicating  the  MDR1  protein  level  at  
indicated  time  points  after  BHPI  treatment.  Concentrations:  U73122,  1  μM;;  2-­APB,  100  
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Figure   4.9.   BHPI   restores   drug   sensitivity   in   MDR1   overexpressing   cells.   MTS  
assays   showing   the   effect   of   BHPI   (1   μM)   plus   either   DMSO   or   the   indicated  
concentrations  of  paclitaxel  (A)  or  doxorubicin  (B)   in  OVCAR-­3  ovarian  cells  (n  =  6)  or  
doxorubicin  in  MCF-­7dox  breast  cells  (C)  (n  =  6).  (D)  Western  blot  analysis  showing  the  
PLC𝛾  protein  level  after  transfecting  the  cells  with  either  non-­coding  SmartPool  siRNA  or  
100  nM  SmartPool  PLC𝛾  siRNA.  (E)  PLC𝛾  knockdown  abolishes  the  ability  of  BHPI  to  
reverse  multidrug   resistance.  OVCAR-­3   cells  were   transfected  with   either   non-­coding  
control  or  PLC𝛾  siRNA  and  the  effect  on  cell  number  in  cells  treated  with  vehicle  of  BHPI  
was  determined  (n  =  6).  Cell  number  in  a-­e  is  from  standard  curves  of  absorbance  versus  
cell  number  for  each  cell  line.  “•”  on  each  graph  denotes  the  number  of  cells  at  the  start  
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Figure  4.10.  BHPI  does  not  restore  cisplatin  sensitivity  in  OVCAR-­3  cells,  does  not  
restore   paclitaxel   sensitivity   in   MDR1   overexpressing   ERa   negative   cells,   and  
exhibits   structure   specificity.   MTS   assays   showing   the   effect   of   BHPI   on   cisplatin  
sensitivity  in  ERa  positive  OVCAR-­3  cells  (A)  and  on  paclitaxel  sensitivity  in  ERa  negative  
NIH/ADRes  cells  (B)  (n  =  6).  (C)  The  effect  of  an  inactive  close  structural  relative  of  BHPI  
compound  8  (C8)  on  OVCAR-­3  cell  proliferation  was  evaluated  with  either  DMSO  vehicle  
and   together  with   paclitaxel   or   doxorubicin   in   (n   =   6).   “•”   on   each   graph   denotes   the  
number  of  cells  at  the  start  of  the  experiment.  The  concentrations  of  BHPI,  C8,  paclitaxel  
and  doxorubicin  were  10  μM,  10  μM,  10  μM  and  1  μM,  respectively.  Data  is  the  mean  ±  
SEM.  
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Figure  4.11.  BHPI  plus  paclitaxel  eliminates  orthotopic  multidrug  resistant  OVCAR-­
3   tumors.   (A)   Tumor   images   showing   the   size   of  OVCAR-­3   tumors   in   vehicle   (Veh),  
paclitaxel,  BHPI  or   paclitaxel   plus  BHPI   treatment   groups   (n  =  5).   (B)  Average   tumor  
weight  from  each  treatment  group  (n  =  5).  For  the  paclitaxel  group  the  secondary  growths  
were   included   in   tumor   weight.   (C)   Circulating   serum   CA125   biomarker   quantitation  
showing  the  progression  of  tumors  in  each  treatment  group  (n  =  5).  Threshold  in  humans  
(dashed   line)  denotes  35  U/ml  of  circulating  CA125.  Data   is   the  mean  ±  SEM.   ***P  <  
0.001.  
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Figure  4.12.  BHPI  and  paclitaxel  are  well  tolerated  in  mice.  The  body  weight  of  mice  
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CHAPTER  5  
INTERPLAY  BETWEEN  STEROID  HORMONE  ACTIVATION  OF  THE  UNFOLDED  
PROTEIN  RESPONSE  AND  NUCLEAR  RECEPTOR  ACTION  4  
  
ABSTRACT  
To  identify  new  pathways  of  estrogen  action  and  novel  estrogen  receptor  a  (ERa)  
biomodulators,  we  performed  high  throughput  screening  and  used  follow  on  assays  and  
bioinformatics   to   identify   small   molecule   ERa   inhibitors   with   a   novel   mode   of   action.  
These   studies   led   to   identification   of   rapid   extranuclear   activation   of   the   endoplasmic  
reticulum   stress   sensor,   the   unfolded   protein   response   (UPR),   as   a   new   pathway   of  
estrogen-­ERa   action.   Moreover,   increasing   evidence   indicates   that   the   mechanism  
underlying   anticipatory   activation   of   the   UPR   is   shared   among   steroid   and   peptide  
hormones  and  is  conserved  from  insects  to  humans.  It  is  likely  that  this  newly  unveiled  
extranuclear   pathway   is   used  by   diverse  mitogenic   hormones   to   prepare   cells   for   the  
increased   protein   folding   load   that   will   occur   during   subsequent   cell   proliferation.  
Demonstrating  biological  relevance,  elevated  expression  of  a  UPR  gene  signature  in  ERa  
positive   breast   cancer   is   a   powerful   new   prognostic   marker   tightly   correlated   with  
subsequent   resistance   to   tamoxifen,   tumor   recurrence   and   poor   survival.   In   addition,  
overexpression  of  epidermal  growth  factor  receptor  and  HER2/neu  is  positively  correlated  
with  increased  UPR  activation  in  breast  cancer.  This  review  describes  recent  research  
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  This  chapter  appeared  in  its  entirety  in  the  Steroids.  Xiaobin  Zheng,  Neal  Andruska,  Liqun  Yu,  
Chengjian  Mao,  Ji  Eun  Kim,  Mara  Livezey,  William  G  Helferich,  David  J  Shapiro.  (2016)  Interplay  
between  steroid  hormone  activation  of  the  unfolded  protein  response  and  nuclear  receptor  action.  
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that   demonstrates   the   importance   of   anticipatory   UPR   activation   in   therapy   resistant  
tumors  and  discusses  a  promising  small  molecule  biomodulator  that  inhibits  tumor  growth  
by  tuning  this  UPR  signaling  pathway.  
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AR,  androgen  receptor;;  
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EGFR,  epidermal  growth  factor  receptor;;  
eIF2a,  eukaryotic  initiation  factor  2  a;;  
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ERa,  estrogen  receptor  a;;  
IP3,  inositol  triphosphate;;  
IP3R,  inositol  triphosphate  receptor;;  
PERK,  protein  kinase  RNA-­like  endoplasmic  reticulum  kinase;;  
PLCg,  phospholipase  C  gamma;;  
SERCA,  sarco/endoplasmic  reticulum  Ca2+-­ATPase;;  
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UPR,  unfolded  protein  response;;  
VEGF,  vascular  endothelial  growth  factor;;  
  
INTRODUCTION  
The   endoplasmic   reticulum   (EnR)   plays   a   key   role   in   synthesis,   folding   and  
transport  of  nascent  peptides.  Protein  maturation  in  the  EnR  is  a  critical  step  in  normal  
cell   function  and   in  cell  survival.  Modest  changes   in   the  cellular  environment,  such  as  
changes  in  the  intracellular  Ca2+  level  in  the  lumen  of  the  EnR,  nutrient  availability,  redox  
state,  or  in  the  rate  of  protein  synthesis,  can  cause  accumulation  of  misfolded  or  unfolded  
proteins.  The  resulting  EnR  stress  [1,  2]  leads  to  activation  of  the  EnR  stress  response  
pathway,  the  unfolded  protein  response  (UPR).  The  UPR  consists  of  three  main  branches  
that   together  balance  the  synthesis  of  new  proteins  with   the  availability  of  chaperones  
and  other  proteins  to  help  fold  and  transport  proteins  within  cells.  EnR  stress  activates  
autophosphorylation   of   the   transmembrane   kinase   PERK   (protein   kinase   RNA-­like  
endoplasmic   reticulum   kinase)   [2,   3].   Activated   p-­PERK   phosphorylates   eukaryotic  
initiation  factor  2a  (eIF2a),  resulting  in  transient  inhibition  of  most  protein  synthesis  and  
increased  translation  of  p58IPK  and  GADD34.  If  the  stress  is  moderate,  the  p58IPK  binds  
PERK,   inhibiting   PERK   activation,   and   the   GADD34   dephosphorylates   eIF2a.   This  
ultimately  reverses  PERK  activation  and  protein  synthesis   is  restored  [4,  5].  The  other  
arms   of   the   UPR   initiate   with   activation   of   the   transcription   factor   ATF6a,   leading   to  
increased   protein   folding   capacity   and   activation   of   the   splicing   factor   IRE1a,   which  
alternatively  splices  the  transcription  factor  XBP1,  leading  to  production  of  active  spliced  
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XBP1   (sp-­XBP1),   increased   protein   folding   capacity   and   altered   mRNA   decay   and  
translation  (Figure  5.1)  [1-­3].  
Diverse  mitogenic  hormones,  acting  via  their  respective  receptors,  stimulate  cell  
proliferation   and   tumor   growth   [6-­11].   Enhanced   cell   proliferation   requires   increased  
protein   production,   potentially   leading   to   insufficient   protein   folding   capacity   and   EnR  
stress.  Although  UPR  activation  has  been  described  in  multiple  cancers  [2,  12-­15],  until  
recently,   it  has  not  been  a  major   research   focus   in  hormone-­dependent  cancers.  This  
review   focuses  on   the  pathophysiological   importance  of  anticipatory  UPR  activation   in  
hormone   signaling   as   an   early   component   of   the   cellular   proliferation   program   and  
discusses  the  preclinical  promises  of  targeting  the  UPR.  
  
STEROID/PEPTIDE  HORMONE  ACTIVATION  OF  THE  UPR  
Steroid   and   peptide   hormones   execute   their   biological   functions   through   direct  
interaction  with   hormone-­specific   receptors   [8,   9].   These   include   binding   of  mitogenic  
steroid  hormones,  17b-­estradiol  (E2;;  estrogen),  dihydrotestosterone  (DHT;;  androgen)  and  
ecdysone  (Ec)  to  their  respective  nuclear  receptors  (ERa,  AR  and  EcR)  and  of  the  peptide  
hormones  epidermal  growth  factor  (EGF)  and  vascular  endothelial  growth  factor  (VEGF)  
to  their  receptors  (EGFR  and  VEGFR).  Steroid  hormones  exert  their  molecular  functions  
by  regulating  gene  expression  in  the  nucleus  and  cross-­talking  with  diverse  extranuclear  
signal  transduction  pathways.  In  the  classical  genomic  action  of  steroid  hormones,  here  
illustrated  using  estrogen,  estrogens  bind  to  ERa;;   this  results   in  receptor  dimerization.  
Estrogen-­ERa   binds   directly   to   genomic   response   elements   and   interacts   with   DNA  
indirectly   through   tethering   to   other   proteins.   This   results   in   activation   of   a   genomic  
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program  that  alters  the  expression  of  thousands  of  genes  and  plays  an  important  role  in  
promoting  the  proliferation  of  ERa  positive  cancer  cells  [16-­18].  
While  the  genomic  actions  of  steroid  hormones  are  initiated  rapidly,  they  play  out  
over  many  hours.  A  disparate  set  of  rapid  extranuclear  actions  of  steroid  receptors,  often  
initiated  at  or  near  the  plasma  membrane,  influence  diverse  cell  functions  and  also  play  
a  pivotal  role  in  modulating  the  receptors  genomic  program  [19-­21].  While  much  attention  
focused  on  rapid  effects  of  steroid  hormones  on  established  signal  transduction  pathways,  
rapid  effects  of  estrogen  and  other  steroid  hormones  on  activation  of  the  UPR  were  largely  
unexplored.  We  recently  showed  that,  within  1  minute,  estrogens,  acting  via  ERa,  activate  
phospholipase  C  gamma  (PLCg),  producing  inositol  triphosphate  (IP3).  The  IP3  binds  to  
and  opens  the  EnR  inositol  triphosphate  receptor  (IP3R)  calcium  channels  allowing  rapid  
efflux   of   calcium   from   the   lumen   of   the   EnR   into   the   cytosol   (Figure   5.1).   This   rapid  
calcium  efflux  activates  the  UPR,  inducing  chaperones  (Figure  5.1).  Notably,  inhibition  or  
knockdown  of  pathway  components  strongly  inhibits  estrogen  stimulated  cell  proliferation  
and   nearly   abolishes   subsequent   estrogen-­ERa   induction   and   repression   of   gene  
expression  (Figure  5.1)  [22].  Moreover,  analysis  of  data  from  approximately  1,000  ERa  
positive   breast   cancers   shows   that   elevated   expression   of   a   UPR   gene   signature   at  
diagnosis   is   a   powerful   new   prognostic   marker   tightly   correlated   with   subsequent  
resistance  to  tamoxifen,  tumor  recurrence  and  poor  survival  [22].  
The  well-­studied  oncogenic  mitogen  EGF,  acting  through  EGF  receptors,  rapidly  
activates  the  ERK  and  AKT  signaling  pathways  and  alters  gene  expression.  EGF-­EGFR  
activation  of  these  pathways  promotes  tumor  growth  and  invasion,  and  is  antiapoptotic  
[23-­25].  Although  EGF  is  a  peptide  hormone  and  EGFR  is  a  plasma  membrane  receptor,  
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EGF-­EGFR  and  E2-­ERa  share  the  same  general  pathway  for  rapid  anticipatory  activation  
of   the  UPR  (Figure  5.1;;  see  Section  2  above)   [26].  Activation  of   the  anticipatory  UPR  
pathway  is  a  newly  described  action  of  EGF,  and  it  facilitates  EGF  stimulated  cell  cycle  
progression  in  different  ways  [26].  We  find  that  EGF-­EGFR  activation  of  the  anticipatory  
UPR  pathway   is   required   for  EGF   induced   immediate  early  gene  expression.  Notably,  
while  blocking  UPR  activation  abolishes  EGF  regulated  immediate  early  gene  expression,  
it  has  no  effect  on  EGF  activation  of  the  ERK  and  AKT  pathways.  This  indicates  that  at  
early   times,   the   anticipatory   UPR   pathway   and   the   ERK   pathway   are   independent  
regulators,  which  converge  at  the  level  of  gene  expression  [26].  EGF  induced  chaperone  
production  also  contribute  to  cell  proliferation;;  knocking  down  the  chaperone  producing  
arms  of  the  UPR  inhibits  EGF  stimulated  cell  proliferation  [26].  
Tumor  growth  and  metastasis  depends  on  new  growth  in  the  vascular  network  [27].  
In   endothelial   cells,   vascular   endothelial   growth   factor   (VEGF),   acting   through   VEGF  
receptors,  promotes  cell  viability  and  angiogenesis,  the  formation  of  new  blood  vessels  
[27-­29].  Recently,  anticipatory  activation  of  the  UPR  has  been  identified  as  a  new  mode  
of  action   in  VEGF  signaling.   In  a  notable  difference  between   the  estrogen  and  VEGF  
pathways,   the   activation   mechanism   is   reported   to   be   independent   of   the   PLCg-­IP3-­
calcium  pathway  [30].  In  the  absence  of  EnR  stresses,  VEGF  primes  cells  by  activating  
the  ATF6a  and  PERK  arms  of  the  UPR  and  anticipates  the  needs  for  subsequent  VEGF-­
induced  vascularization  [30].  
Prostate   cancer   is   a   leading   cause   of   cancer   in   men.   Androgens,   such   as  
testosterone  and  dihydrotestosterone  (DHT),  exert  their  biological  functions  through  the  
androgen  receptor  and  play  a  pivotal  role  in  proliferation  of  prostate  cancer  [31,  32].  At  
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early  time  points,  DHT  did  not  rapidly  induce  sp-­XBP1  and  BiP  mRNA  (Figure  5.2).  As  a  
control,  in  the  AR-­positive  LNCaP  and  LAPC4  human  prostate  cancer  cell  lines,  prostate-­
specific  antigen   (PSA),  which   is  a  classic  DHT   inducible  gene,   is   rapidly  and   robustly  
induced  (8  h;;  Figure  5.2).  Thus,  rapid  UPR  activation  is  not  part  of  DHT  signaling  pathway.  
However,   activation   of   the   UPR   was   observed   at   later   times   (e.g.   24   to   48   h)   [33].  
Together,   these   data   suggest   DHT   may   activate   the   UPR   through   a   reactive   UPR  
mechanism,   in   which   UPR   activation   is   stimulated   by   accumulation   of  misfolded   and  
unfolded  proteins  as  the  cells  proliferate,  or  through  a  nuclear  gene  expression  program  
that  induces  UPR-­related  mRNAs.  Although  the  exact  molecular  mechanism  underlying  
DHT   activation   of   the   UPR   requires   further   exploration,   pharmacological   inhibition   of  
IRE1a   significantly   reduces   prostate   tumor   growth   [33].   This   supports   the   biological  
significance  of  activation  of  the  UPR  pathway  in  prostate  cancer  progression.  
The   transformation   of   insects   from   larvae   to   adults   is   commonly   known   as  
metamorphosis.   Neuronal   remodeling   is   a   crucial   process   for   development   of   both  
vertebrates  and   invertebrates  but   is  particularly  critical   for  metamorphosis.  During   this  
process,  axons  and  dendrites  undergo  a  precisely  controlled  program  of  pruning  via  cell  
death  followed  by  regrowth  [34].  This  remodeling  of  axons  and  dendrite  events  ultimately  
depends  on  the  molecular  function  of  Ec-­EcR  [34].  As  a  part  of  rapid  extranuclear  action  
of   Ec-­EcR,   Ec   regulates   the   cytosolic   calcium   level   through   a   PLCg-­IP3-­calcium  
dependent  pathway,  resulting  in  phosphorylation  and  activation  of  protein  kinase  C  that  
modulates   transcriptional   activity   of   ultraspircle   in   the   lepidopteran   insect  Helicoverpa  
armigera  [35].  Depletion  of  PLCg  leads  to  metamorphosis  defects  and  blocks  induction  of  
Ec  regulated  genes  [35].  
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Although   the   mechanisms   underlying   anticipatory   UPR   activation   vary   among  
different   hormone-­mediated   signaling   pathways,   an   important   consequence   of  
anticipatory  UPR  activation  is  the  induction  of  molecular  chaperones  that  primes  cells  to  
mitigate  damage  due  to   future  cell  stress   that  may  occur  during  proliferation,  or  under  
various   physiological   conditions.   Activation   of   the  UPR   before   the   cellular   stress   and  
before   the   accumulation   of   unfolded   protein   is   the   key   feature   that   distinguishes   the  
anticipatory  UPR  pathway  from  the  well-­studied  reactive  UPR  pathway.  
  
THE  UPR  ACTS  AS  A  DOUBLE-­EDGED  SWORD  TO  CONTROL  CELL  FATE  
Anticipatory  UPR  activation  is  protective;;  deletion  or  inhibition  of  UPR  components  
is   an   emerging   therapeutic   strategy   that   reduces   tumor   growth   and   increases  
susceptibility  of  cancer  cells  to  therapeutic  agents  [33,  36,  37].  Recently,  we  described  a  
novel  strategy  to  target  cancer  cells,  not  by  inhibiting  the  UPR,  but  by  toxic  hyperactivation  
of  the  UPR.  Through  high  throughput  screening  follow  on  assays  and  bioinformatics,  we  
identified  a  clinically  promising  small  molecule  ERa  biomodulator,  BHPI  [38,  39].  BHPI  
binds  non-­competitively  to  ERa  and  distorts  and  exaggerates  the  normal  estrogen-­ERa  
pathway  for  anticipatory  activation  of  the  UPR  [39].  Comparing  the  cytotoxic  actions  of  
BHPI   to   the   protective   anticipatory   activation   of   the   UPR   by   estrogen,   BHPI   induces  
hyperactivation  of  PLCγ,  which  leads  to  greatly  increased  production  of  IP3  and  a  massive  
efflux  of  calcium  stored   in  the   lumen  of  EnR  into  the  cytosol.  Because  of   this  massive  
release  of  calcium  into  the  cytosol,  the  magnitude  and  duration  of  UPR  activation  by  BHPI  
is  much  larger  than  what  is  seen  with  estrogens  [22,  39].  This  leads  to  strong  activation  
of   the  PERK  arm  of   the  UPR,   resulting   in   extensive   eIF2a   phosphorylation   and   near  
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quantitative   inhibition   of   protein   synthesis   [39].   Cytosolic   calcium   levels   are   tightly  
regulated  because  high   levels  of   calcium   in   the  cytosol  are   toxic   [40-­43].  To  maintain  
cellular   calcium   homeostasis,   the   cell   activates   sarco/endoplasmic   reticulum   Ca2+-­
ATPase  (SERCA)  pumps,  which  catalyze  ATP-­dependent   transfer  of  calcium  from  the  
cytosol  into  the  lumen  of  the  EnR  [44-­46].  Since  the  IP3R  calcium  channels  are  still  open,  
the  calcium  pumped   into   the  EnR   leaks  back  out   to  cytosol  creating  a   futile  cycle   that  
rapidly   depletes   cellular   ATP.   This   ATP   depletion   results   in   increased   AMP,   which  
activates  the  metabolic  sensor  AMPK  [39].  Together,  high  levels  of  cytosolic  calcium  and  
AMPK  activation  activate   the  Ca2+/calmodulin-­dependent  kinase,  eukaryotic  elongation  
factor   2   kinase   (CAMKIII/eEF2K).   This   results   in   phosphorylation   and   inactivation   of  
eukaryotic  elongation  factor  2  (eEF2),  inhibiting  protein  synthesis  at  a  second  site  [39,  47,  
48].    Anticipatory  UPR  activation  by  estrogen  is  weak  and  transient  because  the  induced  
expression   of   UPR   molecular   chaperones   helps   resolve   UPR   stress   and   ultimately  
reverses  UPR  activation  [1,  4,  12].  In  contrast,  since  BHPI  blocks  global  protein  synthesis  
including  synthesis  of  UPR-­induced  molecular  chaperones  such  as  p58IPK,  GADD34,  and  
BiP,  BHPI  activation  of  UPR  is  unresolvable.  
BHPI   is  exceptionally  effective  as  a  new  preclinical  anticancer  drug.   It  works   in  
ERα  positive  cancer  cells  that  do  not  require  estrogens  or  ERα  for  growth  and  also  in  cells  
that  are  therapy-­resistant  [39].  Importantly,  at  nanomolar  concentrations,  BHPI  does  not  
only  stop  cancer  cell  growth,  but  also  kills  many  breast  and  endometrial  cancer  cell  lines.  
In   the  mouse  xenograft  model  of  breast  cancer   in  which  BHPI   treatment  was   initiated  
when   tumors   reached   about   45   mm2,   control   and   BHPI   treated   tumors   were   both  
continuously  exposed  to  estrogen.  BHPI,  at  the  reasonable  dose  of  15  mg/kg  daily  for  10  
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days,  rapidly  stopped  tumor  growth  and  induced  substantial  regression  of  48  out  of  52  
tumors  [39].  Moreover,  BHPI  was  well  tolerated  by  the  mice  [39].  
An  intriguing  question  to  ask  is,  since  BHPI  hyperactivates  the  UPR  converting  it  
from  protective  to  toxic,  why  is  BHPI  not  toxic  to  normal  ERα  positive  cells?  The  UPR  is  
nearly  off   in  most  normal  cells.  We  hypothesize   that  since  UPR  expression   is  already  
elevated  as  part  of  the  mechanism  that  protects  cancer  cells  [39],  it  is  actually  easier  for  
BHPI  hyperactivation  of  the  UPR  to  push  the  already  activated  UPR  from  cytoprotective  
to  cytotoxic  in  a  cancer  cell  than  it  is  in  a  normal  cell  that  starts  with  a  much  lower  level  of  
UPR  activation.  
In  summary,  BHPI   is   the   first  example  of  an  ERa  biomodulator   that   targets   the  
UPR  pathway  and  converts  it  from  cytoprotective  to  cytotoxic.  
  
CONCLUSION  
Steroid   and   peptide   hormones   play   key   roles   in   normal   cell   physiology   and   in  
pathology.   The   ability   to   tolerate   various   cellular   stresses   is   crucial   for   cell   survival,  
especially   in   the   tumor  microenvironment.  Anticipatory  UPR  activation   is  an  emerging  
rapid  extranuclear  signaling  pathway  that  is  activated  by  different  mitogenic  hormones  to  
resolve  future  cellular  stresses.  These  rapid  responses  and  early  events  can  also  lead  to  
downstream   genomic   effects   and   are   important   in   cross-­talk,   leading   to   reciprocal  
regulation   of   the   nuclear   and   extranuclear   pathways.   Identification   of   the   players   that  
communicate   molecular   messages,   especially   elevated   intracellular   calcium   and  
increased   chaperone   levels   from   the   UPR   pathway   to   the   nucleus   is   essential   to  
understanding  how  the  UPR  pathway  influences  the  gene  regulation  network.  Moreover,  
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disruption  or  strong  enhancement  of  the  UPR  offers  a  new  approach  to  cancer  therapy  
and  to  overcoming  resistance  to  current  therapies.  
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Figure  5.1.  Model  for  activation  of  the  UPR  by  steroid  or  peptide  hormones.  
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Figure  5.2.  DHT  does  not  induce  rapid  activation  of  the  IRE1α  and  ATF6α  arms  of  
the  UPR  in  prostate  cancer  cells.  qRT-­PCR  time  course  comparing  the  effect  of  DHT  
on  DHT-­AR  induction  of  spliced-­XBP1  (sp-­XBP1),  BiP  and  prostate-­specific  antigen  (PSA)  
in  AR  positive  LNCaP  and  LAPC4  cells.  The  qRT-­PCR  procedures  have  been  described  
previously   [22,   39].   Briefly,   the   cells   were   plated   in   RPMI   growth   medium   with   10%  
charcoal  stripped  fetal  bovine  serum  for  three  days  prior  to  treating  the  cells  with  10  nM  
DHT  at  the  indicated  times.  (n=3;;  0  h  set  to  1).  Data  are  mean  ±  s.e.m.  ***P  <  0.001.  
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CHAPTER  6  
DISCUSSION  AND  FUTURE  PERSPECTIVES  
Endocrine   therapy   using   aromatase   inhibitors   to   inhibit   estrogen   production,   or  
tamoxifen  and  other  antiestrogens  that  compete  with  estrogens  for  binding  to  ERa,  is  a  
mainstay  in  treatment  of  ERa-­positive  breast  cancers  [1,  2].  Selection  and  outgrowth  of  
breast  cancers  resistant  to  endocrine  therapy  is  common,  and  the  most  lethal,  therapy  
resistant  metastatic  tumors  continue  to  express  ERa  [1].  Many  epithelial  ovarian  tumors  
are   ERa-­positive,   but   all   are   resistant   to   endocrine   therapy   and   ultimately   develop  
resistance   to   standard   chemotherapy   [3,   4].   Therapeutic   options   for   these   resistant  
ovarian   tumors   are   limited,   and   clinical   outcomes   are   poor   [5-­7].   Most   importantly,  
although   resistance   mechanisms   are   diverse,   the   presence   of   ERa   in   gynecologic  
cancers  suggests  additional  modes  of  ERa  action  that  contribute  to  therapy  resistance  
and  are  potentially  targetable  with  small  molecules.  
We  describe  a  new  pathway  that  represents  the  initial  cell  response  to  estrogens  
and  is  required  for  subsequent  actions  of  E2-­ERa.  In  less  than  1  minute,  E2  elicits  ERa-­
dependent  activation  of  phospholipase  C  g  (PLCg),  producing  inositol  triphosphate  (IP3)  
and    diacrylglycerol  (DAG).    On  the  one  hand,  IP3  binds  to  and  opens  EnR  IP3R  calcium  
channels,  resulting   in  a  rapid  efflux  of  calcium  from  the   lumen  of   the  EnR  into  the  cell  
body.   Loss   of   EnR   calcium   activates   the   EnR   stress   sensors,   the   unfolded   protein  
response  (UPR)  and  increases  intracellular  calcium.  Moreover,  we  demonstrated  that  E2-­
ERa  activation  of  the  UPR  is  mild  and  protects  against  estrogen-­mediated  proliferative  
stress.  On  the  other  hand,  DAG,  a  lipid  secondary  messenger  transiently  generated  upon  
PLC   activation,   is   a   classic   activator   of   Protein   Kinase   C   superfamily   that   plays   an  
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important   role   in   tumor   development   and   progression,   including   in   late   stages   of   the  
disease  and  metastasis  [8].  However,  the  pathophysiological  roles  of  DAG  remain  elusive.  
Notably,  ErbB2-­dependent  activation  of  PKC  promotes  cell  invasion  in  breast  cancer  cells  
[9].  MCF-­7  breast  cancer  cells  that  overexpress  PKC  show  enhanced  motility;;  this  was  
attributed  to  decreased  expression  of  E-­cadherin  and  b-­catenin  and  to  high  expression  of  
matrix  metalloprotease  (MMP)-­2/MMP-­9  [10,  11].  
Estrogen  or  Epidermal  Growth  Factor  (EGF)  rapidly  activates  the  PERK  arm  of  the  
UPR,   resulting   in   transient   phosphorylation   of   eIF2a   and   inhibition   of   global   protein  
synthesis  (Figure  2.4  A-­C  and  Figure  3  in  [12]).  At  early  times  after  mild  UPR  activation,  
p-­PERK   induces  expression  of  diverse  protective  microRNAs.  These   include  miR-­211  
microRNA  expression  that  increases  histone  methylation  at  the  CHOP  promoter  region  
to  repress  CHOP  expression,  which   is  a  pro-­apoptotic   transcription  factor   [13].  Altered  
glucose  metabolism  as  a  result  of  increased  glycolysis  and  glucose  uptake  is  a  hallmark  
of   cancer.   miR-­122   is   one   of  most   abundant  microRNA   in   the   liver   and   can   also   be  
regulated  through  the  UPR  [14,  15].  Most  importantly,  studies  show  that  breast  cancer  
cells  can  secret  vesicles  that  contain  a  high   level  of  miR-­122  that  suppresses  glucose  
uptake  by  non-­tumor  cells  in  the  pre-­metastatic  niche  to  increase  nutrient  availability.  High  
expressions  of  miR-­122  in  the  circulation  have  been  associated  with  metastatic  breast  
cancer  patients  [16].  
Abundant  nutrient  supplies  coupled  with   limited  physical  activity  are  responsible  
for  the  rising  incidence  of  obesity-­related  diseases  and  cancers,  including  type  2  diabetes,  
metabolic   syndrome,   and   nonalcoholic   fatty   liver   disease   [17-­20].   Although   multiple  
mechanisms   have   been   put   forth   to   explain   these   phenomena,   excess   nutrients   can  
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trigger  EnR  stress  and  UPR  activation  in  premalignant  and  transformed  cells  in  the  tumor  
microenvironment,  which  contribute   to  cancer  development  and   tumor  cell  metabolism  
[17].  Hypercholesterolemia   is   a   risk   factor   for   ERa-­positive   breast   cancer   and   is   also  
associated  with  endocrine  therapy  resistance  [21,  22].  27-­hydroxycholesterol,  a  primary  
metabolite  of  cholesterol,  can  stimulate  ERa-­dependent  tumor  growth  and  increase  liver  
X  receptor-­mediated  breast  cancer  metastatic  potential  [21,  22].    Taken  together,  it  will  
be  of  great  interest  to  determine  the  pathophysiological  importance  of  estrogen-­mediated  
PLC  downstream  targets  and  roles  of  anticipatory  UPR  signaling  in  tumor  progression,  
development,  metabolism,  and  invasion.  
The  preclinical  anticancer  drug  BHPI  causes   lethal  hyperactivation  of   the  UPR,  
blocking  proliferation  of  diverse  therapy-­resistant  and  ERa-­positive  breast  cancer  cells.  
BHPI  was  the  most  effective  biomodulator  to  emerge  from  an  unbiased  high  throughput  
screen  for  small  molecules  that  inhibit  the  expression  of  an  E2-­ERa  regulated  luciferase  
reporter.  Surprisingly,  BHPI  elicited  rapid,  near  quantitative  inhibition  of  protein  synthesis,  
a   seemingly   unlikely   action   for   a   small   molecule   inhibitor   of   E2-­ERa   regulated   gene  
expression.  The  PERK  arm  of   the  UPR  was   identified  as   the  pathway   responsible   for  
rapid   BHPI   inhibition   of   protein   synthesis.   This   led   to   the   finding   that   BHPI  works   by  
hyperactivating   the   little-­studied   anticipatory   UPR   pathway.   Although   identified   in  
precursors  to  immunoglobulin  secreting  B  cells,  this  pathway  had  not  been  studied  in  the  
context   of   hormone   action.   Compared   with   E2,   BHPI   more   strongly   activates   PLCg,  
producing  much  higher   IP3   levels,  calcium  release   from   the  EnR,  and  UPR  activation.  
BHPI  potently  inhibits  protein  synthesis  by  inducing  rapid  and  robust  phosphorylation  of  
PERK  and  eIF2a.  Supporting  the  role  of  the  PERK  arm  of  the  UPR  in  inhibiting  protein  
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synthesis,  knockdown  and  inhibition  of  ERa,  PLCg,  the  IP3Rs,  and  PERK  blocked  rapid  
BHPI  inhibition  of  protein  synthesis.  The  substantial  level  of  IP3  produced  by  strong  BHPI  
activation   of   PLCg   binds   to   and   opens   the  EnR   IP3Rs,   resulting   in   the   rapid   efflux   of  
calcium  stored  in  the  lumen  of  the  EnR  into  the  cytosol.  To  restore  EnR  calcium,  the  cell  
activates  SERCA  pumps,  which  catalyze  the  ATP-­dependent  transfer  of  calcium  from  the  
cytosol   into  the   lumen  of   the  EnR.  Since  the  IP3R  calcium  channels  are  still  open,   the  
calcium  pumped  into  the  EnR  leaks  back  out  creating  a  futile  cycle  that  rapidly  depletes  
cell  ATP.  Depleting  intracellular  ATP  activates  the  metabolic  sensor,  AMP  kinase  (AMPK).  
Supporting  this  model,  thapsigargin,  which  inhibits  the  SERCA  pumps,  blocks  the  BHPI-­
mediated  decline   in  ATP   levels  and  AMPK  activation.  Together,  AMPK  activation  and  
elevated   intracellular   calcium   activate   the   eukaryotic   elongation   factor   2   kinase  
(CAMKIII/eEF2K).  Activated  eEF2K  phosphorylates  eEF2,  inhibiting  protein  synthesis  at  
a   second   site.   This   prevents   synthesis   of   BiP   and   other   chaperones   and   p58IPK   and  
GADD34   (growth  arrest   and  DNA  damage-­inducible  protein  34)   that   normally   reverse  
PERK  activation.  Working  together,  several  actions  of  BHPI,  including  long-­term  inhibition  
of  protein  synthesis,  sustained  UPR  activation,  ATP  depletion  and  AMPK  activation  likely  
contribute  to  BHPI’s  ability  to  block  proliferation  and  often  kill  ERa-­positive  cancer  cells.  
At   nanomolar   concentrations,   BHPI   blocked   growth   and   killed   diverse   ERa-­positive  
breast,  ovarian,  and  endometrial  cancer  cells  that  are  resistant  to  endocrine  therapies.  In  
a  mouse  xenograft  model  of  breast  cancer,  BHPI  stopped  tumor  growth  and  induced  rapid  
and  substantial  regression  of  large  tumors.  
Mild   UPR   activation   enhances   protein   folding   capacity   to   meet   the   need   for  
increased  protein  synthesis  and  cell  proliferation  [23].  Cancer  cells  adopt  the  protective  
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features   of   the   UPR   pathway   to   exhibit   constitutive   activation   of   IRE1a   or   increased  
expression  of  BiP,  which  is  anti-­apoptotic  [24-­27].  In  contrast,  sustained  hyperactivation  
of  UPR  is  lethal.  Long-­term  PERK  activation  can  induce  CHOP,  which  binds  to  and  induce  
transcription  of  the  promoters  of  p53  an  upregulated  modulator  of  apoptosis,  lipocalin  2,  
tribbles  homologue  3,  and  death  receptor  5  that   is  responsible  for  EnR  stress-­induced  
apoptosis  via  caspase  8  in  cancer  cells  [28-­32].  In  addition,  CHOP  can  transcriptionally  
activate   of   the   AKT   inhibitor   TRIB3   [30],   which   inhibits   mTOR   pathway   to   block  
proliferation   and   activate   autophagy,   a   stress-­adaptive   self-­eating   process   [33].  While  
activation   of   autophagy   has   been   documented   in   some   cancer   cells   to   be   protective,  
similar  to  UPR  activation,  activation  of  autophagy  can  also  lead  to  cell  death  [33].  Similar  
to   PERK,   if   IREa   signaling   is   not   attenuated,   sustained   IRE1a   activation   can   trigger  
apoptosis  [24].  Hyperactivated  IRE1a  cleaves  many  mRNA  in  addition  to  its  well-­known  
substrate,  XBP1,  a  process  called  regulated  IRE1-­dependent  decay  (RIDD)  [34].  RIDD  
reduces   the   expression   of   some  microRNAs   that   repress   caspase   2   expression   [35].  
Whether  caspase  2  plays  a  role  in  UPR-­induced  apoptosis  is  unknown  [35].  In  addition,  
activated   IRE1a   binds   to   TNF   receptor-­associated   factor   2,   which   recruits   apoptosis  
signal-­regulating  kinase  1  and  JUN  N-­terminal  kinase  (JNK),  resulting  in  JNK-­mediated  
apoptosis   [36].   Sustained   UPR   activation   by   pharmacological   UPR   inhibitors  
(Tunicamycin,   Thapsigargin)   can   cause   these  UPR-­induced   apoptosis   cascades   [37].  
However,  BHPI   is  a  new  class  of  UPR  biomodulator   that  works  by  hyperactivating  the  
UPR,   resulting   in   persistent   inhibition   of   global   protein   synthesis.   While   the   exact  
mechanism  underlying  BHPI  induced  cell  death  is  under  investigation,  we  anticipate  that  
BHPI  integrates  multiple  UPR-­induced  cell  death  pathways  to  kill  ERa-­positive  tumors.  
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BHPI  indirectly  inactivates  MDR1  activity  and  restores  sensitivity  to  chemotherapy  
in   resistant   ovarian   cancer   by   selectively   depleting   intracellular   ATP.   De   novo   and  
acquired  multidrug  resistance  is  a  core  problem  in  cancer  chemotherapy  [5].  In  ovarian  
cancer,  the  primary  driver  of  multidrug  resistance  is  overexpression  of  energy  dependent  
MDR1   pumps   [38].   BHPI   has   emerged   as   a   uniquely   promising   and   well-­tolerated  
therapeutic   candidate   for   multidrug   resistant   ovarian   cancer.   Central   to   BHPI’s  
therapeutic   potential   is   its   novel  mechanism  of   action  based  on   robust   and   sustained  
hyperactivation  of  the  anticipatory  UPR  pathway,  resulting  in  ATP  depletion  and  MDR1  
inactivation.   This   enables   BHPI   to   resensitize   multidrug   resistant   tumors   to  
chemotherapeutic  intervention  and  reduce  ovarian  tumor  burden  to  undetectable  levels.  
Interestingly,   in   an   orthotopic   xenograft   study,   using   paclitaxel   resistant   MDR1  
overexpressing  ovarian  cancer  cells,  the  control  paclitaxel-­treated  group  exhibited  large  
metastases.   This   is   a   previously   unexplored   phenotype   and   may   represent   a   new  
resistance  mechanism  induced  by  chemotherapy  agents  in  multidrug  resistant  cells.  BHPI  
is  a  novel  candidate  for  further  development  for  combination  therapy  for  the  treatment  of  
multidrug  resistant  ovarian  cancer.  
Although   tumors   often   exhibit   multiple   regulatory   alterations,   anticancer   leads  
usually  focus  on  inhibiting  a  protein  target  or  pathway.  We  employ  an  alternative  approach  
and   use   BHPI   to   hyperactivate   the   up-­regulated   tumor-­protective   UPR   pathway,  
converting   it   from  protective   to   lethal.  Targeting   therapy-­resistant  cancer  cells   through  
proteins  overexpressed  as  part  of  a  therapy  resistance  mechanism  is  a  novel  therapeutic  
idea,  with  the  potential  for  significant  impact  on  the  treatment  of  aggressive  and  therapy-­
resistant  ERa-­positive  breast  and  ovarian  tumors.     
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